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ABSTRACT 
 
Hepatitis C is a notifiable disease in South Africa (SA), but there is a lack of surveil-
lance and reporting systems. The availability of routine, reliable and validated meth-
ods of hepatitis C virus (HCV) detection and genotyping, together with better surveil-
lance strategies is vital to ensure optimal patient diagnosis, treatment and disease 
management.  This is the first extensive molecular study on the HCV in this country 
to identify circulating genotypes, host immuno-genetics and patients responses to 
combination therapy.   
  
HCV genotypes in the patient and blood donor groups were determined by sequenc-
ing of the 5’untranslated (5’UTR) and non-structural -5B (NS5B) regions.  Three mo-
lecular-based tests, line probe assay (LiPA), real-time and palindromic nucleotide 
substitutions (PNS), were compared to the sequencing method. Molecular sequence 
analyses of the core, envelope 1(E1), NS4B and NS5B were determined. The in-
ferred amino acid data was used to determine epitope variation across immu-
nodominant regions. Viral load monitoring was performed on patients receiving com-
bination treatment.  
  
A positive HCV polymerase chain reaction (PCR) result is necessary to confirm ac-
tive infection.  A National HCV surveillance database was established to collate pa-
tient demographics with results from public health laboratories.  Genotype 5a pre-
dominates in patients with liver disease.  Changing frequencies and introductions of 
other subtypes were determined. The LiPA (5’UTR) was found to surpass the other 
genotyping tests, as it was quick and easy. Geographical clustering within the geno-
4 
type 5a clade was evident in the E1 and NS4B regions. The branching order of 
genotype 5a suggests that genotype 5a is older than genotype 3, inferring that pa-
tients with genotype 5a may respond better to therapy than those infected with 
genotype 3. The divergence estimate of genotype 5a was found to be between 100-
156 years.  Despite the homogeneity of genotypes 1 and 5 epitope sequences, well-
published epitopes  were predicted to bind sub-optimally to the common human leu-
kocyte antigen (HLA) alleles, making a vaccine less effective in SA.  The treatment 
response for genotype 5a was higher in this study compared to previous global 
studies.  
 
This new molecular knowledge on HCV genotypes circulating in SA will allow in-
formed decisions when planning preventative and treatment strategies relevant to 
local viral and host genetics. 
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CHAPTER ONE 
 
1.1. INTRODUCTION 
The hepatitis C virus (HCV) is a major cause of cirrhosis and chronic liver disease 
and a reason for liver transplantation in most developed countries (World Health Or-
ganization, WHO, 2007).  It is estimated that about 3% (170 million) of the world’s 
population are infected with HCV (WHO, 2010).  About 80% of HCV infected people 
become chronic carriers.  The seroprevalence of HCV in Sub-Saharan Africa is 
comparatively low with a prevalence of 1.7%-3.2% reported in South Africa (SA) 
(Lavanchy, 2011; Ellis et al., 1990) compared to a high prevalence of 14% in Egypt 
(WHO, 2002).  The contribution of HCV to liver disease in South Africa is not known 
as studies have been small and limited and were performed 8 to 15 years ago with-
out current technology. An ongoing, up-to-date, large-scale, molecular epidemiologi-
cal study of circulating HCV strains is thus long overdue. Understanding the hetero-
geneity of HCV can improve diagnostic technologies, vaccine development and 
therapeutic interventions.  
 
1.2. HEPATITIS C VIRUS (HCV) 
HCV is a member of the Flaviviridae family, of the genus, Hepacivirus (Robertson et 
al., 1998) together with the putative species tamarin GB-virus and closely related 
human GBV-C (International Committee on Taxonomy of viruses, ICTVdB, 2006). 
Humans are the only known natural host, although HCV has been transmitted ex-
perimentally to chimpanzees (Bukh et al, 1998). Hepaciviruses are different from 
flaviviruses and pestiviruses in that not all viral types can propagate efficiently in cell 
culture, and the precursor protein is cleaved at the NS2/3 junction via a Zn-
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dependent proteinase (ICTVdB, 2006). HCV is the most labile of the blood-borne 
viruses (Elder et al., 2004), is highly mutable (10-3 to10-5 mutations per nucleotide 
per generation (Bartenschlager and Lohmann, 2000, Table 1) with a high replication 
rate of 1012 virions/day (Neumann et al., 1998, Table 1) compared to 108 virions/day 
for HIV (Weber, 2001).  The mutations accumulate within a single host giving rise to 
a population of virus genomes, known as the viral quasispecies, which differ from 
the virus first transmitted (Davis, 1999). This high diversity of HCV poses a major 
challenge to vaccine development. 
 
1.2.1. HCV Structure and Life Cycle 
Virions are spherical and 40-60 nm in diameter with a lipid envelope (Fig.1).  Like 
other flaviviruses, HCV acquires its envelope by budding through the endoplasmic 
reticulum (ER) membrane (Blanchard et al., 2002).  The virion has spike-like surface 
projections made up of the envelope proteins (E1 and E2, Fig.1) and an isometric 
 
HCV Properties Reference 
Half-life is  2 to 5 hours Neumann et al., 1998 
Viral turnover  is  1010 to 1012 virions/day/
individual 
Neumann et al., 1998, Herrmann et al., 2000 
Low viral viraemia of 106 to 107IU/ml Yao et al., 2005 
Error rate of 10-3 to 10-5 mutations/nucleotide 
site/replication 
Bartenschlager and Lohmann, 2000 
Mutation rate (substitution/site/replication):   
in chimps  (1.4 X 10-3) Okamoto and Mishiro, 1994, Major et al., 1999 
in humans (1.9 X 10-3) Okamoto and Mishiro, 1994 
in vitro ( 3.5-4.8 X 10-3) Kato et al., 2009 
NS5B has poor fidelity, is error-prone and lacks 
repair mechanism 
Steinhauer et al., 1992 
Evolutionary rate (substitution/site/year):   
Core (1.8 X 10-4) Pybus et al., 2009 
NS5B (3.3 – 4.1 X 10-4) Okamoto and Mishiro, 1994, Pybus et al., 2009 
E1 (7.1-7.2  X 10-4) Okamoto and Mishiro, 1994, Verbeeck et al., 
2006 
NS4B (5.4 X 10-4) Verbeeck et al., 2006 
Table 1.  Properties of the HCV genome as summarized from the references provided. 
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nucleocapsid of 25-30 nm (Kaito et al., 1994). Electron microscopic observations 
have shown that the HCV core protein self-assembles at the ER membrane, rather 
than in the cytoplasm, forming a structured capsid (Blanchard et al., 2002) The nu-
cleocapsid houses a single, linear, positive-sense RNA strand of 9.6 kB (Choo et al., 
1991). 
Progress in understanding the HCV life cycle has accelerated since the JFH1 
(genotype 2a) strain was successfully cultured (Wakita et al., 2005 and Zhong et al., 
2005).  Studies on the viral life cycle (summarized below) have contributed to devel-
opments in anti-viral therapies and targets for neutralizing antibodies (reviewed in 
Zeisel et al., 2007).    
(1) HCV attaches to the host cell membrane by the viral envelope glycoproteins, 
E1 and E2, binding to factors such as heparin sulfate [HS] (Barth et al., 2003).  
Lipoproteins may facilitate the entry of HCV into the liver cell as both use a 
common receptor, scavenger  receptor class B type 1 [SR-B1] (Scarselli et al., 
2002).   
Fig.1. Diagrammatic 3D model depicting the structure of the hepatitis C virus (adapted from a figure 
by Louis E. Henderson published online, March 2001, www.prn.org) 
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 Adsorption to the cell membrane and entry into the cell occur in a multi-step 
 process, via the host receptor proteins CD81 (Pileri et al., 1998), claudin-1 
 (Evans et al., 2007), occludin (Liu et al., 2009) and lectins [dendritic cell (DC)-
 specific intracellular adhesion molecule-3 grabbing non-intergrin (SIGN) and 
 liver-specific (L)-SIGN] (reviewed in Burlone and Budkowska, 2009]. 
(2) The virus is internalized in a clathrin-coated pit, by endocytosis, in a pH-
dependent environment (Blanchard et al., 2006). 
(3) The virus is transported in the cell in an endosome and prior to genome proc-
essing, the viral envelope fuses with the endosomal membrane in the acidic 
cytosol and the capsid is removed, exposing the ssRNA to the replication proc-
ess (reviewed in Zeisel et al., 2007). 
(4) The ssRNA serves as a template for replication into many copies of negative 
and positive stranded RNA and direct translation into polyprotein.   Assembly 
and packaging of new virions occur on the rough ER (reviewed in Langhans et 
al, 2010).  However, the exact mechanism for the assembly and maturation of 
virions is still unknown. 
 
The viral binding, post-attachment and fusion processes are potential targets to neu-
tralize viral infection (reviewed in Zeisel et al., 2007).  Antibody binding to the free 
virus will block viral attachment to the cell.  Neutralizing antibodies (NAb) may pre-
vent post-binding stages by binding and blocking host entry molecules at the cell 
surface or preventing internalization via the endosome.  NAb may also prevent the 
fusion process by changing the conformation of the protein involved or hinder con-
tact between the membranes (Zeisel et al., 2007).  NAb can interfere with viral un-
coating and replication too (Zeisel et al., 2007). 
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1.2.2. Genes and their function/s during the life cycle 
A single large open reading frame (ORF) encodes a polyprotein of about 3000 
amino acids (Choo et al., 1991, Fig.2).  The polyprotein is cleaved into ten viral pro-
teins by host cellular and viral proteases.  The three structural proteins are the core 
(C) and the two envelope proteins, E1 and E2. There are seven non-structural pro-
teins, the p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B (Lohmann et al., 1996; Su-
zuki et al., 1999).  The structural proteins which are cleaved by host cellular proteins 
(signal peptidase) and aggregate to form the viral particle (Suzuki et al., 1999) are 
located at the 5’ terminus end (Fig.2).  The non-structural proteins are cleaved by 
viral proteases (serine protease, Moradpour et al., 2002) and are located further 
downstream (Fig.2).  Linear and conformational epitopes are found throughout the 
viral polyprotein and are thought to be involved in both innate and adaptive immune 
responses of the host to HCV infection (chapter 6 for a more detailed discussion). 
Fig.2. A schematic representation of the HCV genome, indicating numbering of amino acid (aa) and 
nucleotide (nt) bases according to Choo et al., 1991.  The shaded areas are the larger genes 
(>1000bp). 
The structural genes are the core (C) and envelope proteins (E1 and E2).  The non-structural genes are the p7,NS2 –NS5B.  
The 5’ and 3’ untranslated regions (UTR) are found at the amino (NH2) and carboxyl (COOH) ends, respectively.   
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1.2.2.1. 5’ and 3’ untranslated region (5’UTR and 3’UTR)  
The 5’ untranslated region (UTR) of HCV RNA is approximately 340 nucleotides 
long (Fig.2) and is highly conserved among different HCV strains (Suzuki et al., 
1999).  Studies on the secondary structure of the 5’UTR region of HCV have re-
vealed the presence of four domains, three of which are shown in Fig.3, with strong 
stem-loop structures and a pseudoknot (Fig.3, Wang et al., 2005).  The proximal 
part of the 5’UTR of domains II, III and IV, with some of the core region serve as an 
internal ribosome entry site [IRES] (Honda et al., 1996).  The function of the IRES is 
to initiate translation of the polyprotein in a cap-independent manner (reviewed in 
Suzuki et al., 1999), forming a stable complex with the 40S ribosomal subunit 
(Tsukiyama-Kohara et al., 1992).  IRES-mediated polyprotein translation is com-
monly used by many viruses, eg. enteroviruses (Borman et al., 1995). Several stud-
ies have indicated that the IRES interacts specifically with cellular factors of different 
cell types, either enhancing or reducing protein translation (Forton et al., 2004; Lerat 
et al., 2000) and that mutational changes in certain subdomains, eg. IIId, can affect 
structure and function of the IRES (Barria et al., 2009).    
 
The highly conserved 5’UTR and the stable IRES has thus been the target of (a) an-
tisense-based ribozymes, siRNAs, (b) oligonucleotides and peptide nucleic acids 
[PNA] (Alt et al., 1999; Zhang et al., 1999; Alotte et al., 2008),  (c) many commer-
cially available diagnostic PCR and genotyping assays (discussed in chapter 3) and 
(d) its “palindromic” sequence structure has been used to genotype HCV 
(Giangaspero et al., 2008, discussed in chapter 5).  
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The 3’UTR has three regions namely, (1) a variable region, with sequences that dif-
fer among different genotypes  for example, the CACTCC motif is different for geno-
types 2a and 2b  compared to genotypes 1a, 1b, 1c and 3a (Tokita et al., 1998) , (2) 
a long poly (U/UC) tract and (3) a highly conserved X-region with three stem loop 
structures (Tanaka et al., 1996).  The poly (U/UC) tract and the X-region are impor-
tant for viral replication (Friebe and Bartenschlager, 2002). The secondary structure 
may be important for proper termination of translation (van Doorn, 1994) as the 
structure at the 5’UTR IRES is for initiation.  
 
1.2.2.2. Structural proteins 
Core region 
The first cleavage product of the polyprotein at the amino end is the core protein of 
molecular weight 17-23 kDa.  The core protein is a highly basic, non-glycosylated 
protein and forms the major part of the nucleocapsid (reviewed in Bartenschlager 
and Lohmann, 2000).  The core protein has two domains (i) domain I, involved in 
Fig.3.  The IRES structure in the 5’untranslated region, with stem-loop domains IIa, IIb, IIIa-f, IV and 
pseudo-knot, red in figure (adapted from Wang et al.,2005) 
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binding to RNA and nuclear localization and (2) domain II, associates the core pro-
tein to the ER or lipid droplets (Suzuki et al., 2005) for particle assembly.  Mutations 
in domain II reduce core stability and result in loss of production of infectious virus in 
JFH1 cell cultures (Boulant et al., 2007). Multimeric complexes between the core 
and E1 (Baumert et al., 1998) and p7 and NS2 (Murray et al., 2007) may play a role 
in the morphogenesis of HCV.   
 
The amino acid sequence of the core protein is highly conserved among different 
HCV strains in comparison with other structural and non-structural proteins (Suzuki 
et al., 1999) and encompasses several immunodominant epitopes. The core epi-
topes bind to multiple human leukocyte antigen (HLA) class II alleles and generate 
proliferative CD4+ T-cell responses, clearing the virus in healthy individuals with low 
viral load (Botarelli et al., 1993).  Whereas the core protein can stimulate an immune 
response and clear infection, it was also associated with Fas-mediated apoptosis 
(Honda et al., 2000), contributing to severe hepatitis and hepatocellular carcinoma.  
The core protein may bind to apolipoproteins involved in lipid metabolism, form fat 
droplets in hepatocytes, and contribute to steatosis (Moriya et al., 1998). 
 
Linear core epitopes are used in enzyme linked immuno-absorbent assays (ELISA) 
to detect antibodies in patient sera (van Doorn et al, 1994).  Probes in the core and 
the 5’UTR region have been incorporated into a new line probe assay (LiPA) to spe-
cifically subtype genotypes 1 and 6 (Noppornpanth et al., 2006b) and this is dis-
cussed in further detail in chapter 4.   
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During natural HCV infection, an alternate reading frame (ARF) that overlaps the 
core protein is expressed (Branch et al., 2005).  This protein, also known as the 
frameshift (F) protein is seemingly due to the unusual events of core translation, 
such as ribosomal frameshifting and may be involved in HCV persistence (reviewed 
in Chevaliez and Pawlotsky., 2007a).   
 
Envelope regions  
Envelope proteins (E1 and E2) are highly glycosylated type 1 transmembrane pro-
teins with a large N-terminal hydrophilic domain on the outer part of ER membrane 
and a small C-terminal hydrophobic transmembrane domain [TMD] (reviewed in Op 
De Beeck et al., 2001).  The TMD anchors and retains the envelope proteins in the 
ER membrane (Cocquerel et al., 2001).  E1 and E2, have molecular weights of 33-
35kDa and 70-72 kDa, respectively and are responsible for interacting with the host 
cellular receptor tetraspanin CD81.  E1 is thought to fuse the virus with the cellular 
membrane (Ciczora et al., 2007).  The E2 receptor binding domain (RBD) has three 
variable regions, namely, the hypervariable region 1 (HVR1), HVR2 and an inter-
genotypic variable region [igVR] (reviewed in Gottwein and Bukh, 2008).  The HVR 
can differ up to 80% between genotypes and subtypes (Weiner et al., 1991).  The 
HVR1 (27 aa) is a basic region with a positive charge and interacts with the nega-
tively charged cell surface, playing a role in cell recognition, attachment and cell 
compartmentalization (Barth et al., 2003).  
 
The HVR1 is the strongest target for NAb responses (Farci et al., 1995) and has 
been considered for peptide-based vaccines.  However, it is also the most variable 
region (Kato et al., 1992), and is responsible for the evolution of quasispecies which 
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alternatively contribute to progression of chronic disease (Farci et al., 2000) or  re-
sult in an early virological response to antiviral therapy (Fan et al., 2006).  Despite 
producing a strong immune response, infection is not cleared (Ray et al., 1999) as 
escape mutants, not recognised by the circulating NAb (Sklan et al., 2009), persist.  
 
The HVR2 appears to adjust the E2 receptor binding process (Roccasecca et al., 
2003), but the function of the igVR, which is conserved within a genotype, is unclear 
(Gottwein and Bukh, 2008).   Further downstream from these variable domains in 
the E2, is a sequence of 12 amino acids that inhibits the activity of protein kinase R 
(PKR), an antiviral protein (Taylor et al., 1999). 
 
1.2.2.3. Non-structural proteins 
The non-structural genes, p7 and NS2-NS5 are required for viral morphogenesis 
(Gottwein and Bukh, 2008) and replication (reviewed in Bartenschlager and Loh-
mann, 2000), respectively. The small, 63 aa protein, p7, functions as a transmem-
brane protein with two domains (TM1 and TM2), connected by a short cytoplasmic 
loop (Sakai et al., 2003). The p7 protein acts as a putative ion channel (Griffin et al., 
2003) and the ER-associated p7 is thought to be important in particle production 
(Brohm et al., 2009).    
 
The NS2 protein is a 23 kDa transmembrane protein, responsible for ER association 
(Santolini et al.,1995).  The NS2 protein and the amino-terminal domain of the NS3 
form the NS2/NS3 protease, which is responsible for self-cleavage at a single site 
(Grakoui et al., 1993).  The NS2 protein has a short half-life as it is degraded after 
self-cleavage from NS3.  The NS3 protein (70 kDa) is multi-functional, containing 
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the N-terminal serine protease and the C-terminal helicase/NTPase domain 
(reviewed in Chevaliez and Pawlotsky, 2007a).  Serine protease activity is vital for 
the viral life cycle as it releases the rest of the polyprotein at the NS3/NS4A, NS4A/
NS4B, NS4B/NS5A, NS5A/NS5B junctions. This protease function makes the NS3 a 
target for antiviral therapies and potential vaccines. The helicase/NTPase activity is 
necessary for unwinding the secondary structures of RNA before replication, RNA 
binding and separation of nascent strands from template strands during replication 
(Tai et al., 1996). NS3/NS4A contain highly immunogenic epitopes (discussed in 
chapter 6) and the C100 antigen from this region is used in most ELISAs (reviewed 
in van Doorn, 1994).    
 
The NS4A protein is a cofactor of the NS3 protease activity and stabilizes the pro-
tein.  It appears to anchor the NS3/NS4A complex and localizes it at the ER mem-
brane (Bartenschlager et al., 1995).  The NS4B protein [26 kDa] (Bartenschlager 
and Lohmann, 2000) is an integral membrane protein found in the ER and is essen-
tial for the assembly of the HCV replication complex (Egger et al., 2002).  The NS5A 
is a 56-58 kDa serine phosphor-protein with three domains (Tellinghuisen et al., 
2004, 2005).  Domain I is characteristic of hepaci- and pestiviruses (Tellinghuisen et 
al., 2004) and serves as an RNA-binding pocket during viral replication 
(Tellinghuisen et al., 2005).   The NS5A interacts directly with the NS5B and is 
thought to be involved with the polymerase activity of the NS5B (Chevaliez and 
Pawlotsky, 2007a).  A domain of 40 aa in the NS5A, called the interferon-sensitivity-
determining region [ISDR] (Enomoto et al., 1995), binds to the PKR and inhibits its 
antiviral function (Gale et al., 1998).  The NS5A protein can also induce interleukin 
(IL)-8 expression and blocks the assembly of interferon stimulated gene factor -3 
34 
(ISGF-3) complex, hence reducing antiviral activity by interferon (IFN) (Polyak et al., 
2001).  
  
The NS5B (65 kDa) protein encodes the viral replicase, RNA-dependent-RNA poly-
merase (RdRp) and is anchored to the ER (Moradpour et al., 2004).  The RdRp has 
the classical “finger” structure of polymerase, with the “finger” and “thumb” domains 
channeling the ssRNA toward the deoxyribonucleotide triphosphates [dNTPs] (Ago 
et al., 1999).  The NS5B RdRp synthesizes the minus-stranded RNA that then acts 
as a template for the plus-stranded RNA by the polymerase. As this polymerase 
plays an important role in viral replication, it is a target for antiviral drugs (Chevaliez 
and Pawlotsky, 2007b).  The RdRp is highly error-prone as it lacks any proofreading 
mechanism (Steinhauer et al., 1992), resulting in HCV heterogeneity (Table 1).  
Seemingly, HCV mutations do not, in most cases, affect survival and fitness of the 
virus and allow for immune escape (Gottwein and Bukh, 2008).  The NS5B protein 
is semi-conserved among different strains of HCV and is used in phylogenetic 
analyses of sequences to differentiate between genotypes and more so between 
subtypes (see 1.2.3 and chapter 3).  
1.2.3. HCV Genotypes 
HCV is classified into six genotypes [1-6] (Simmonds et al., 1993a) and >80 sub-
types by phylogenetic analyses of the 5’UTR and NS5B regions (Simmonds et al., 
1993a, b). A provisional classification for a genotype 7a was given to a single full-
genome sequence of a Canadian emigrant (Murphy et al., 2007).  Different HCV 
genotypes display a nucleotide divergence of 30% or greater (Fig.4) while subtypes 
(described as a, b, c, etc.) are defined by a 10-30% divergence (Simmonds et al., 
1994b, Fig.4).  Strains within the same subtype, or within a host quasispecies, differ 
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by <10-15% (Davis, 1999 Fig.4) with comparisons clustered around a consensus 
reference sequence (Bukh et al., 1995).  This extreme heterogeneity of HCV within 
and between hosts enables the virus to escape host immunity and hinders the de-
velopment of vaccines. 
 
HCV genotyping is of clinical, epidemiological and surveillance importance.   From a 
public health perspective, knowledge of the genotype frequencies and changes in 
these provide important epidemiological information which informs screening and 
preventative public programs.  HCV genotype 1b is associated with severe liver dis-
ease leading to cirrhosis and hepatocellular carcinoma (HCC; Prieto et al., 1999) 
and genotype 3 appears to be associated with pronounced development of liver 
steatosis (Abid et al., 2005).  Different genotypes also vary in their responsiveness 
to interferon/ribavirin combination therapy (see section 1.10).  Moreover, the impact 
on the sensitivity and specificity of commercial virologic assays is influenced by the 
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Fig.4.  A comparison of the viral homogeneity among HCV isolates of different genotypes (68%), 
same genotype but different subtypes (77%) and within a subtype (quasispecies, 85%).  
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molecular change in the virus. 
 
HCV genotypes are distributed depending on geography and route of infection 
(Bourliere et al., 2002) but travel and migration are changing these patterns.  Fig.5 
is a representation of the prevalence of common genotypes and subtypes across 
the world (Kuiken et al., 2005). Genotypes 1a and 1b are the major genotypes in 
Europe, North and South America and Australia. Genotype 1b predominates in Ja-
pan, China and Russia (Bourliere et al., 2002) and this subtype has the highest 
global prevalence (45%, Fig.5).  Genotype 2c is common in Western and Southern 
Europe (WHO, 1999).  Genotype 4a is widespread in Egypt (Kamel et al., 1992) 
while 4c is found in Central Africa (WHO, 1999).  Genotypes 3a and 6a are most 
common in South East Asia (Bourliere et al., 2002).   
 
A unique genotype, genotype 5 (Ohno et al., 1994), with only one subtype, subtype 
a (Chamberlain et al., 1997), was first reported from South Africa.  Although origi-
nally thought to be unique to South Africa, genotype 5 has more recently also been 
found in other countries including Central France (14.2%; Henquell et al., 2004) and 
in the West Flanders Province of Belgium (27.7%; Verbeeck et al., 2006).   
 
Naturally occurring inter-and intragenotypic recombinants (Fig.5) of HCV have been 
documented since 2002; intergenotypic recombinants, 2k/1b in Russia (Kalinina et 
al., 2002) and Uzbekistan (Kurbanov et al., 2008), 2i/6p in Vietnam (Noppornpanth 
et al., 2006a), 2/5a in France (Legrand-Abravanel et al., 2007), 2b/1b in Phillipines 
(Kageyama et al., 2006) and intragenotypic recombinants, 1a/1b in Peru (Colina et 
al., 2004) and Uruguay (Moreno et al., 2006), 1a/1c in Japan (Cristina and Colina, 
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2006) and Ireland (Moreau et al., 2006).  In order for a recombination event to oc-
cur, different genotypes (intergenotypic) or subtypes (intragenotypic) must infect the 
same cell of the patient.  Multiple exposures are the norm in intravenous drug users 
(Gottwein and Bukh, 2008), although mixed infections in a single person are thought 
to be uncommon (Viazov et al., 2000).  However, many of the genotyping tests ana-
lyse the conserved 5’UTR  and mixed infections are not always detected (discussed 
in chapter 4).   
 Superinfections have also been described in individuals with chronic HCV infec-
tions, that get infected with another genotype (Kao et al., 1993) or subtype (Yokota 
et al., 1994), either via blood transfusions or intravenous drug use (reviewed in 
Blackard and Sherman, 2007).  The clinical impact of mixed infections, superinfec-
tions and recombinants is not fully understood but this viral heterogeneity will further 
challenge diagnostic techniques, vaccine design and therapeutic management.   
2k/1b 
2i/6p, 
2b/1a, 
1a/1c 
6a 2/5a 
1a/1b 
1a/1b 
) 
3a 
1a/1c 
In SA, 5a (LD) and 
1 (haem) 
Fig.5. The worldwide geographic distribution of HCV genotypes and subtypes with locations on the 
current recombinants and genotypes 3a, 5a and 6a (adapted from Kuiken et al., 2005) 
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1.3. GLOBAL EPIDEMIOLOGY 
HCV infection is not seasonal in transmission.  The WHO estimates that there are 
170 million people infected with HCV globally and more than 350 000 are at risk of 
developing liver cirrhosis and/or liver cancer (WHO, 2009).  Approximately 4 million 
people in the USA (~1.9% of the population) are HCV seropositive (Armstrong et al., 
2006), compared to the 42 000 infected with human immunodeficiency virus (HIV) 
(Centers for Disease Control and Prevention, CDC, HIV statistics 2008, http://
www.cdc.gov/hiv).  Globally, of the 33 million people with HIV/AIDS, 4-5 million are 
co-infected with hepatitis C (Alter, 2006).  In the USA, the seroprevalence of HCV in 
patients with HIV is highest in intravenous drug users (60-90%) and haemophiliacs 
(50-70%) compared with homosexual men (4-8%; Sterling et al., 2003).   
 
Seroprevalence rates are reported worldwide as it is the most cost-effective way to 
identify HCV in large populations.  The lowest seroprevalence of HCV is reported 
from northern Europe where figures range between 0.5 and 2% in countries includ-
ing Great Britain, Germany and France (Eurasian Harm Reduction network, EHRN, 
2007 http://www.harm-reduction.org/hepatitis-c.html).  Higher seroprevalence rates 
have been reported in Southeast Asia (Malaysia (2.3%) and Philippines (2.3%) re-
viewed in EHRN, 2007).   South Africa has a seroprevalence of 1.7%-3.2% 
(Lavanchy, 2011; Ellis et al., 1990) whereas other African countries, like Egypt, 
reach as high as 14.5% (WHO, 2002). Apart from the universal spread of HCV via 
blood products prior to 1994, Egypt’s extremely high prevalence is a result of HCV 
transmission through widespread anti-schistosomal injection treatment in the 1970s 
(WHO, 2002). 
Seroprevalence studies both locally and globally have targeted specific regions and/
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or high-risk cohorts, eg. in Europe, HCV seroprevalence rates are monitored in the  
intravenous drug-users cohorts (EHRN, 2007).  Since this high risk group is a major 
risk for HCV transmission, there are many national programs which test, counsel 
and provide clean syringes and needles to drug users.   Hence, hepatitis B and C 
surveillance networks are well established in this group of individuals.   
 
A large number of individuals (21% in Canada, Public Health Agency of Canada, 
PHAC, 2010, http://www.phac-aspc.gc.ca) that are HCV infected remain undiag-
nosed.  HCV is highly infectious and this pool of chronic carriers continues to pro-
mote the epidemic (EHRN, 2007, also discussed in chapter 2).   
 
1.4. EPIDEMIOLOGY OF HCV IN SOUTH AFRICA  
 ELISAs to detect anti-HCV became available in the early 1990s. However, care 
must be taken when comparing the results of these first generation assays with sec-
ond and third generation ELISAs because of the differences in their sensitivity and 
specificity (Thakur et al., 2003).  While the South African seroprevalence results of 
Ellis et al., 1990 and Lavanchy, 2011 compare with global figures (see above), a 
Kwa-Zulu Natal (KZN) hospital study (Soni et al., 1996) reported high seropositivity 
in three high risk sentinel cohorts; patients with cirrhosis, HCC and chronic active 
hepatitis (Table 2).  
 
 
 
 
 
 
40 
  Seroprevalence 
(%) 
Location in SA Reference 
Population-based       
Blood donors 1.4 
N=66000 
Western Cape Tucker et al., 1997 
Hospital-based       
Cirrhosis 23 
N=77 
KZN Soni et al., 1996 
Hepatocellular carcinoma 24 
N=33 
20.86 
N=532 
KZN 
 
 
Southern Africa 
Soni et al., 1996 
 
 
Kew et al., 1990 
Chronic active hepatitis 33 
N=6 
KZN Soni et al., 1996 
AIDS 1 
N=100 
CHB (GA) Lodenyo et al., 
2000 
HIV positive 13.4 
N=1937 
KZN Parboosing et al., 
2008 
Health care workers (HCWs) 1.8 
N=402 
CHB (GA) Vardas et al., 2002 
Haemodialysis 21 
N=103 
Groote Schuur 
(Cape) 
Cassidy et al., 1995 
1.4% of the blood donor group (Tucker et al., 1997, Table 2), 1% of AIDS patients 
(Lodenyo et al., 2000,Table 2) and 1.8% of HCWs (Vardas et al., 2002, Table 2) 
were found to be seropositive compared to a recent study on HIV positive patients
(13.4%) in a Durban hospital  (Parboosing et al., 2008,Table 2).  
 
Tucker et al. (1997) and others (Thakur et al., 2003) found that the positive predic-
tive value (PPV) for viraemia of a positive ELISA result is affected by the population 
seroprevalence, viral load and the method used to confirm viraemia.   
 
KZN, Kwa-Zulu Natal; CHB, Chris Hani Baragwanath; GA, Gauteng Province. Population-based indi-
cates volunteer blood donors and the hospital-based groups include patients in health care facilities.  
Table 2.  An overview on the studies on HCV seroprevalence in SA. Since 1990.  
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The survey of blood donors from the Western Cape area of South Africa found de-
tectable viraemia by nucleic acid amplification testing (NAAT, one example of which 
is Polymerase Chain reaction, PCR, analysis) in only 0.056% of the 1.41% found to 
be seropositive (Tucker et al., 1997).  This lack of specificity of ELISA in low risk 
groups is particularly evident when optical density (or signal) to optimal cut-off ratio 
(OD/OCR or s/co) is low. For these reasons, the CDC in Atlanta recommends rou-
tine confirmatory NAAT testing (Morbidity and Mortality weekly reports, MMWR, 
1998 http://www.cdc.gov/mmwr/pdf/rr/rr4719.pdf).  PCR was implemented at the 
NICD in 2003 (Chapter 2).  The current testing algorithm for HCV diagnostics in SA  
is shown below (Fig. 6). 
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Fig.6. The HCV testing algorithm as illustrated in the current National guidelines for the prevention 
and control of Hepatitis C virus in SA, final draft, 2010.  The primary screen test for HCV is the HCV 
antibody test.  A positive antibody test is confirmed by a qualitative PCR to indicate presence or ab-
sence of active infection.  If the PCR test is positive, further medical evaluation is recommended at 
tertiary hospitals where specialized diagnostic and molecular tests can be done. NAT=NAAT in text 
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 1.5. TRANSMISSION AND RISK FACTORS 
The existence of HCV (previously known as non-A, non-B, NANB hepatitis) was 
postulated in 1975 (Feinstone et al., 1975).  HCV is primarily parenterally transmit-
ted through infected blood and blood products.  It was the most common cause of 
post-transfusion hepatitis worldwide prior to donor screening for antibodies to HCV 
in 1992 (reviewed in Richter, 2002).  Thirty-five percent of injecting drug users are 
infected with hepatitis C (MMWR, 2009, http://www.cdc.gov/mmwr/pdf/ss/
ss5803.pdf). 70-80% of HCV transmission in Canada (www.phac-aspc.gc.ca) is via 
injection drug use and the sharing of preparatory materials (syringe/needle, spoon, 
cooker, filters, straws (McMahon et al., 2004) and pipes.  The only other common 
transmission route is via accidental exposure to infected blood (e.g. needlestick in-
jury, reviewed in Richter, 2002).  In a German hospital, HCV transmission in HCWs, 
occupationally acquiring HCV, is 3 and 10%, depending on the HCV viral load in the 
source  (Wicker et al., 2008).   
 
Injection use is the major route of HCV transmission.  However, body piercing, tat-
tooing and traditional markings are also risk factors. Fishermen in Japan were given 
tattoos for easy identification in case they died at sea, and this may explain the high 
incidence of HCV-related HCC seen today at most harbour towns (Yoshizawa, 
2002).  Non-parenteral transmission of HCV is not so well defined.  Sexual transmis-
sion is relevant in persons with high risk behaviours and the immuno-suppressed.  
Mother-to-baby transmission occurs in 5% of infants born to HCV infected women,  
also dependent on viral load (reviewed in Richter, 2002).  A fairly large number of 
HCV cases (41%) have no identifiable risk factor in South East Asia (Nguyen et al., 
2010).   
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1.6. IMMUNE RESPONSES DURING HCV INFECTION  
What determines whether an HCV infected individual resolves infection or becomes 
chronically infected, and in those who are infected, whether they will respond to 
therapy?  The answer partially lies in viral factors such as viral tropism, viral varia-
tion or an immune deficient syndrome caused by a virus, for eg. HIV, but host genet-
ics also plays a role (Freeman et al., 2001).  Genetic variables which affect the host 
immune response are important and depend on the interplay between the virus and 
the host.   
 
Figure 7 summarizes the two arms of the immune system, the host’s innate and 
adaptive immune responses (IR), respectively.  The key components of the adaptive 
IR to HCV are further described in figure 8. 
IMMUNE RESPONSE (IR)
Innate, non-specific and not 
long-lasting
inflammation
cytokine release
complement cascade to 
recruit antibodies, MBP
Adaptive, activated by 
the innate, specific 
and long-lasting
Cells of the innate IR
Leukocytes, mast cells 
which recruit neutrophils
and macrophages, 
Phagocytes  
(neutrophils, 
macrophages, dendritic
cells, monocytes) which 
react to cytokine 
production, eosinophils, 
basophils, phagocytes, 
NK + NK cells
Effector cells
T-cells (cell-
mediated)
CD4+TH
Non-cytolytic
Naïve cells + 
MHC-II + Ag 
complex
activation-
effector cells
release 
cytokines
CD8+CTL
Cytolytic
Naïve cells + 
MHC-I Ag 
complex
effector cells 
release
enzymes that 
lyse
cells - apoptosis
Memory cells
TH1
(IFN-gamma, IL-2)
activate macrophages,
induces B-cells, more 
effective against
intracellular pathogens, 
viruses
TH2
(IL-4, IL-10)
activate
B-cells-NAb’s
humoral response
effective against 
extracellular pathogens
B-cells 
(humoral, 
antibody 
producing cells 
for 
neutralization of 
virus
Not maintained 
for long during 
infection
Figure 7:  A summary of the breakdown of the innate and adaptive immune system, indicating the 
functions of the different cells 
IR, immune response; MBP,mannose binding pro-
tein; NK, natural killer cells; CD4+ TH; CD4+ T-
helper cells; CD8+ CTL; CD8+ cytotoxic T-
lymphocytes; Ag, antigen; IFN, interferon; IL, inter-
leukin 
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1.6.1. THE INNATE IMMUNE RESPONSE  
The innate IR occurs early, is non-specific and activates the adaptive response.  It  
is the first step toward viral recognition and attempts to clear infection by the host 
cells (reviewed in Szabo and Dolganiuc, 2008, Fig.7).  Both the innate IR and the 
specific humoral response facilitate the production of antibodies that, among other 
things, interfere with viral entry and replication within the cell.  
 
Cytokines (IL-12, TNF-alpha) and IFN production suppress viral replication and acti-
vate natural killer cells (NK) to destroy infected cells via apoptosis (reviewed in 
Branch and Seeff, 2000).  
 
1.6.2. THE ROLE OF HLA IN HCV DISEASE 
Numerous studies link host immuno-genetic factors to HCV infection/clearance or 
response to therapy.  Different haplotypes of NK cell receptors are associated with 
protection or persistence, respectively (Khakoo et al.,2004).  Individuals with 
KIR2DL3 and HLA-C1 are more likely to recover from HCV than those with 
KIR2DL1 and HLA-C2 (Kanto and Hayashi, 2006).  Also, recently single nucleotide 
polymorphisms (SNPs) on the IL-28B gene (Ge et al., 2009) were found to correlate 
with early response to pegylated interferon (PEG-IFN) and ribavirin therapy.  Stud-
ies on the molecular typing of HLA alleles and their association with HCV have var-
ied in terms of sample size and methodology,  however, the consensus is that the 
HLA genotype does influence the outcome of HCV infection (acute/self limiting ver-
sus chronic/persistent) and/or the response to therapy (sustained response versus 
no response) (Table 3 and 4, Kuniholm et al., 2010).  Interestingly, there is some 
correlation with HLA alleles associated with HCV and that with HIV disease, for ex-
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ample, HLA-B*27, HLA-B*57 and DRB1*13:03 are associated with lower HIV viral 
load (Altfeld et al., 2003; Kiepiela et al., 2004; Julg et al., 2010).  The same two HLA
-B alleles have been linked with HCV clearance (Tables 3 and 4) and HLA class II 
DRB1*13:01 was found to be associated with HCV clearance in Caucasians in Ger-
many (Hohler et al., 1997; Table 4).  Hence, going forward in efforts to develop HCV 
vaccines for the diverse populations worldwide, lessons must be learnt from the HIV 
vaccine initiatives (Kim et al., 2010).  Whereas great strides have been made with 
regard to developing epitope-based vaccines for HIV, longer and broader immune 
responses is the focus as longer epitope sequences and multiple epitopes may gen-
erate a better range of immune responses (Kim et al., 2010).  Compared to epitope 
vaccines (EV), subunit protein vaccines elicit mainly CD4 and CD8 T-helper re-
sponses and  hardly any CTL and antibody responses and DNA vaccines take 
longer to elicit an immune response (Cavicchi and Kowalski, 2009; http://
www.wipo.int/patentscope/en/programs/patent_landscapes/documents 
itti_patent_ls_hiv_protein_vaccines.pdf).  An understanding of HLA interactions with 
immunodominant epitopes is essential for the development of an effective EV.  
These host and viral specific characteristics, respectively, affect the CD4+ and 
CD8+ T-cell responses which, in turn affects disease outcome.   
 
Different HCV genotypes have different natural and/or escape mutations within the 
T-cell epitopes.  Viral peptides bind (within the antigen presenting cell) with the HLA 
class-I and - II molecules and this complex becomes exposed at the surface of the 
cell.  This complex is recognized by the T-cell receptor.  In case of viral variance, 
there is no binding or no recognition. So, the protective effects associated with the 
HLA allele and a peptide of one HCV genotype may not be present when chal-
47 
lenged by a variant of another HCV genotype (Bengsch et al., 2009).  There is a 
need to study epitope changes within and across HCV genotypes as well as con-
sider how binding of an epitope to heterogenous HLA molecules can influence im-
mune responses (further discussed in chapter 7).       
HLA TYPE I ETHNIC 
GROUP* 
HCV GENO-
TYPE 
HCV DISEASE REFERENCE 
A2 Ca, J, CH, 
Afn 
1a chronic Wertheimer et al., 2003 
A2   1 chronic Cerny et al., 1995; 
Himoudi et al., 2002 
A2   1 Chronic, respond to  
therapy 
Vertuani et al., 2002 
A2     Acute/clearance Thimme et al., 2002 
A01 Ca 1b, 3a chronic Neumann Haefelin et al., 
2008 
A1101 AA + Ca   clearance Thio et al., 2002 
A23   1 chronic Koziel et al., 1995 
A2301 AA   Viral persistence Thio et al., 2002 
A30 Ca   acute/clearance Minton et al., 1998 
B8 Ca (Irish)   Viral persistence   
B14 Ca (Italian); 
Egypt 
  Susceptibility/
persistence 
  
B27 Ca (German)   Viral clearance   
B35 Ca (Russian); 
Korean 
  Viral persistence   
B53 AA + Ca 1 chronic Koziel et al., 1995 
B57 AA + Ca; WA; 
Ca (Irish) 
  Viral clearance Thio et al., 2002; Chuang 
et al., 2007; McKiernan et 
al., 2004; Kuniholm et al., 
2010 
B14/Cw8 Ca   chronic/severe   
B41/KIR3D51 J   Protection from HCC   
Cw3 Ca   Mild/acute/protection   
Cw7+Nk Ca (Italian)   HCC   
Cw8/C2/KIR Ca (Spanish)   Viral persistence   
Cw01/
C1C1+KIRDL3 
Ca   clearance   
Cw01 Ca (US)   protection   
Cw04 AA + Ca   Viral persistence Thio et al., 2002 
  
*
 Ca, Caucasian; J,Japanese; CH, Chinese; Afn, African; AA, African American; WA, West Africans 
Table 3:  The associations of HLA Class I alleles and outcome of HCV disease, where available, eth-
nic groups, HCV genotypes and epitope regions have been included.   
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HLA TYPE II ETHNIC 
GROUP* 
HCV 
GENO-
TYPE 
HCV DISEASE REFERENCE 
DRB DQB1         
1*11 *03 Ca  1a Spontaneous recovery Day et al., 2002 
1*04, 1*10 *01, *03 Ca 1a Spontaneous recovery Day et al., 2002 
1*04, 1*08 *03 
  
Ca 1a Spontaneous recovery Day et al., 2002 
1*1104, 3*0202 *0301   Serotype 
1 
Spontaneous recovery Schulze zur Weisch, 2005 
1*0401, 1*1001 
4*01 
*0301 
*0501 
  Serotype 
1 
Spontaneous recovery Schulze zur Weisch, 2005 
1*0801, 1*0404 
4*0101 
*0301 
*0302 
  Serotype 
1 
Spontaneous recovery Schulze zur Weisch, 2005 
1*1101 *0301     Spontaneous recovery Harcourt et al., 2004 
1*0402, 1*0701   3 Sustained response Sarobe et al., 2006 
1*0101, 1*0701   3 Sustained response Sarobe et al., 2006 
1*1302, 1*1601   3 Non-responder Sarobe et al., 2006 
DRB1 DPB1 DQB1     
  
ND 
  
1a 
  
  
3a 
  
  
1a 
  
1a 
  
  
Self-limited hepatitis 
  
  
Chronic hepatitis 
  
Self-limited hepatitis 
  
Self-limited hepatitis 
  
Self-limited hepatitis 
  
  
Lamonaca et al., 1999 *17 
*1101 
*0201 
*1401 
*0301 
*0603 
*0311 
*1101 
*02012 
*3401 
*0201 
*0301 
*0407 
*1104 
*0401 *0201 
*0301 
*1109 
*0305 
*0201 
*0301 
*0201 
*0301 
*0801 *01011 
*0401 
*0501 
*0402 
*0801 
*1501 
*0401 *04 
*0602 
  1b chronic  Lamonaca et al., 1999 
DRB1 DQA1 DQB1   
  
  
Ca 
Ca 
Thai, Ca 
(German) 
  
 Ca 
  
  
  
AA 
Ca (German) 
  
  
  
  
  
  
  
  
  
  
  
  
Clearance 
Chronic 
Chronic/persistent 
  
  
 Clearance, response to IFN/
ribavirin 
  
Clearance, response to IFN/
ribavirin 
Viral clearance  
  
  
  
Wawrzynowicz et al., 2000 
Thursz et al., 1999 
 Hohler et al., 1997 
Vejbaesya et al., 2000 
Harcourt et al., 2001; Minton et 
al., 1998 
  
 
Donaldson, 2004 
  
Hohler et al., 1997 
    *0301 
*1501 *01 *0602 
*0701 *0201 *02 
*0301     
  
  
  
*1101   *0301 
 *1301     
DR5 
DRB1*11 
DQ3 DQB1*0301 Ca 1a, 1b, 
2a, 2b, 3a 
Clearance Tillmann et al., 2001 
DR13   J   mild Aikawa et al., 1996 
DRB1*0405 J 
Ch 
  Severe/chronic 
No response to therapy 
Aikawa et al., 1996 
DRB4*0101 Ca   Chronic/persistent Thursz et al., 1999 
  
DQB1*03 J, Ca (French + 
Europe), AA 
  Viral clearance   
DQB1*04 J, Ca (North 
Europe + Po-
land) 
  Chronic/persistent   
*denotes, Ca= Caucasian, J= Japanese, AA= African American, Ch=Chinese  
Table 4.  The associations of HLA Class II alleles and outcome of HCV disease, where available, 
ethnic groups, HCV genotypes and epitope regions have been included.   
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1.6.3. THE ADAPTIVE IMMUNE RESPONSE 
Peptides associate with HLA and this complex of peptide-HLA is presented to CD4+ 
or CD8+ T-cells.  When there is no recognition, there is no signal. The CD4+ TH 
cells act as immunoregulators because they respond to non-self peptides by secret-
ing lymphokines that direct and support the proliferation of memory CD8+ CTL im-
mune response, (Fig.8 TH 1 cytokines: IL-2, IFN-gamma, TNF-alpha) or B-cells neu-
tralizing antibodies (Fig.8 TH 2 cytokines: IL-4, IL-5, IL-10, IL-13)  (Mosmann and 
Sad, 1996).  The virus enters the hepatocytes using the claudin-1 protein and the co
-receptor CD81, internalising viral antigen which is presented to the MHC-class I 
molecule (HLA-A, B or C molecules).   
 
Like other viral infections, the CTL response can clear HCV by either direct or indi-
rect cytolysis. The former involves molecular proteins (FasL) and enzymes (caspase
-8) (reviewed in Kanto and Hayashi, 2006) together with the release of perforin and 
granzyme B while the latter uses non-cytolytic mechanisms involving cytokines and 
their co-receptors (Fig.8).  IFN-gamma suppresses HCV replication and decreases 
HCV viral load (Thimme et al., 2002).  CCR5 and RANTES were found to be 
upregulated in HCV chronic infection (Promrat et al., 2003), as reported for HIV-1 
infection.  
 
In HCV infection, CD4+ T-cell responses are short-lived (Day et al., 2002), while 
CD8+ T-cell responses are elevated in the acute phase but decrease as viral persis-
tence develops (Lechner et al., 2000) and the humoral B-cell response (particularly, 
NAb) remains ineffective in controlling viraemia (reviewed in Zeisel et al., 2009).   
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1.6.3.1. Humoral Response (TH2- antibody response) 
NAbs appear several weeks after infection (Battegay et al., 1993).  The core, E2, 
NS3, NS4B and NS5A peptides were identified as immunogenic proteins in chronic 
infection with HCV genotypes 1, 2, 3 and 4 (Sillanpaa et al., 2009). However,  E1 
and particularly E2 peptides seem to produce NAb responses (Zeisel et al., 2009). 
During acute infection, cellular immune responses increase and then decrease and 
lose function (Osburn et al., 2010) and then NAbs appear.  In chronic infection, 
Fig.8. The processes involved in the adaptive immune response when HCV infects the antigen-
presenting cell (APC) and the hepatocyte (adapted from Freeman et al., 2001) .  The class II-
restricted Th cell response: (i).  Induces virus –specific CTL (Th1 pathway promoted by Th1 cyto-
kines [IL-2, IFN-gamma] and (ii) helps HCV-specific B cells (Th2 pathway) promoted by Th2 cyto-
kines [IL-4, IL-5, IL-10] and (iii) to produce neutralizing antibodies.  The anti-viral CD8+ CTL re-
sponse: ( iv) identifies and kill virus-infected cells through recognition of endogenously synthesized 
HCV antigen presented to HLA class-I molecules at the hepatocyte membrane and (v) they inhibit 
replication by secretion of the cytokines IFN- and TNF- triggering their target hepatocyte mem-
brane to undergo apoptosis. 
(DC, macrphages, 
Kuppferr cells) 
(iv) 
(iii) 
(ii) 
(i) 
(v) 
Claudin-1 apoptosis 
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weak cellular immune responses with cross-reactive NAb responses was evident 
(Lechner et al., 2000).  The delayed humoral response in chronically infected indi-
viduals drives viral escape (Zeisel et al., 2009).  While the role of NAbs during re-
infection is not fully understood, cross-reactive NAbs in patients with frequent re-
infections were seen, indicative that the humoral responses are primed to generate 
broadly NAbs (Osburn et al., 2010). 
 
1.6.3.2. Cell-Mediated IR  
An ineffective response is reflected when CD4+ and CD8+ T-cell responses are 
weak or even absent while viraemia persists (Fig. 9a). These proliferative responses 
are important to control infection but the breadth of these responses is  vital for viral 
clearance.  Breadth is measured as the number of HLA-restricted epitopes to which 
the T-cell can bind.  CD4+ T-cells recognize as many as 14 different epitopes pre-
sented by the MHC class II-complex (Day et al., 2002). In patients with chronic in-
fections, very few MHC class II epitopes are targeted in contrast to individuals that 
resolve infection, reflecting the ineffective response.  Weak anti-HCV CD4+ re-
sponses correlate with viral persistence (Thimme et al., 2002, Fig. 9a,b) while good 
responses correlate with viral control and clearance (Fig.9c). 
 
The CD8+ CTL responses are the best characterized and have been found to be 
variable in acute and chronic infection.  A sustained vigorous response during acute 
infection  correlates with viral clearance (Chang, 2003, Fig.9c).  CD8+ CTL re-
sponses have been shown to peak with increased ALT levels (Tillman et al., 2001, 
Fig.9b, c).  Strong CD8+ T-cell responses that target many MHC-class I restricted 
epitopes have been associated with good immunity as compared to poor responses 
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to fewer epitopes which may lead to viral persistence (Grakoui et al., 2003,).  How-
ever, the lack of memory T-cell induction in cross challenge studies have shown that 
CD8+ T-cells fail in their function during HCV infection (Farci et al., 1995).  This is 
due to broad viral diversity and escape from the immune system (Encke et al., 2007, 
Fig.9d).   CD8+ T cells localized to the liver protect from re-infection as they are ca-
pable of rapid expansion (Shoukry et al., 2003). Antibody depletion of CD8+ and 
CD4+ T-cells (Fig.9d) results in persistent viraemia until memory CD8+ T-cell re-
sponses are restored in the liver (Shoukry et al., 2003). 
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 Fig.9.  CD4+ and CD8+ T-cell re-
sponses during progression or clear-
ance of HCV infection.  (a) Viraemia 
rises early and then falls but is still 
present throughout infection.  CD4+ 
and CD8+ T-cell responses are weak 
or even absent and serum transami-
nases are present. (b) CD4+ and 
CD8+ T-cell responses are stronger 
and associated with transient control 
of viraemia, with a rise in serum 
transaminases.  T-cell responses are 
not maintained and viraemia re-
bounds in persistent infection.  CD8+ 
T-cell responses may persist during 
persistent viraemia. (c) Although vi-
raemic at early stages, CD4+ and 
CD8+ T-cell responses are strong 
and maintained.   Serum transami-
nases rise and viraemia decreases, 
with possible rebound before clear-
ance. (d)  Experimental data on chal-
lenge studies on monkeys with HCV, 
indicating the decline of CD4+ and 
CD8+ T-cell responses over a period 
of time, providing a means for virus 
escape and persistence of infection 
(Bowen and Walker, 2005). 
  
d 
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1.7. CLINICAL FEATURES 
Most studies have reported that cirrhosis develops in 10%-20% of persons with 
chronic hepatitis C over a period of 20-30 years, and HCC in 1%-5%, with striking 
geographic variations in rates of this disease. Persistent HCV infection is the cause 
of 70% of HCC cases in Japan (Yoshizawa, 2002).   
 
1.7.1 Acute infection  
The incubation period for acute hepatitis C averages 6 to 10 weeks (WHO, 2002).  
Most persons (~80%) who develop acute hepatitis C have no symptoms (Mast et 
al., 1999, Fig. 10). The onset of disease is usually insidious, with anorexia, vague 
abdominal discomfort, nausea and vomiting, fever and fatigue, progressing to jaun-
dice in about 25% of patients. Jaundice is less frequent in hepatitis C than in hepati-
tis B virus (HBV) infection (Marcellin, 1999).  Severity ranges from asymptomatic 
(75% of infections) to rapid, fulminant liver failure. Spontaneous elimination of the 
virus is rare and 70 – 90% of infected people fail to clear the virus during the acute 
phase of the disease and become chronic carriers (Fig. 10; WHO, 1999). Anti-HCV 
antibody is not always present when the patient presents with symptoms. It may 
take 10 weeks or more from the time of infection to develop detectable antibodies to 
HCV (MMWR, CDC Report, 1997; Fig. 11a). However, HCV RNA may be detect-
able in serum as early as 1-3 weeks after exposure. The silent clinical nature of 
HCV infection may account for the large reservoir of infected persons.  
 
1.7.2  Chronic infection 
Chronic hepatitis is diagnosed when disease continues, without improvement, for at 
least six months (Fig. 11b).  Chronic hepatitis C is not a single disease, but rather a 
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complex clinico-pathological syndrome with multiple causes and varying stages of 
necro-inflammatory and fibrosing liver damage.  This complexity leads to different 
prognoses. Persistent or fluctuating ALT elevations (MMWR, CDC Report, 1997; 
Fig.11b) may indicate active liver disease while the remaining 30-40% may have 
normal ALT levels. No clinical or epidemiologic features among patients with acute 
infection have been found to be predictive of either persistent infection or chronic 
active liver disease (MMWR, 1998).   
Fig.10.  A flow diagram representative of the various stages of HCV mono-infection in humans, from 
acute to progressive disease (adapted from MMWR, 1998).  HIV and/or other co-factors, for exam-
ple, alcohol abuse, will increase the risk of disease progression. 
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Fig.11. Serologic Pattern of Acute HCV Infection with (a) Recovery and (b) progression to Chronic 
infection (adapted from MMWR, CDC Report, 1997) 
 
1.7.3  HCV/HIV co-infection 
Studies have shown that people infected with HIV have increased levels of HCV vi-
raemia and the risk of cirrhosis (Pol et al., 2002).  The exact mechanism for the 
pathogenesis of HCV in HIV-infected persons is not fully understood but, since HCV 
has not been shown to be cytopathic, the liver injury associated with chronic liver 
disease may be related to the host immune system (Sterling et al., 2003).  Patients 
with CD4 counts below 200 cells/µL have an increased risk of severe liver disease 
in co-infection (Graham et al. 2001; Goedert et al. 2002) and it has been postulated 
that marked decrease in the CD4 cell count may result in selection of HCV quasis-
pecies with increased cytopathogenicity (Pol et al., 2002).  HIV itself may have a di-
rect cytopathic effect on liver cells or may upregulate (or downregulate) cytokine 
production leading to severity of liver disease (Pol et al., 2002).  
1.7.4.  HBV/HCV co-infection 
HBV and HCV co-infection is more common in areas where both viruses are en-
demic (Jamma et al., 2010), like Japan, where 23% of HBsAg-positive patients were 
found to anti-HCV positive (reviewed in Liu and Hou., 2006).  In SA, very little is 
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known of HBV/HCV co-infection but this may because of poor collation of data in the 
past. 
 
1.8. DIAGNOSTIC TESTS FOR HCV  
There are several markers that can be used to detect HCV infection: indirect and 
direct markers, indicating presence of antibody to HCV or the presence of the virus 
itself, respectively.  Table 5 summarizes the various tests for the detection, quantita-
tion and genotyping of HCV.   
Table 5.  A summary of the diagnostic and research tests for the detection of HCV antibody, RNA 
and genotypes.   
 Test Purpose Comments Reference 
Serology (Anti-HCV) 
  
Screening tests for HCV anti-
body (indirect marker) by EIA 
or RIBA 
  
Most widely available and 
cheap test 
Uses core, NS3/4/5 proteins 
High sensitivity (99%) – 3rd 
generation EIA. 
Indicates past or present 
infection. Detects anti-HCV in 
80% of patients within 5-6 
weeks of onset of hepatitis. 
Late seroconversion can oc-
cur. Screen in high preva-
lence populations 
High false-positive rate 
for EIA in low prevalence 
populations and in those with 
autoimmune disorders.  A 
positive result needs confir-
mation by NAAT 
Aoki et al., 1996 
Richter, 2002 
Serotyping Serotyping HCV 1-6 by EIA Use of NS4 peptides 
Average sensitivity (85-90%) 
when compared to molecular-
based genotyping tests 
Difficulty to subtype and de-
tect mixed infections 
Chemello et al., 1994 
Prescott et al., 1997 
Core antigen Detection and quantification  
of core antigen by EIA 
Less sensitive than molecular 
PCR tests 
Lower limit of detection is 
20000IU/ml 
Takahashi et al., 2005 
  
Qualitative PCR 
· PCR 
Polymerase chain reaction 
  
Detect presence or absence 
of virus. 
Detects virus 1-3 weeks after 
exposure. Detection of HCV 
RNA during course of infec-
tion may be intermittent. A 
single negative PCR is not 
conclusive.  Repeat test or 
repeat anti-HCV. 
False positive and false nega-
tive results can occur from 
improper handling, storage, 
and contamination of test 
samples. 
Amplicor HCV qualitative test 
has high sensitivity and speci-
ficity (95%), lower limit of 
detection is 50IU/ml. 
Used at the NICD 
  
Gretch et al., 1992 
Lee et al., 2000 
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Quantitative tests 
· PCR 
· Viral load 
Determines titer of HCV 
To monitor patients on antivi-
ral therapy 
Should preferably not be 
used to confirm or exclude the 
diagnosis of HCV or to moni-
tor treatment end point. 
Taqman has high sensitivity, 
with lower detection limit of 
15IU/ml. Easy, quick and 
reproducible but expensive.  
No/little cross contamination 
as all steps in one tube.  Used 
for patients on therapy.  Used 
at NICD 
Kawai et al., 1999 
Aoki et al., 1996 
Gretch et al., 1995 
MMWR, CDC reports, 1997, 
2008 
  
  
TMA- Transcription-mediated 
amplification 
Amplifies HCV RNA by T7 
RNA polymerase  
Good correlation with other 
PCR tests.  Lower limit of 
detection is 5IU/ml. 
Krajden et al., 2002 
Ross et al., 2001 
Genotype 
- LiPA 
  
Recommended when consid-
ering therapy regime and 
management 
LiPA is a nitrocellulose dot 
blot assay, quick and easy 
Can detect mixed infections. 
Poor differentiation of geno-
types 1a and 1b in 5’UTR but 
can use core + 5’UTR ver-
sion. Lower limit of detection 
is 1000IU/ml. 
  
Andonov and Chaudhary, 
1995 
Roque-Afonso et al., 2002 
Buoro et al., 1999 
Verbeeck et al., 2008b 
Noppornpanth et al., 2006b 
Genotype 
- sequencing 
  
Uses the 5’UTR to genotype 
HCV 1-6 and less conserved 
regions, core and/or the NS5B 
for subtyping. 
Sequencing – gold standard, 
highly specific and sensitive 
for all genotypes. Phyloge-
netic analyses groups isolates 
into 6 genotypes based on 
genetic differences. Lower 
limit of detection is 1000IU/ml. 
Specialized technique, time 
consuming, available as diag-
nostic and research tool at the 
NICD. 
  
Simmonds et al., 1993a,b, 
1994b, 1996, Chen and 
Weck, 2002 
Kalinina et al., 2002 
Accapezzato et al., 2002; 
Ohno et al., 1997, Ohno and 
Mizokami,1999 
Genotype 
- real-time Lightcycler 
  
  
specific primers and hybridi-
zation probes in the 5’UTR for 
amplification and detection of 
point mutations using tem-
peratures at which 50% of 
probe-target duplexes sepa-
rate (Tm). 
  
  
No/little cross contamination 
as all steps in one tube. 
Quick and easy but expen-
sive. 
Lower limit of detection is 
10000IU/ml. Does not differ-
entiate subtypes and mixed 
infections. 
  
  
Landt et al., 2002 
Yang et al., 2002 
Schroter et al., 2002 
Genotype 
- RFLP 
  
  
detection of amplicons frag-
mented by restriction endonu-
cleases at specific sites of 
nucleotide sequences. Re-
striction patterns are visual-
i s e d  o n   a g a r o s e /
polyacrylamide gels. 
  
  
Time-consuming, no commer-
cial kit available, trial and 
error with restriction enzymes, 
contamination is moderate to 
high does not effectively 
separate the subtypes of 
genotype 1 specimens 
(1a/1b).  Sensitivity compara-
ble to PCR and sequencing 
(92%). 
  
  
Davidson et al., 1995 
Pohjanpelto et al., 1996 
Buoro et al., 1999 
Genotype 
- Trugene 
  
  
Genotyping kit based on se-
quence analysis of the 5’UTR 
region 
  
  
Trugene sequencing has 
100% specificity and 97% 
sensitivity when compared to 
LIPA, reproducible and rea-
sonably rapid (<5hours), sub-
typing results was often mixed 
  
  
Halfon et al., 2001 
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Genotype 
-heteroduplex 
tracking analysis 
(HTA) 
  
  
Uses E1 and E2 genes 
Genetic relatedness is esti-
mated by calculating the de-
gree of migration in high-
resolution gel electrophoresis 
and compared to homoduplex 
controls. 
  
  
  
E1 HTA studying HCV trans-
mission between individuals, 
E2 HTA for tracking HCV 
quasispecies evolution in an 
infected individual, effective 
and inexpensive molecular 
technique for screening HCV 
heterogeneity, time consum-
ing, contamination is moder-
ate to high, works well if viral 
load is high 
  
  
Gretch et al., 1996 
Gerotto et al., 1999 
Sullivan et al., 2001 
 
1.8.1.  Phylogenetic analyses 
The measurement of sequence changes, either nucleotide or amino acid, can be 
performed by phylogeny, using different models (revised in Lemey et al., 2009).  
The basic model, p-distance, measures the genetic distance from the ancestral se-
quence to its derivatives but is an under-estimation of genetic change.  The Jukes-
Cantor (JC69) model (Jukes and Cantor, 1969) is the simplest substitution model  
and assumes that all base frequencies and mutation rates are equal.  The Kimura-2 
parameter (Kimura, 1980) assumes that all base frequencies are equal but transi-
tions (A<->G, purine to purine or C<->T, pyrimidine to pyrimidine) and transversions 
(purine<-> pyrimidine and vice versa) occur at different rates.  The Hasegawa-
Kishino-Yano (HKY) model (Hasegawa et al., 1985) assumes that base frequencies 
are unequal and transitions and transversions occur at different rates.  The most 
complex is the general time reversible model (GTR, Tavare, 1986) and assumes 
that base frequencies are unequal and all substitution types occur at different rates 
(revised in Lemey et al., 2009).  Once a model is chosen to measure the nucleotide 
changes, an algorithm for the drawing of phylogenetic trees can be applied.   
 
The simplest and least computer-intensive method is the use of the neighbor-joining 
(NJ) algorithm that calculates the distance between two sequences, generating a 
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cluster tree (in Lemey et al., 2009).  Maximum-likelihood methods are more com-
puter intensive and time-consuming but offers a more direct way of finding a tree for 
a set of data using the probability model.  Bootstrap values on tree nodes indicate 
the repeated sampling of data and reconstruction of trees to provide support for the 
clustering of the species (sequence). Branch lengths are a measure of the amount 
of divergence between two nodes in the tree. The unit of measure (for the branches 
and scale bar) is number of nucleotide (or amino acid) substitutions per site(Kumar 
et al., 2008). 
 A rooted tree is a directed tree with an outgroup species/sequence (usually a most 
recent common ancestor, MRCA) that infers a relation to other species on the tree.  
An unrooted tree will depict the relation of all the species/sequences on the tree 
without an inference to ancestry (in Lemey et al., 2009).  The molecular clock phy-
logeny uses a rooted tree to estimate the changes from the ancestor (root) to the 
subsequent species/sequences over a unit of time (in Lemey et al., 2009).  This is 
further discussed in chapter 7. 
 
1.9. FURTHER MEDICAL EVALUATION OF HCV DISEASE 
Histological assessment such as fibrosis scores (Ishak et al., 1995), as well as other 
factors, such as quality of life, age, co-morbidity and virological factors influence the 
risk-benefit ratio of treatment and can be considered in the treatment decision espe-
cially in patients with mild chronic hepatitis or chronic hepatitis infection associated 
with normal transaminase levels (Botha et al., 2005).  However, fibrosis is not a re-
quirement for treatment (Botha et al., 2010). If liver histology is available for a pa-
tient, then treatment is considered if fibrosis is advanced (F2 or F3, according to 
METAVIR scoring system, Bedossa and Poynard., 1996) (Botha et al., 2010). 
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1.10. MANAGEMENT AND TREATMENT 
1.10.1  Drug therapy for HCV 
In South Africa, treatment should be considered in all adults with confirmed diagno-
sis of hepatitis C infection and chronic disease, especially individuals who are at risk 
of developing cirrhosis (Botha et al., 2010).  Patients with acute hepatitis C should 
be treated with standard interferon (IFN) monotherapy (Gerlach et al., 2003) or PEG
-IFN (Botha et al., 2010).    The current standard hepatitis C treatment in South Af-
rica, is weekly injections subcutaneously of PEG-IFN-, combined with twice-daily 
oral doses of the broad-spectrum antiviral agent ribavirin (800-1400 mg/day de-
pending on body weight; Botha et al., 2010). Two PEG-IFN medications are avail-
able, PEG-IFN alfa-2b (1.5 g/kg/wk; Ghany et al., 2009; Peg-Intron, Schering-
Plough) and PEG-IFN alfa-2a (Botha et al., 2005; 180 g weekly; Pegasys Roche).  
 
The rationale for treatment of chronic hepatitis are: 
 to reduce inflammation, 
 to prevent progression to fibrosis, cirrhosis and HCC in chronically infected pa-
tients through the eradication of the virus, and 
 to decrease infectivity as a means to control the spread of the disease. 
 
The following are the recommended, genotype-dependent, adult treatment dura-
tions (from Botha et al., 2005, 2010): 
Genotype 1 and 4 – 48 weeks of treatment 
Genotype 2 and 3 – 24 weeks of treatment 
Genotype 5 and 6 – 48 weeks of treatment (This treatment regimen is 
still experimental as there is not enough data available at present regarding 
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treatment outcome in HCV genotype 5  infection to meaningfully predict 
response to treatment, Botha et al., 2010)  
 
In genotype 1-infected slow responders, an extension of treatment to 72 weeks can 
be considered (Pearlman et al., 2007).  It is recommended that for those patients 
receiving continued therapy through 48-72 weeks and if HCV RNA is not detected at 
end of treatment, then retesting for HCV RNA after 24 weeks is done to determine a 
sustained virological response [SVR] (Botha et al., 2010).   
 
In genotype 2/3-infected slow responders, an extension of treatment to 48 weeks 
can be considered.  It is recommended that for those patients receiving continued 
therapy through 24-48 weeks and if HCV RNA is not detected at end of treatment, 
then retesting for HCV RNA after 24 weeks is done to determine a SVR (Botha et 
al., 2010).  
  
Approximately 40-50% of individuals infected with genotypes 1b and 4 have 
achieved a SVR (after 48 weeks of treatment) as compared to 80% of genotype 2 
and 3 infected patients after 24 weeks of treatment (Manns et al., 2001, 2006, Table 
6).  Genotype 5 (Legrand-Abravel et al., 2004; Nguyen and Keeffe, 2005) and geno-
type 6 has shown sensitivity in between genotype 1 and genotype 2/3 (Hui et al., 
2003, Table 6), although data for these studies have been small and limited.   Re-
cently it has been reported that genotype 3 infections are associated with lower sus-
tained virological responses than genotype 2 infections (Powis et al., 2008).  
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HCV genotype 
  
  
HCV subtypes 
GT2 and GT3 are more sensitive to treatment than GT1 or 
GT4 and GT5 appears to be intermediate between GT1 and 
GT2 and GT3.  (Nguyen and Keeffe, 2005) 
1b, 4a or 4d may respond better to therapy as compared to 
those with subtype 1a (Legrand-Abravanel et al., 2009a) 
HCV viral load Treatment is more effective at viral loads <400 000IU/ml 
Early treatment response rates were better when therapy began within 12 
weeks of diagnosis (Corey et al., 2010) 
Young age <40 years (Ghany et al., 2009) 
Gender Female 
Race Treatment was found to be less effective in African-
Americans (Donlin et al., 2007) 
Amount of liver damage and steato-
sis 
less effective with cirrhosis and steatosis 
Genotype and liver damage Patients with GT3 and cirrhosis respond less well to therapy 
than those with GT2 and cirrhosis (Powis et al., 2008). 
HIV status Less effective in HIV co-infection 
Adherence to therapy Full dose of ribavirin and PEG-IFN at least 80% of the time 
Body weight Less effective for people who weigh more than 75kg (Ghany 
et al., 2009), obesity is a risk factor for steatosis 
Effective management of side ef-
fects 
Neutropenia, thrombocytopenia, depression and anaemia 
(Botha et al., 2005). 
insulin resistance Poor prognosis if present (Ghany et al., 2009) 
Table 6.  Predictors of good and poor responses to HCV therapy 
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1.10.2   HCV/HIV co-infection and treatment 
Management of HCV/HIV co-infection is complex in South Africa and the infected 
individual should be referred to a specialist for appropriate treatment and manage-
ment.  HIV drugs, like Didanosine (DdI) and zidovudine (AZT) can interact with ri-
bavirin and causes lactic acidosis, pancreatitis and the risk of liver failure in people 
with advanced cirrhosis with the increased risk of anaemia (Brook et al., 2010). It 
was indicated that highly active antiretroviral therapy, or HAART, has been related 
to histological deterioration, direct viral cytotoxicity or increased drug hepatotoxicity 
(Pol et al., 2002).  Although, PEG-IFN and ribavirin have proved to be effective in 
HIV/HCV co-infected persons (Chung et al., 2004), further ongoing studies on long-
term effect on outcome and survival need to be done. 
 
Some of the newer drugs that are currently in phase 1 trials include: 
• Specifically Targeted Antiviral Therapy for hepatitis C (STAT-C) antivirals drugs 
directly target enzymes required for HCV replication and production of new virions
(April 2009)  
• polymerase inhibitors: ABT-072 (December 2009) and MK-3281 (November 
2009); RG7128 (April 2009) 
• Clemizole (August 2009) is an NS4B inhibitor 
• Protease inhibitors: ACH-1625 (June 2009) and RG7227(April 2009) 
(summarized in Rodriguez-Torres, 2010; Franciscus, 2010) 
 
1.11.  PREVENTION AND CONTROL 
The major objectives of Hepatitis C prevention and control are: 
 to reduce the number of new infections through prevention of transmission 
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 to identify cases early in order to minimize the risk of disease progression 
 to educate all high-risk individuals 
 to implement infection control practices to limit spread in nosocomial setting 
 to introduce needle exchange programmes and educate public to reduce the 
spread of HCV, HBV and HIV in South Africa 
 to caution HCV-positive mothers to refrain from breast feeding if nipples are 
cracked or bleeding.   
 
To date, there are no effective vaccines or immunoglobulins available for the treat-
ment and prevention of HCV infection.  However, there are currently two therapeutic 
peptide vaccines undergoing phase II trials: IC41(Intercell) and GI-5005(Tarmogen, 
Globe Immune) and one DNA-based therapeutic vaccine, ChronVac-C (Onovio/
Tripep),  undergoing phase I studies on for genotype-1 infected individuals  
(Franciscus, 2010). 
 
The literature has pointed out that many studies have focused on genotypes 1a and 
1b as these account for the majority of infections in the developed countries.  The 
purpose of this thesis was to gather information on HCV prevalence and the geno-
type distribution in different study groups, describe the molecular characteristics, 
particularly of genotype 5a, predominantly seen in South Africa, determine binding 
efficiencies of putative vaccine epitopes to prevalent HLA alleles in the SA popula-
tion and establish the response to therapy in patients with genotype 5a. The present 
study has endeavored to: update information on HCV in SA, improve the notification 
and surveillance reporting, allow informed decisions when planning preventative and 
treatment strategies and increase public awareness/education. 
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1.12. STUDY OBJECTIVES 
(1)  RATIONALE OF THE STUDY 
Although South Africa is a low-endemic region for HCV infection, the contribution of 
HCV to liver disease in the country is unknown as HCV testing has been limited and 
surveillance systems are lacking.  It remains imperative that the most rapid and reli-
able tests are available and validated for accurate diagnostic screening and geno-
typing. The establishment of baseline data is pressing in South Africa since the im-
pact of immigration and travel may contribute to changing frequencies of genotypes 
in the country. Well designed databases will allow informed decisions when planning 
preventative and treatment strategies relevant to local viral and host genetics. The 
major aim of this project was to characterize South African HCV strains so as to pro-
vide valuable epidemiological information and to select suitable vaccines and thera-
peutic strategies in the future.  
 
(2)  SPECIFIC OBJECTIVES 
(a) To establish a national HCV database for the public sector, validate and opti-
mize methodologies to determine baseline prevalence of HCV, including the 
occurrence and frequency of the various genotypes, in available South Afri-
can cohorts. 
(b) To evaluate rapid techniques for genotyping HCV (by real-time PCR and by 
line probe assays) using specimens well characterized by PCR and se-
quence analysis.  
(c) To add local genome sequence data to the global HCV database and to 
study the phylogenetic relatedness of these data. 
(d) To molecularly characterize the unique and poorly studied HCV genotype 5 
67 
strain because this is the most prevalent genotype in South Africa. 
(e) To use the inferred consensus amino acid sequence of the genotype 5 HCV 
to map immunodominant regions in the context of host genomics (eg. HLA) 
and thus provide baseline information for therapeutic and vaccine strategies. 
(f) To quantitatively describe the response rates (in weeks) of patients infected 
with a genotype or mixed genotypes of HCV to combination therapy.  
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CHAPTER TWO 
Establishing the framework for better HCV diagnosis, data collection 
and management in SA 
 
2.1. INTRODUCTION 
Although Hepatitis C is one of the notifiable diseases in SA, there were only two 
cases reported to the National Department of Health (NDoH) during 2008-2009 
(Statistics notes,  http://www.doh.gov.za/facts/index.html, November 2009).  This 
poor reporting and almost total lack of information on HCV and its contribution to 
liver disease in South Africa was the driving force behind this study.   Developed 
countries, like the UK, Europe and USA have established surveillance databases to 
facilitate the notification of hepatitis diseases, improve management and treatment 
of diagnosed cases, and raise public and clinician awareness (Centers for Disease 
Control and Prevention, CDC,  2005 http://www.cdc.gov/hepatitis; Health Protection 
Agency, HPA, 2009, http://www.hpa.org.uk). 
 
Presently, HIV, tuberculosis (TB) and malaria are major health problems in SA. 
However, for diseases with low prevalence such as HCV, where “prevention is bet-
ter than cure”,  focus and organization are lacking.  Systems to identify, control and 
treat HCV infection in order to prevent the development of its serious chronic seque-
lae, cirrhosis and HCC and their subsequent burden on health care costs later do 
not exist.  The NHLS can provide this framework as it provides diagnostic laboratory 
services to over 80% of the population through approximately 265 laboratories 
(National Health Laboratory Services, NHLS Annual report, 2009-2010, http://
www.nhls.ac.za). 
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Previous reports on hepatitis C have focused mainly on serological tests and few 
performed molecular analyses and even these did not use more modern viral load 
and sequencing methods (Smuts and Kannemeyer, 1995; Tucker et al., 1997).  Al-
though antibody tests for HCV are convenient and cheap for screening large popula-
tions, the antibody test does not distinguish between active (present) or past infec-
tion.  HCV diagnosis must be confirmed by PCR and infected individuals require fur-
ther medical evaluation before therapy can be considered (Fig.6, page 42).  A nega-
tive antibody result with a positive PCR can indicate (1) an early stage of acute in-
fection prior to the development of antibodies, (2) chronic infection in an immuno-
suppressed individual or (3) a false positive RNA PCR result (Ghany et al., 2009).  
 
Reliable and early detection of HCV can facilitate an early decision to treat.  It has 
been reported that early treatment can prevent progression to chronic disease 
(Poynard et al., 2000) or, failing this, produce better response rates to therapy 
(Corey et al., 2010).  Early diagnosis, followed by counseling, enables the infected 
individual to make informed choices with respect to lifestyle [to reduce transmis-
sion], habits [to prevent exacerbating disease] and regular follow-up [treatment op-
tions, liver fibrosis stage] (Seymour, 1996). Although South Africa is a low-endemic 
region for HCV infection, it remains essential that the most rapid and reliable tests 
are available and validated for diagnostic screening.  The first cohort consisted of 
seropositive specimens from hospitals in the Johannesburg area and these were 
screened for active disease by establishing and validating  a qualitative PCR. 
 
The aim of the study was to establish a national database to record serological and 
PCR positive HCV results together with available demographic information. 
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2.1.1.  Objectives: 
(a) Confirmation of antibody seroprevalence results with nucleic acid amplification 
 testing in a large cohort of anti-HCV positive specimens from Johannes-
 burg hospitals 
(b) To determine the number of individuals infected with HCV by (i) seropreva-
 lence and (ii) PCR positive cases in the public health sector leading to the es-
 tablishment of a national HCV surveillance system. 
 
2.2. METHODS 
2.2.1.  Nucleic acid amplification test (NAAT) 
Three hundred and eight HCV antibody seropositive serum specimens were ob-
tained from provincial hospitals within the Johannesburg area (ethics clearance 
M051114, see appendix). The specimens had been sent to the laboratories of the 
NICD for routine hepatitis serology testing during the years, 2000, 2001 and 2002. 
Antibody tests were done as per routine diagnostic procedure at the NICD hepatitis 
serology laboratory.  Specimens were tested for HCV RNA by NAAT, using the Am-
plicor HCV Qualitative assay, version 2.0, (Roche Diagnostics, Germany).  The test  
was validated in our laboratory and subsequently accredited  by the South African 
National Accreditation System (SANAS) in 2004. 
 
2.2.2.  National HCV Surveillance Database 
Results for requested HCV tests are reported on the NHLS secured online labora-
tory data capture system (DISA).  In the last few years, the results from all national 
laboratories have been retrieved from DISA and captured on the NHLS Corporate 
Data warehouse (CDW, ethics clearance M060449, see appendix) (Fig.12).  The 
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hospitals in the rural and urban areas of South Africa send specimens for testing to 
an NHLS laboratory, usually in close proximity to the clinic/hospital and the re-
quested test is performed.  The results are deposited in a local repository, collated 
in a central database and acquired from CDW using specific test codes and pa-
rameters.  The HCV data is extracted from all NHLS laboratories countrywide and 
presented in an Excel format for surveillance reporting.  The NICD of the NHLS is 
an example of a laboratory that performs HCV PCR tests for hospitals/clinics in the 
following provinces: Gauteng, Mpumalanga, Free State, Limpopo and Kwa-Zulu Na-
tal.  The internal validation of the system checks each DISA entry with the entries 
received from the CDW.  Validation checks for the Western Cape Province and ex-
ternal audits on the CDW retrieval process are projected for 2011.  Although sero-
logical tests were performed prior 2007, the collation of serology data only began 
from 2007 to 2008 and the PCR data from 2004 to 2008.  All relevant data (age, 
gender, hospital/clinic, ward, test result, test date, date of specimen receipt) was 
mined on MS Excel spreadsheets and interpreted as tables and figures. 
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Hospitals/clinics
(Rural areas) NHLS laboratory 
performs
HCV tests
Hospitals/clinics
(Urban areas)
Data deposited in
local repository -
DISA
CDW-NHLSTest codes, test parameters
Database manager to extract 
data from repository
Central repository
Project manager – retrieve 
and present data
 
Fig.12.  A summarized flow diagram  to explain the data processing and capturing from the time of 
referral for HCV tests until the result is captured on the HCV National Surveillance Database by the 
project manager (student) 
2.3. RESULTS 
2.3.1.  Nucleic acid amplification test (NAAT) 
In the first part of this study, it was observed that 75% of specimens tested had 
shown concordance between serology and RNA tests. Of the 308 specimens, 232 
(75,33%) specimens were positive by serology and RNA.  Sixty-five (21,10%) were 
positive by serology and negative for RNA, indicating discordant results and re-
iterating that confirmation by PCR is necessary.  Eleven (3,57%) were positive by 
serology but showed PCR inhibition as evident  by the lack of amplification of both 
the target RNA and the internal control of the qualitative assay.  The confirmatory 
testing process has led to the next part, whereby both serology and PCR data were 
captured onto a national database. 
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2.3.2. National HCV Surveillance Database 
 
The collation process was validated for 2008 by retrieving data manually from the 
DISA system and compared to the CDW retrieval for the Gauteng province.  There 
was a 100% concordance for the data retrieval on 721 specimens (including all re-
peats) and this verifies the extraction process by CDW.  This internal validation 
process for all other provinces will proceed in 2011. 
 
There was an increase in the number of hospitals/clinics at various geographical lo-
cations nationwide that requested HCV serology and PCR tests (Fig.13).  In 2007, 
there were 175 sites nationally that requested HCV serology tests with an increase 
to 235 sites in 2008.  The number of PCR requests were fewer but increased over 
the years from 12 in 2004 to 29 in 2008 (Fig.13).  
 
Fig.13. The number of hospitals/clinics nationwide requesting HCV tests (serology and PCR) respec-
tively. 
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Table 7 summarizes the serology results for the years 2007 and 2008 and PCR re-
sults for years 2004-2008.  Although the total number of serology requests appear 
to have decreased from 2007 to 2008, there was a higher recorded HCV seroposi-
tivity in 2008 (1745/18128, 9.6%) as compared to 2007 (1371/25944, 5.28%). There 
were more males than females in the 2007 group compared to the 2008 group 
(Table 7). The mean age for the serology positive group and PCR positive group 
ranged from 37 to 47 years. Many of the individuals may have had first signs of 
chronic hepatitis, hence were referred for HCV testing as most cases of persistent 
disease are asymptomatic in the early stages.  
For this analysis, it was not indicated whether any of the samples tested serologi-
cally were tested by NAAT. Fig.14 indicates the PCR positive results for the years 
2004-2008, indicative of current infection. The number of PCR positives has in-
creased over the years from 43 cases (43/132, 32%) in 2004 to 195 (195/483, 40%) 
and 191 cases (191/490, 39%) in 2007 and 2008 respectively.  
  SEROLOGY   PCR 
Year 2007 2008 
  
2004 2005 2006 2007 2008 
Total No. 25944 18128 
  
132 285 342 483 490 
negative 24573 16383 
  
89 206 229 288 299 
positive 
(%) 
1371 (5.28) 1745 (9.6) 
  
43 (32.5) 79 (27.71) 113 
(33.04) 
195 
(40.37) 
191 (38.97) 
Males (%) 708 (51.6) 828 (47.4) 
  
23 (55.5) 50 (63.3) 57 (50.4) 119 (61) 114 (59.7) 
Females 
(%) 
618 (45.1) 871 (49.9) 
  
17 (39.6) 26 (32.9) 49 (43.4) 71 (36.4) 73 (38.3) 
Unknown 
(%) 
45 (3.3) 46 (2.7) 
  
3 (6.9) 3 (3.8) 7 (6.2) 5 (2.6) 4 (2) 
Mean age 
(years) 
38.8 39.9 
  
37 45 44 45 47 
No. Age 
unknown 
(%) 
99 (7.2) 108 (6.2) 
  
5 (11.6) 6 (7.4) 11 (9.7) 12 (6) 6 (3) 
Table 7.  A descriptive summary of the serology (2007-2008) and PCR (2004-2008) results  
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This probably reflects an increasing awareness of the availability of HCV tests 
among clinicians in South Africa, also indicated by the number of hospitals request-
ing HCV tests (Fig.13).   
 
Fig.15 indicates the number of cases positive by PCR per province for the years 
2004 to 2008.  Gauteng had the most HCV PCR positive cases (67%), followed by 
Western Cape (22%).  The Northern Cape and North West provinces had the least 
number of cases reported (0.5%). 
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Fig.14.  Total number of HCV PCR positive cases, 2004-2008, South Africa 
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The hospitals which had the highest number of HCV seropositive cases were Chris 
Hani Baragwanath and Johannesburg Hospital (Charlotte Maxeke) in Gauteng Prov-
ince and Groote Schuur Hospital in Cape Town, Western Cape Province for 2007-
2008. These are busy academic centres and specialist clinics where one would ex-
pect referrals.  
Fig.15.  Distribution of HCV PCR positive cases by province between 2004 and 2008, South Africa 
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EC, Eastern Cape; FS, Free State; KZN, Kwa Zulu Natal; LP, Limpopo Province; MP, Mpumalanga; NC, Northern Cape; NW, North West; 
WC, Western Cape; GA, Gauteng 
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2.4. DISCUSSION 
Clearly, this study illustrates the need for confirmatory HCV RNA NAAT testing as 
recommended by CDC in order to confirm HCV active disease. Other studies on 
confirming HCV antibody tests have shown PCR or RIBA concordance to range 
from 52% (Gonzalez-Perez et al., 2004) to 79% (Kleinman et al., 2006). The PCR is 
our choice of a NAAT method over the RIBA because the PCR confirms active in-
fection and the amplicon from the qualitative PCR is used for a genotyping test 
(explained in chapter 4). The PPV of ELISA is low in areas of low HCV prevalence 
and hence a high proportion of HCV-RNA negative results were expected in this 
study.  Other reasons for a positive antibody test and negative RNA test are: tran-
sient clearance of virus in an acute infection or, more commonly, recovery from in-
fection (Ghany et al., 2009).  There are soluble factors in serum which cause inter-
ference, inhibiting the Amplicor Qualitative assay.  These specimens must be re-
tested and/or a separate/new specimen requested.  If the PCR is inhibited, then an 
alternative test, such as, the HCV core antigen test, can be used to test for viraemia, 
although with a lower sensitivity.  This study provided the basis for the recom-
mended algorithm for HCV testing in SA (Fig.6, page 42).  Without supplemental 
testing, results are unreliable. This needs to be considered when comparing older 
“serology only” studies with those using newer NAAT based technology. “True” 
prevalence rates, as indicated by PCR results, still need to be established in South 
Africa.   
 
The national surveillance database established for the storage and collation of HCV 
serology and PCR data and to which genotyping data will be added collects data 
from NHLS laboratories countrywide and thus reflects HCV positive results in the 
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public sector.  The seropositive figures for years 2007 and 2008 were higher (1371 
and 1745, respectively, than the PCR positive figures for the same years (195 and 
191 respectively), re-iterating the recommendation that antibody results be con-
firmed by NAAT.   
 
Nationally, the total number of HCV PCR positives in the public sector, was 621 over 
the 5 year period from 2004 -2008. HCV PCR prevalence does not appear to have 
increased significantly over the years but clinicians are becoming more aware of the 
availability of tests for HCV diagnosis at NHLS laboratories. Awareness of HCV 
tests is spreading to outlying areas in SA as the number of requests received from 
public hospitals in Mpumalanga and Limpopo increased between 2007 and 2008. 
HCV tests are also available at private laboratories and, after consultation with 
NICD, HCV surveillance and reporting has now also been established for the private 
health care system.  These initiatives, together with the imminent circulation of the  
NDoH guidelines for the control and treatment of HCV in SA should increase the 
number of requests for PCR to confirm seropositive results and increase the care 
and management of HCV infected individuals.  The establishment of the databases 
will facilitate better notification of the disease and allow for improved follow-up. 
 
Limitations of this study include that these data did not include data from private 
laboratories.  Insufficient clinical and patient demographic information in 30% of 
specimens (eg, ethnicity, place of residence, place of origin) including details of pos-
sible transmission risk was not provided. The NAAT confirmation study was limited 
to specimens collected from local Johannesburg hospitals because of easy trans-
port and follow-up. All molecular tests were conducted on stored frozen specimens 
and the extent of the study was confined by volume and condition of the specimens. 
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The viability of the specimen can be examined by testing the specimen for PCR am-
plification.  As these were retrospective specimens, we infer that amplification did 
not occur in some samples because the virus had lost its viability due to poor stor-
age and many freeze/thaw cycles. 
 
The continuing collation of HCV PCR surveillance data will provide the national au-
thorities with information on the current state of HCV infections in SA.  Dissemina-
tion of the information should increase national awareness and improve the rate of 
notification of positive cases.  Attempts to reduce the level of missing demographics 
include the distribution of questionnaires as part of routine surveillance. To guaran-
tee return of questionnaires, these need to be generated at the hospital/clinic site.   
However, additional challenges on the quality of data collection in our South African 
situation needs to be improved.  This may include: (i) availability of clinical staff/
translator/computer to collect data, (ii) quality checks on the data, together with stor-
age and location, (iii) electronic versus manual entries, (iv) telephonic/email/online 
surveys not practical in SA, (v) high number of patients lost to follow-up. 
 
In South Africa and elsewhere, (Verbeeck et al., 2008a) very little is known of the 
possible risk factors for HCV. Presumably, as with western countries, intravenous 
drug use (predominant in young adults; EHRN, 2007), haemodialysis, sexual or in-
trafamilial transmission (Verbeeck et al., 2008a), tattooing, piercing and other tradi-
tional markings may be ways of acquiring HCV in South Africa.  However, education 
in the form of surveillance reports, HCV awareness campaigns, information pam-
phlets and questionnaires will help to inform the public of transmission risks and en-
courage change of lifestyle habits and improve prevention and treatment options. 
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HCV is a disease that can be cured if patients respond to therapy.  Patients with 
genotypes 2 and 3 have a better chance of clearing the infection on combination 
therapy (section 1.10 , chapter 1).  We recommend that genotyping and hence, 
early treatment be provided for all HCV PCR positive patients to reduce transmis-
sion and the burden of hospital costs.  Ongoing genotype and regular viral load sur-
veillance will clarify the level of response to therapy in patients with less-studied 
genotypes in SA, for example, genotypes 4 and 5. Genotypes will be added to this 
national database.  This will enable monitoring of the changing frequency of geno-
types in the country over time and across sentinel groups. Various cohorts of further 
high-risk study groups, for example, prisoners and HIV positive individuals will be 
sourced, tested and added to the database.  It seems important that HCV-PCR is 
performed on all HIV+ samples, since antibodies can be absent, as indicated in the 
recommended algorithm for HCV testing in SA (Fig.6, page 42).  The national HCV 
surveillance system will report regularly to the NDoH, providing baseline data from 
new HCV positive cases in the different sentinel groups. The positive outcomes of 
this system include: 
(1) serial data which can be used to measure the epidemiological impact of the 
disease in the country 
(2) contributions (specific for our genotypes and population groups) to the National 
Guidelines for the Prevention and Control of Hepatitis C Virus in South Africa 
(3) recommendations to all health authorities on the notification of HCV disease 
(4) recommendations for drug subsidies enabling early treatment (estimated costs 
in Canada from time of diagnosis is $39000/per patient, with 30% of costs related to 
liver disease, Nguyen et al., 2008) 
(5) increased awareness and education to the public 
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(6) provide information to reduce transmission and for early cure before the devel- 
opment of cirrhosis and HCC 
 
2.5. CONCLUSION 
We have shown that PCR is a reliable test for confirming a positive HCV antibody 
result.  In future, all seropositive HCV tests should be confirmed as recommended in 
the National Guidelines for the Prevention and Control of Hepatitis C Virus in South 
Africa (final draft, 2010).  Like other surveillance systems in England, Scotland and 
the US, we have established a national database recording the results of HCV serol-
ogy and PCR positive cases in SA.  Information is being used to make national 
health authorities aware of HCV prevalence, plan preventative and treatment strate-
gies, increase public awareness/education, reporting (notification) and finally to be 
better able to calculate the burden of HCV disease in SA.  The availability of routine, 
reliable and validated methods of HCV detection, together with better surveillance 
strategies and concomitant collection of patient demographic data and database 
management, is vital to ensure patient treatment and disease management in South 
Africa. 
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CHAPTER THREE 
 
Hepatitis C Virus genotype surveillance in three SA sentinel study 
groups 
 
 
3.1. INTRODUCTION 
Genotyping of HCV is the first line in determining a beneficial treatment regime, but 
it also provides information on global and local patterns of strain epidemiology and 
surveillance.  There have been limited HCV genotyping studies in South Africa. The 
first of these used 5’UTR RFLP to determine genotypes of patients with chronic re-
nal failure and liver disease in Cape Town and blood donor groups from KZN, JHB 
and Western Cape (Smuts and Kannemeyer, 1995). Overall, genotype 5 (51/130; 
39%) was found to be the predominant genotype in all of the blood donor and pa-
tient study groups.  This was followed by genotype 1 (43/130; 33%), genotype 2 
(18/130; 13%), genotype 3 (10/130; 7%) and genotype 4 (3/130; 2%). Five (3.8%) 
specimens could not be typed.  A study on HCV-seropositive patients with liver dis-
ease at Ga-Rankuwa Hospital, northwest of Pretoria, South Africa also used the 
5’UTR RFLP method (Sithebe et al., 1996). The predominant genotype in this study 
group was genotype 2 (9/26; 35%), followed by genotype 5 (8/26; 31%) and geno-
type 1 (2/26; 8%).  A high percentage, 26.9% (7/26), of this small group was re-
ported untypable.  Although only two of the seven HCV-infected HCWs in the Var-
das et al. (2002) study were typed, they too were found by RFLP analysis to be in-
fected with genotype 5. 
 
Only one study in SA (Smuts and Kannemeyer, 1995) determined genotypes in the 
blood donor group.  The volunteer blood donors are a group at low risk of blood-
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borne infections for example, HCV (Vermeulen et al., 2009).   South African blood 
units were first screened in pools of 8 in November 1992 by anti-HCV testing but the 
South African National Blood Service (SANBS) policy changed thereafter to provide 
individual unit testing with NAAT (Chiron Procleix Tigris system) in October 2005 
(Vermeulen et al., 2009).  Since 2005, there have been no new cases of transmis-
sion of HCV via blood products from SANBS.   
 
The aim of this study was to determine the prevalence of HCV genotypes in three 
study groups, two hospital-based groups (haemophiliacs (H) and patients diagnosed 
with liver disease, (LD) during two time periods, 2000–2002 and 2007) and a volun-
teer blood donor group (BD during 2006-2008).   
 
3.1.1.  Objectives: 
(a) To genotype HCV in the two hospital-based patient groups over two time pe-
riods (2000-2002 and 2007, respectively) and a volunteer blood donor group 
(2006-2008) by 5’UTR sequencing-based technique (SBT)  
(b) To compare and validate the sequencing results from the 5’UTR to those 
from the NS5B region in available specimens from same patient groups 
above 
 
3.2.  METHODS 
3.2.1. Hospital-based patient specimens 
The study was retrospective and approved by the ethics committee of the University 
of the Witwatersrand, Johannesburg, South Africa (WITS HREC M051114, see ap-
pendix), and was therefore performed in accordance with the ethical standards of 
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the 1964 Declaration of Helsinki.  A total of 308 specimens were collected from a 
local Johannesburg hospital, Charlotte Maxeke Johannesburg Academic Hospital. 
Sera were numbered in our laboratory and stored at -70 0C. All molecular tests were 
conducted on stored frozen specimens and the extent of the study was limited by 
volume and condition of the specimens.  Fifty-three specimens were excluded due 
to volume and condition.  Since patient specimens were tested for HCV-specific an-
tibody at external diagnostic laboratories in the region, the storage and transport 
conditions of the specimens, prior to receipt in the laboratory, have not been rigor-
ously documented. Data on clinical presentation, diagnosis and demographics for 
each patient was limited to the availability of data captured from request forms.  
Specimens with incomplete demographic data (N = 70) were excluded from the 
study (Strobe statement; Vandenbroucke et al., 2007). Patients with chronic liver 
disease (CLD) were divided into two groups based on time of attendance at the liver 
clinic. The first cohort of HCV antibody-positive specimens was collected during the 
period 2000–2002 (LD1), and the second 5–7 years later in 2007 (LD2). Haemo-
philiacs (H) were grouped together as a single cohort.  The number of PCR-
confirmed HCV cases in the laboratory determined the sample size of each group.   
 
One hundred and eighty-five hospital-based specimens in total [45 H, 67 LD1 and 
73 LD2] were sequenced in the 5’UTR region. Specimens collected during the ear-
lier 2000–2002 period (H = 15, LD1 = 67) were additionally subtyped in the NS5B 
region. At the beginning of the study, we validated our choice of the two regions for 
phylogenetic analysis by constructing histogram plots of the frequency versus the 
distribution of relevant ranges of the pairwise distances between specimens of the 
2000–2002 study group together with representative GenBank specimens.   
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3.2.2. Specimens from volunteer blood donors (BD 2006-2008)  
Specimens were obtained from SANBS during the years 2006 [N=20] and 2008
[N=155], from anonymized BD.  The specimens were collected from all provinces in 
the country and tested for the presence of HCV antibody at SANBS.   Each speci-
men received a unique laboratory number and once received at NICD, the sera 
were stored at -700C until required for viral load and genotyping tests.  Eighteen of 
the twenty specimens in the 2006 collection and 100 of the 155 specimens collected 
in 2008 were PCR positive.  A total of 118 specimens from the blood donor group 
(2006-2008) was sequenced in the 5’UTR. The available demographics (age, gen-
der and ethnicity) for the group were obtained from SANBS.   
 
3.2.3. HCV RNA detection and quantitation 
HCV RNA was detected and quantified using standardized methods of qualitative 
(Cobas Amplicor HCV version 2.0, Roche Diagnostics, Germany) and automated 
quantitative RT-PCR (Cobas Amplicor HCM Monitor version 2.0, Roche Diagnos-
tics, Germany). Version 2.0 has been validated for accurate quantitation of HCV 
RNA without genotype bias (Lee et al., 2000). The lower limits of detection of the 
qualitative and quantitative assays are 50 and 600 international units per ml (IU/ml), 
respectively.  HCV RNA quantitation for the blood donor  group (2006-2008) was 
performed with the Cobas Ampliprep/Cobas TaqMan (Roche Diagnostics, Ger-
many).  The lower limit of detection for this assay is 15 IU/ml.   
 
3.2.4. Specimen extraction 
RNA was isolated from patient sera using the Magna Pure Total Nucleic Acid Ex-
traction kit (Roche Diagnostics, Germany) and the method specified by the manu-
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facturer.  In brief, 200 µl of serum or plasma sample was added in the appropriate 
well of the sample cartridge.  The proteinase K was reconstituted by adding 5 ml of 
elution buffer to the vial.  The lyophilizate was dissolved by mixing and the appropri-
ate volume added into the reagent tub.  The appropriate wash buffers (for the re-
moval of PCR inhibitors, salts and proteins), the lysis buffer (cell lysis and binding of 
total nuclei acid) and the elution buffer (for nucleic acid elution) were aliquoted into 
the reagent tub, according to the set-up protocol on the Magna Pure LC 2.0 instru-
ment (Roche Diagnostics, Germany).  The magnetic glass beads were added last to 
prevent sedimentation.  The viral nucleic acids in the sample/control were bound to 
the bead surfaces and unbound particles were washed off during the several wash 
steps. The purified total viral nucleic acids were eluted in 50 µl of the low-salt elution 
buffer and stored at -700C for genotyping. 
 
3.2.5. Reverse transcription (RT) and the nested PCR reaction 
RT and first-round PCR were performed using the TITAN One Tube RT-PCR sys-
tem (Roche Diagnostics, Germany). The 50 µl reaction mix contained 5 µl of purified 
RNA, 400 nM of each primer, 200 µM of each dNTP, 10 units of ribonuclease inhibi-
tor (Roche Diagnostics, Germany), 5mM dithiothreitol (DTT), 1 µl enzyme mix (AMV, 
Taq and Tgo DNA polymerase) and a 1x concentration of RT-PCR buffer (with 1.5 
mM MgCl2). After initial reverse transcription, first-round PCR was carried out using 
35 cycles of PCR, 9700 Applied Biosystems (ABI) thermocycler, USA (940C for 30 
s, 550C for 30 s, 680C for 45 s) and a final elongation step at 680C for 7 min. Nested 
PCR reactions were carried out in a final volume of 100 µl with 5 µl of the first-round 
product, 400 nM of each primer, 200 µM of each dNTP, 2.5 U Taq polymerase and 
1x concentration of PCR reaction buffer. The nested reaction was subjected to 35 
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cycles of PCR (940C for 60 s, 500C for 60 s, 720C for 60 s) and a final extension 
step at 720C for 5 min. The amplified PCR products were fractionated by electropho-
resis through a 2% metaphore agarose gel (Cambrex, Rockland, USA) and visual-
ized by staining with ethidium bromide under ultraviolet light. The annealing tem-
perature was adjusted according to the Tm values of the primers.   Primer and am-
plicon details, numbered according to (Choo et al., 1991) are shown in Table 8. 
 
3.2.6. Sequencing  
Sequencing of the 5’UTR and the NS5B regions was performed in both directions 
using the ABI Sequencing Ready Reaction kit (Applied BioSystem, USA) and cycle 
sequencing conditions as specified by the manufacturer. The amplicons were puri-
fied from excess dye terminators using ethanol precipitation with sodium acetate at 
a final concentration of 120 mM. Automated sequencing was performed using the 
ABI PRISM 3100 Genetic Analyzer using the nested primers as indicated in Table 8. 
A panel of specimens of known genotypes, received from the external quality assur-
ance program (Quality Control for Molecular Diagnostics, QCMD), was used to vali-
date our sequencing method. 
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Region Primer Sequence Tm G:C Ampli-
con 
size 
Method 
5’UTR Outer Sn1 
(-297-277) 
5’-CTGTGAGGAACTACTGTCTT-3’ 55.2 45.0   
269 
  
RT 
  
Outer Asn1 
(-45-28) 
5’- GCACTCGCAAGCACCCTA-3’ 53.0 61.0 
  
Inner Sn1 
(-278-258) 
5’- TTCACGCAGAAAGCGTCTAG-3’ 55.6 50.0   
238 
  
Nest/
seq 
  
Inner Asn1 
(-60-42) 
5’- CCTATCAGGCAGTACCACAA-3’ 55.6 50.0 
NS5B Outer Sn1 (7904
-7922) 
5’- TGGGGTTCTCGTATGATACCC-3’ 54 52.3   
397 
  
RT 
  
Outer Asn1 
(8300-8282) 
  
5’- GAGTACCTGGTCATAGCCT-3’ 50 55.0 
  
or           
  NS5B Outer Asn2 
(8274-8244) 
  
5’- 
GGCGGAATTCCTGGTCATAGCCTC
CGTGAA-3’ 
66 57.0 370 RT 
  
Inner Sn3 (7916-
7935) 
  
5’- GATACCCGCTGCTTTGACTC-3’ 54 55.0   
367 
  
Nest/
seq 
  
Inner Asn3 
(8254-8266) 
5’- CCTCCGTGAAGGCTCTCA-3’ 53 61.1 
  
or           
  NS5B Inner Asn3 
(8265-8247) 
5’- GCTAGTCATAGCCTCCGT-3’ 50 56.0 349 Nest/
seq 
3.2.7. Data analysis 
The statistical analysis software programme Statistica (Statistica Advanced, 
StatSoft, USA, version 9.1) was used to calculate whether the two liver disease co-
horts differed significantly from each other with regard to age, sex and viral load. 
Fisher’s exact and Chi-square tests were used for variables with normal curves, and 
the Mann– Whitney test, Kruskal-Wallis analysis for non-normality. A p-value of 
<0.05 was regarded as statistically significant. Multiple alignments of the sequenced 
regions were done with CLUSTALW, supplied within the MEGA software package, 
version 3.0; (Kumar et al., 2004), and phylogenetic analyses, using neighbour-
1Chan et al., 1992; 2Sandres-Saune et al., 2003; 3Chen and Weck, 2002 
sense, Sn,  anti-sense, Asn, RT, reverse transcriptase; nest, nested PCR, and seq, sequencing PCR   
Table 8.  List of primers, primer sequences and combinations and amplicon sizes for the method 
used.  The numbering is according to Choo et al., 1991. 
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joining and the Kimura-2 parameters (Kimura, 1980), were conducted using MEGA. 
A thousand bootstrap replicates were used, and a bootstrap value of >70% was 
taken to define a stable phylogenetic cluster (Muerhoff et al., 1997). Trees were cre-
ated with Tree Explorer in the MEGA programme.  All data spreadsheets and 
graphs were generated with MS Excel 2003.   
 
3.3.  RESULTS 
The demographics for the hospital-based study groups (Haemophiliac, Liver disease 
1 and Liver disease 2) during the respective time periods are summarised and com-
pared in Table 9a and b and that of the blood donor group (2006-2008) in Table 9c.  
The numbers of patients with liver disease and infected with HCV that visited the 
Liver Clinic during the two time periods remained constant, with no significant in-
crease. There were more males in both the liver disease and blood donor (2006-
2008) groups than females. The percentages of males versus female in the LD1 and 
LD2 groups, respectively were compared and a statistical significant power was in-
ferred using the Mann-Whitney test. Patients with liver disease were older (52 years, 
Table 9b) than those with haemophilia (34 years, Table 9a) and the blood donor 
(2006-2008)  group (39 years, Table 9c). Patient records for the liver disease groups 
in the two time frames were insufficient to allow conclusions with respect to the pos-
sible risk factors for HCV in these groups.  The rounded geometric mean absolute 
viral load titres were slightly higher in the haemophiliac group (1260317 +/- 1669843 
IU/ml, Table 9a) versus the liver disease and blood donor (2006-2008) group 
(807609 +/- 2361790 and 541006 +/-527306 IU/ml, respectively, Table 9b, c). There 
was an increase in the number of haemophiliacs tested at the clinic between the two 
time frames studied, which may reflect active recruitment and/or an increase in the 
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clinic screening activity over this period.  The numbers of specimens for the blood 
donor (2006-2008) group as indicated in Table 9c are numbers received in the labo-
ratory during that time period and may not necessarily reflect date of donation.  Al-
most half of the blood donors positive for HCV were male and Caucasian (Table 9c). 
(a) Haemophiliac (H) 
N=45 
2000-2002 
N=15 
2007 
N=30 
  
Age (years)a 34 ± 12 28 ± 11 37±12 
  
Geometric Mean Viral 
Load (IU/ml)a 
1260317 ± 1669843 992119 ± 1648628 1394417 ± 1699113 
  
(b) Liver Disease (LD) 
N=140 
LD1 
N=67 
LD2 
N=73 
p-valuec 
Male 69 37 (55)b 32 (43) 0.321d 
Female 48 19 (28) 29 (39) 
  
Unknown 23 11 (16) 12 (18) 
  
Age (years) 52 ± 14 51 ± 16 53 ± 13 0.862e 
Geometric Mean Viral 
Load (IU/ml) 
807609 ± 2361790 503313 ± 599646 1031174 ± 3062504 0.444e 
a
 Mean ± std deviation (SD), b percentages N for each time period, c p-values as calculated by t-test, d Mann-Whitney test, e 
Chi-square test 
(c) blood donors (2006-2008) 
  
N=118 
Male 59 (50)b 
Female 38 (32) 
Unknown 21 (18) 
Age (years) a 39 ±13 
Ethnic group: 
  
Indian 4 
Black 21 
Coloured 2 
Caucasian 52 
Unknown 39 
Mean Viral Load (IU/ml) a 541006 ±527306 
a
 Mean ± SD, b percentages N for each time period 
Table 9.  Demographic information for the patient and blood donor groups (a) Haemophiliac (H); (b) 
patients with liver disease, LD, (LD1 and LD2) and (c) blood donor (BD) 2006-2009 
 
Table 9c.  Demographic information for blood donors (2006-2008), with available ethnic information 
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 Table 10 indicates genotyping results of the three study groups as determined by 
sequencing in the 5’UTR region using sequence-based technique (SBT) only. For 
each genotype, the % of genotypes among the three groups (H, LD and BD) were 
compared for statistical significance, using the Kruskal-Wallis ANOVA test.  Geno-
type 5 was dominant in patients with liver disease over the two time periods studied 
(Table 10; 67.16 and 57.58%, respectively, p = 0.27, average 62.14%) while geno-
type 1 predominated in the individuals with haemophilia (51.12%; Table 10). Geno-
types 1 (32.21%) and 5a (38.98%; Table 10) had a similar prevalence in the blood 
donor (2006-2008) group.  Genotype 5 was present in 33.33% of the people with 
haemophilia followed, in decreasing prevalence by genotype 3 (8.89%), genotype 2 
(4.44%) and genotype 4 (2.22%). In contrast, the prevalence of genotype 1 was 
22.87% in patients with liver disease, followed by genotype 3 (8.57%) and genotype 
4 (6.42%). Genotype 3 was found to be highly prevalent in the blood donor group 
(2006-2008; 20.34%), compared to the other two study groups (Table 10).  Geno-
type 2 was not detected in patients with liver disease (Table 10) and only one speci-
men was positive for this genotype in the blood donor (2006-2008) group. There 
was an increase in the prevalence of genotype 3 (from 5.97 to 10.96%) and 4 (from 
4.48 to 8.22%) in the liver disease 1 and liver disease 2 groups (Table 10), but 
these differences were not statistically significant (p>0.05). Genotype 6 was not 
found in this or any of the previous South African studies.   
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HCV 
geno-
type 
H LD BD(2006-2008) p-
valueb 
  
N=45 Total (%) LD1 
2000-2002 
N=67 
LD2 
2007 
N=73 
Total (%) BD 
N=118 
Total 
(%) 
  
1 4 (8.89)a 51.12 5 (7.46) 4 (5.48) 22.87 18 
(15.25) 
32.21 0.36 
1a 9 (20.00) 
  
9 (13.44) 6 (8.22) 
  
8 (6.79) 
    
1b 10 (22.22) 
  
1 (1.49) 7 (9.59) 
  
12 
(10.17) 
    
2 1 (2.22) 4.44 0 0 0 1 (0.84) 0.84 0.447 
2b 1 (2.22) 
  
0 0 
  
0 
    
3 0 8.89 1 (1.49) 4 (5.48) 8.57 3 (2.54) 20.34 0.349 
3a 4 (8.89) 
  
3 (4.48) 4 (5.48) 
  
21 
(17.80) 
    
4 1 (2.22) 2.22 3 (4.48) 6 (8.22) 6.42 8 (6.79) 7.63 0.22 
4a 0 
  
0 
    
1 (0.84) 
    
5a 15 (33.33) 33.33 45 (67.16) 42 (57.58) 62.14 46 
(38.98) 
38.98 0.27 
Ninety-one sample sequences, together with representative GenBank sequences, in 
bold type with their known genotypes/subtypes, in parenthesis after their accession 
numbers (Fig. 16), were aligned and analyzed over 198 bp of the amplified 5’UTR 
region. The alignment of nucleotides in the 5’UTR region (not shown) confirmed that 
a double adenine (A106A107) defined specimens of genotype 5 (Smuts and Kanne-
meyer, 1995). However, a group of our specimens and one GenBank specimen, 
U33430, lacked A106 but were otherwise identical to other genotype 5 specimens 
over the 198-bp region studied. These clustered together, away from other genotype 
5 specimens (see clade labelled ‘‘Atypical Genotype 5a’’; Fig. 16). For clarity, and 
because intraclade genetic distances are small, only 91 of the 303 5’UTR se-
a
 percentages N  
b
 p-values as calculated by the Kruskal-Wallis ANOVA test 
Table 10.  HCV genotypes in the three different study groups, people with haemophilia, liver disease 
and volunteer blood donors (2006-2008), based on 5’UTR sequence analysis 
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quences were included in the final tree (Fig. 16). Specimens 5126 and 5633, from 
the 2007 haemophiliac group, partitioned significantly, and away from all other 
specimens, with genotype 2 in the 5’UTR region. However, specimen 5126 formed 
an outlier away from 5633 and known subtype 2a, 2b and 2c reference sequences 
(Fig. 16).  Specimens 1182 and 1909 clustered in a clade that had both genotype 4a 
and 4c reference sequences, 2575 and 4303 grouped with a subtype-unknown ref-
erence genotype 4 sequence (L29600), and four other specimens from patients with 
liver disease, 1678, 2045, 1158 and 2406, clustered with a reference sequence, 
L29619, from subtype 4g.  Blood donor specimens 9389 and 9402 clustered within 
genotype 4 by phylogenetic analyses (Fig. 17). The 5’UTR is too conserved to parti-
tion genotype 4 into significant subtype clusters and this can also be seen for geno-
type 1 (Fig. 16).  In the 5’UTR region, specimens 9297 and 9298 grouped as outliers 
of the genotype 1 cluster and specimen 9411 was an outlier in the genotype 4 clus-
ter (Fig.16). 
 
NS5B sequencing was performed to confirm the 5’UTR segregation pattern (Fig. 18; 
41 of the 61 specimens that could be amplified in both regions are shown). Subtyp-
ing within genotypes was now also possible due to the greater variability of this re-
gion. There was a 71% (61/86) success rate for the amplification of products in the 
NS5B region using published methods and primers. Two specimens (1909 of the 
haemophiliac cohort and 1182 of the liver disease 1 cohort) that had clustered with 
the clade of genotype 4a and 4c in the 5’UTR region, clustered significantly with the 
genotype 4c reference sequence, L29602, in the NS5B region (Fig. 18). The 
branching of specimen 1678 of the LD1 cohort with L29618, a genotype 4g refer-
ence, in the 5’UTR region was confirmed in the NS5B analysis (Fig. 18). The speci-
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mens previously typed genotype 5 in the 5’UTR region formed a significant clade 
with the genotype/subtype 5a reference sequences in the NS5B regions together 
with recently published genotype 5 NS5B sequences from South Africa, Belgium 
and France (Belgian and French specimens labelled by country in Fig. 18). There 
was, however, no distinction between the ‘‘typical’’ and ‘‘atypical’’ clusters of geno-
type 5 in this region. Specimens that were found in the ‘‘atypical’’ cluster in the 
5’UTR region grouped as genotype 5a in the NS5B region (3788/LD1; 3494/LD1; 
363/LD1).  This indicates that the specimens in the ‘‘atypical’’ cluster are not recom-
binants or belong to a different subtype.  Specimen 1485, which grouped with the 
subtype 1b reference in the 5’UTR analysis (Fig. 16), clusters significantly with Gen-
Bank reference M62321, which is known to be subtype 1a, in the NS5B tree (Fig. 
18). Apart from this subtype switch, all specimens partitioned into the same geno-
typic clusters in both regions. All genotypic clusters on the NS5B tree had significant 
bootstrap values. Except for the 2 haemophiliac genotype 2 specimens, there was 
no significant monophyletic clustering of sequences according to the haemophiliac 
group or patients with liver disease in either of the regions sequenced. 
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Fig.16.  Unrooted neighbour-joining tree of 91 HCV 5’UTR fragments of the H, LD1 and LD2 groups.  Significant bootstrap 
percentages from the consensus tree (1000 sets) are shown.  GenBank accession numbers are in bold print with subtypes in 
parentheses.  Genotypes are labelled according to the nomenclature of Simmonds et al., 1994a.  The scale bar represents 
0.005 substitutions/nucleotide site. 
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Fig.17. Unrooted neighbour-joining phylogenetic analyses of 61 5’UTR sequences in the volunteer 
blood donor (2006-2008) cohort. Significant bootstrap percentages from the consensus tree (1000 
sets) are shown. GenBank accession numbers (in bold print) and genotypes are labelled according 
to the nomenclature of Simmonds et al. 1993b.The scale bar represents 0.02 substitutions/nucleotide 
site. 
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Fig.18.  Unrooted neighbour-joining tree of 41 HCV isolates of the haemophilia, liver disease 1 and 2 
groups.  The region sequenced is 202bp in the NS5B region and clusters are shown of different 
genotypes and subtypes.  Significant bootstrap values are indicated. GenBank accession numbers 
are in bold print with subtypes in parentheses. Genotypes are labelled according to the nomenclature 
of Simmonds et al., 1993a.The scale bar represents 0.05 substitutions/nucleotide site. 
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3.4. DISCUSSION 
 
Screening of blood products in South Africa began in the early nineties, and no fur-
ther transmission of HCV has been observed in the haemophiliac clinic since then 
(Dr. Mahlangu, personal communication, Haemophiliac Clinic, Charlotte Maxeke 
Hospital, 2008). This is reflected by the lower age range in the haemophiliac group 
over the time periods studied. Asymptomatic haemophiliacs are screened at regular 
intervals because of routine exposure to blood products, whereas most of the pa-
tients presenting at the liver clinic would either be symptomatic (which occurs after 
long-term infection) or have had abnormal blood tests prompting further investiga-
tion. Since HCV disease is normally diagnosed at the late disease stage, it is not 
surprising that the average age of the patients with liver disease (early 50s) is older 
than that of the people with haemophilia and the volunteer blood donors. In the lat-
ter, the majority of the donations received at SANBS are from Caucasian (M. Ver-
meulen, SANBS; personal communication, 2008), male donors, around the age 
range of 41-47 years.  There is no significant increase in patient numbers between 
the two liver disease groups, indicating that HCV prevalence may still be low in the 
Johannesburg urban areas. However, the numbers in these groups have to be inter-
preted with caution as this group of individuals were referred to the liver clinic. There 
was no significant difference in viral load between the haemophilia, liver disease 
and blood donor groups.  
  
Although the mean viral loads for the specimens were high (Table 9a, b), our suc-
cess rate in amplifying the NS5B region (71%) was not as high as that reported by 
others (Sandres-Saune et al., 2003; Tamalet et al., 2003). This study is retrospec-
tive and was performed on specimens that were stored for long periods and sub-
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jected to frequent freeze/thaw cycles between tests. RNA degradation due to poor 
storage and poor maintenance of the cold chain during specimen transport may be 
plausible explanations and it is also possible that unknown variation (leading to 
suboptimal primer design in this less conserved region) could have contributed to 
this rate discrepancy, as published primers were used. 
  
Sequencing and phylogenetic analysis in the 5’UTR was accurate in determining 
genotypes, but the greater variability of the NS5B coding region enabled differentia-
tion of both genotypes and subtypes (Simmonds et al., 1993a). As previously de-
scribed (Simmonds et al.,1993b), the 5’UTR region could distinguish genotypes but 
not subtypes as the histogram of genetic distances in the 5’UTR region (not shown) 
had two peaks, indicating this separation. However, the distribution of genetic dis-
tances in the NS5B region revealed three separate and non-overlapping partitions, 
confirming the ability of this region to discern subtypes (Simmonds et al.,1993a). 
Whereas 5’UTR RFLP does not readily differentiate between subtypes, this analysis 
has shown, for the first time in South Africa, the presence of subtypes 4c and 4g by 
sequencing (Fig.16). These genotype 4 subtypes were characterized previously 
among patients in Cameroon, the Central African Republic and Gabon (Stuyver et 
al., 1994).  
  
The overall distribution of genotypes between the two time frames in the respective 
groups, patients with liver disease and individuals with haemophilia, remained the 
same in this study, with minor variations that were not statistically significant. How-
ever, with the blood donor (2006-2008) group, we have seen an increase (although 
nor statistically significant) in genotype 3 as compared to those with liver disease 
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and haemophilia (Table 10).  Our genotyping results were compared to two previous 
South African studies (Fig.19), that used RFLP to determine genotypes in their re-
spective cohorts. This study did not consistently corroborate previous SA studies 
and it would seem that genotype prevalence varies across the country and in the 
different cohorts studied in the Johannesburg area.  This could reflect the facts but 
there are other possible explanations for this.  Earlier studies report genotypes in 
smaller cohort sample size compared to ours (Fig.19).  Earlier methods such as 
RFLP analysis depend on point mutations and are not as accurate as sequencing 
and this is reflected in the number of untypable specimens in these studies. 
Genotype 5 was the most common genotype (Fig.19, table 10) in South Africa, with 
variable percentage prevalence seen among the different cohorts studied in this 
chapter and previously reported (LD2000-2002; LD2007; BD1995). Based on se-
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Fig.19.  Genotypes determined in this study cohorts compared to two other  South African studies, 
Smuts and Kannemeyer., 1995 (CRF, chronic renal failure; LD liver disease; haem, haemophiliac; 
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quence data of the BD (2006-2008), genotype 1 is almost as abundant as genotype 
5. Genotype 1 predominated in people with haemophilia (Fig.19). Although not 
much is known about the source of blood products or time of infection of people with 
haemophilia, it is known that imported factor concentrates from USA were adminis-
tered to some individuals attending the clinic during the period 1982–83, but thereaf-
ter, fractionated product from local unpaid donors has been used exclusively (Dr. 
Mahlangu, personal communication, haemophiliac clinic, Charlotte Maxeke Hospital, 
2008).  
  
The prevalence of genotype 1 among blood donors remained constant over the 
2006-2008 time periods and genotype 1 prevalence similar to that of Smuts and 
Kannemeyer, 1995 study.  Relative to each other, the prevalence of genotypes 3 
and 4 increased in the patients with liver disease over the 2 time periods, although 
this is not statistically significant. Neither genotype was present in previous studies 
of patients with liver disease (Fig.19). This increase in prevalence of genotypes 3 
and 4 may be due to travel and immigration from India, other eastern countries and/
or neighbouring African countries, where genotypes 3 and 4 predominate (Hissar et 
al., 2006; Pasquier et al., 2005). With the blood donor group, we have seen an in-
crease in genotype 4 (9%, Fig.19).    In the 1995 study of Smuts and Kannemeyer, 
genotype 4 was only seen in the haemophiliac population (3/23).  We detected only 
two genotype 2 specimens, and both of these were in the haemophiliac group of 
2007 (Table 10). This may be a consequence of the method used, population stud-
ied or the patient group examined, since Smuts and Kannemeyer, 1995 found geno-
type 2 in the blood donor group (10/79), haemophiliacs (7/23) and a patient with 
liver disease (1/19), and Sithebe et al., 1996 found genotype 2 to be the predomi-
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nant genotype in patients with liver disease (5/11) and renal failure (4/8; caution 
should be taken when interpreting these results as patient numbers were low in that 
study).  We detected one genotype 2 in the blood donor (2006-2008) group by SBT.   
There was also a change in prevalence of genotype 5 between the two liver disease 
groups (from 67 to 58%; Table 10).  These effects may be explained by the variation 
in the prevalence of other genotypes, emigration, study design limitations, geo-
graphical region or technological improvements. It is possible that, in the approxi-
mately 5–12 years between our studies and previous South African studies, im-
provements in technology and methodology have enabled more accurate typing of 
genotypes, as both earlier studies reported a proportion of specimens that could not 
be typed. 
  
This study has optimized and validated diagnostic methods for genotyping HCV in a 
national laboratory, identified circulating genotypes in patient groups and population-
based groups from Johannesburg and surrounding areas.  All of the sequences, ex-
cept for the subtype variation of one specimen, displayed concordant results for 
both of the regions that were sequenced. The occurrence of a single genotype 5a 
clade in the NS5B region is in accordance with the results reported by Verbeeck et 
al., 2006. Although the Verbeeck study reported that the phylogenetic signal in the 
NS5B region is too conserved to provide information regarding subtypes within 
genotypes (Verbeeck et al., 2006), this study and others (Laperche et al., 2006) 
have found the region effective in differentiating the major subtypes. 
  
Despite the advantages of using the more variable NS5B region for fine subtyping, 
genotype inference was identical between the two regions sequenced. In addition, 
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while the conserved 5’UTR region is less specific at the subtype level, it is more ro-
bust and sensitive for diagnostic genotyping, particularly in a setting where less 
characterized variants (e.g. genotype 4 and 5) are being detected and may be the 
predominant types. For these reasons, 5’UTR PCR amplification and sequencing 
was used for routine genotyping in our laboratory and was used as the gold stan-
dard to test and evaluate other techniques in later studies. 
  
3.5. CONCLUSION 
This study has described HCV genotypes in three sentinel groups; patients with liver 
disease, haemophilia and volunteer blood donors.  In the context of South Africa, 
the major HCV genotype in patients with liver disease is still 5a, as evident in this 
study in previous studies.   However, there is a difference in the distribution of HCV 
genotypes between the liver disease and haemophiliac/blood donor study groups 
and we have identified previously unknown subtypes in South Africa. Although, 
knowledge of HCV genotypes is now an essential part of treatment regimes and 
prognosis of infection, the addition of genotypes onto the surveillance databases, 
further helps to understand the changing frequencies of genotypes in the country 
and in different study cohorts.  From such surveys, the identification of new geno-
types, subtypes, recombinants and/or superinfections can be determined.   
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CHAPTER FOUR   
  
The Advantages and disadvantages of commercial and experimental  
HCV Genotyping assays 
  
  
4.1. INTRODUCTION 
Accurate HCV genotyping methods are required for surveillance, molecular epidemi-
ology, vaccine development and clinical management.  HCV genotype is the most 
important predictor of treatment outcomes and prognosis of clinical disease.  Until 
recently, no significant difference had been reported in response rates among the 
HCV subtypes (Wohnsland et al., 2007).  However, with the development of prote-
ase and RNA-dependent-RNA polymerase (RdRp) enzyme inhibitors, different anti-
viral responses and resistance patterns in subtypes 1a and 1b have been observed 
(Erhardt et al., 2009; McCown et al., 2009) and HCV subtyping must be considered 
in order to optimise treatment regimes.  Although, the gold standard of diagnostic 
genotyping is sequence-based technologies (SBT) on various regions of the ge-
nome, this method is labour intensive (Table 11), with many PCR steps and clean-
up applications.  SBT is relatively cheaper than a commercialized LiPA test, but SBT 
has longer turn-around times (TAT, Table 11) and subtypes of genotypes were not 
identified optimally in the 5’UTR SBT as indicated by the phylogenetic analyses of 
the two regions (5’UTR and the NS5B region) compared in chapter 3.   
The 5’UTR remains the most popular target for diagnostic genotyping but cannot 
accurately subtype.  Newer methods are therefore constantly explored.  In this 
study, three alternate technologies were evaluated for HCV diagnostic genotyping, 
namely, (1) real-time PCR, (2) line probe assay using the 5’UTR and (3) line probe 
assay using  the 5’UTR plus core. 
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Summary LiPA Sequencing 
Cost Genotyping kit $2903(X40) 
Amplification kit $5500 (X40) 
COBAS Amplicor or Amplicor Manual kit 
$3428 (X96) 
Titan kit (RT-one step) $758 (100 Rxns) 
Nested PCR  $219(100 Rxns) Sequencing 
ABI kit $2224 (100 Rxns) 
PCR Clean-up $507(50 Rxns) 
Sequencing ABI clean-up $2857 (100 Rxns) 
Primers $86(100 Rxns) 
Cost per specimen $244 (if amplification for subtyping genotype 1 
is needed) 
$107 genotyping only 
 (excluding  consumables,  repeats, controls, 
failed runs, equipment and maintenance costs) 
$ 79 (excluding consumables, repeats, con-
trols, failed runs, equipment and mainte-
nance costs) 
Time per specimen 4 hours 2-3 days 
Advantages Quick and easy to use (see workflow in meth-
ods). High throughput. Can pick up mixed in-
fections. Can use COBAS AMPLICOR manual 
amplicon for test. Can amplify core region for 
subtyping 
Gold standard. Highly specific and sensitive 
(both strands, sense and anti-sense strands 
are sequenced) Can target 5’UTR, core, 
NS5B regions using specific gene primers. 
Disadvantages Relies on visual subjectivity. Interpretation 
requires experience. Can get the presence of 
too many bands or “ghost” bands which make 
it un-interpretable. 
Too many steps, RT, nested PCR,  se-
quencing PCR 
Misses mixed infections 
Requires skilled staff for phylogenetics and 
to interpret chromatograms 
Success rates depend on the design of 
primers, storage and quality of RNA 
 
Several real-time PCR methods for genotyping HCV have been described (Schroter 
et al., 2002; Rolfe et al., 2005; Schutzbank et al., 2006).   HCV RNA is amplified us-
ing sequence specific PCR primers as before but the detection of the PCR products 
is automated using fluorescent dyes and light cycler technology (Schroter et al., 
2002).  Real-time LightCycler genotyping method use Fluorescence Resonance En-
ergy Transfer (FRET) technology. Energy is transferred from the donor probe with a 
fluorescein dye to an acceptor probe with another dye (eg. LCRed640).  When they 
lie close to each other at the end of the annealing step of PCR, emitted light 
Table 11. Costs, advantages and disadvantages between the LiPA and SBT genotyping tests 
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(energy) is captured by the fluorimeter in the LightCycler and is proportional to the 
target concentration. 
 
The presence of different amplicons is detected by observing the melting curve of 
the product. Melting temperatures, (Tm) the temperatures at which 50% of probe-
target duplexes separate) vary dependent on the number of SNPs in the product 
(Roche Applied Science, http://www.roche-applied-science.com).  This “melt off” is 
also proportional to the length and the GC content of the target sequence. 
 
The line probe assay (LiPA) hybridizes biotinylated PCR amplicons to immobilized 
probes on nitrocellulose strips (Andonov and Chaudhary, 1995).  Streptavidin-
alkaline phosphatase reacts with the biotin group.  Chromogenic compounds detect 
the enzyme conjugate.  The hybridization pattern identifies not only the dominant 
genotype but also mixed genotypic infections (Table 11).  The LiPA using the 5’UTR 
was able to discriminate the different genotypes 1-6 but was limited in subtyping, 
especially of genotype 1 and 6 (Stuyver et al., 1996).  When the LiPA assay was im-
proved by incorporating the amplified core region together with the 5’UTR (LiPA 
5’UTR plus core), better subtyping of genotype 6 (Noppornpanth et al., 2006b) and 
1 (Verbeeck et al., 2008b) was evident but no mixtures were included in their stud-
ies.   
 
The aim of this study was to validate and compare these three technologies (real-
time, LiPA (5’UTR) and LiPA, 5’UTR plus core) against the gold standard SBT. 
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4.1.1. Objectives:  
Validation and assessment of: 
(a) the real-time LightCycler Genotyping method and  
(b) the LiPA (5’UTR) and the LiPA (5’UTR plus core) assays  
 
4.2. METHODS 
A QCMD (Quality control for molecular diagnostics) panel of specimens from an ex-
ternal quality assurance (EQA) program, for HCV genotyping was used as stan-
dards against which the results for each assay could be validated.  Calculations for 
accuracy, negative predictive (NPV) and positive predictive values (PPV), sensitivity 
and specificity were performed using the NHLS standard operating procedure 
(NHLS/NICD SOP NIC0563, version 1, 2008).  Known negative specimens in the 
EQA panel were included as negative controls.  All specimens used in the study 
were previously genotyped by SBT (chapter 3) and genotypes were known. 
 
4.2.1. Real-time LightCycler method 
Twenty-eight specimens were typed using the LightCycler (Roche Diagnostics, Ger-
many) and the method of Schroter et al., 2002. Three different pairs of hybridization 
probes were used with primers 27 and KY81. Briefly, 2 µl of a 10X concentrate of 
the LightCycler-DNA Master Hybridization probe mix (LightCycler-DNA Master Hy-
bridization probe, Roche Diagnostics, Germany; with LightCycler Faststart Taq DNA 
polymerase, PCR buffer, dNTP mix and 10mM MgCl2), 2 µl (5pM) of each primer, 
2.4 µl (3mM) MgCl2 and 0.6 µl (3pM) of each hybridization probe was added to a fi-
nal  genotyping PCR volume of 20 µl.  Distilled water was used as the negative con-
trol.  The position and sequences of the hybridization probes and primers  are num-
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bered according to Landt et al., 2002 and are shown in Table 12 (numbering in pa-
rentheses is according to Choo et al., 1991). The fluorescence signal in channel 2 
(F2) was measured for LCRed640 emission and the signal in channel 3 (F3) was 
measured for LCRed705 emission.  The genotypes were discriminated by the differ-
ent melting temperatures (Tm’s) of the amplicons.    
 
4.2.2. LiPA (5’UTR) and LiPA (5’UTR plus core) 
 
4.2.2.1. LiPA (5’UTR) 
The denatured 5’UTR PCR amplicons (from the previously genotyped blood donor 
group 2006-2008, chapter 3) obtained from the HCV Amplicor (Cobas Amplicor 
HCV version 2.0, Roche Diagnostics, Germany) were used for genotyping with the 
VERSANT line probe assay (LiPA, version 2.0) according to the methods recom-
mended by the manufacturer (Siemens Medical Diagnostics, Belgium).  The LiPA 
(5’UTR) was optimised by using varying volumes (10-40 µl) of the denatured ampli-
con in the test.  After optimization 30 µl of denatured product was added to the hy-
bridization buffer and incubated with the LiPA nitrocellulose indicator strip. All incu-
bations in the hybridization buffer and wash solution were performed at 500C and 
the conjugate and substrate steps at room temperature, as recommended by the 
manufacturer. The chromagen substrate reacts with the conjugate, forming a pre-
cipitate, which results in a visible banding pattern on the nitrocellulose paper. The 
results were interpreted per instructions on the reading card and interpretation chart, 
supplied in the assay.  The Student t-test analysis was used to compare the LiPA 
(5’UTR) to SBT (Statistica, Statistica Advanced, StatSoft, USA, version 9.1).  The 
performance of the LiPA (5’UTR) was also assessed using standardised QCMD 
109 
panels (2007 and 2008) with low copy number and mixed genotypes.  The BD 2009 
specimens were also tested by LiPA (5’UTR).  
 
4.2.2.2. LiPA (5’UTR plus core) 
Thirty-five previously typed specimens and 8 QCMD samples were re-typed using 
the LiPA (5’UTR) amplicons and the LiPA (5’UTR plus core) assays.  The two spe-
cific regions of the HCV genome used in the extended analysis were co-amplified 
using the Versant HCV Amplification LiPA assay (Siemens Medical Diagnostics, 
Belgium) and the procedure was performed as recommended by the manufacturer.  
The viral RNA extraction was performed using the QIAamp Mini RNA assay 
(Qiagen, Germany) and 5 µl of this extract was added to the PCR mix. The amplifi-
cation mix (AMP MIX) provided in the Versant HCV Amplification LiPA assay con-
tains two pairs of biotinylated primers targeting the 5’UTR (240 bp amplicon) and 
core (270 bp amplicon) regions, respectively, together with dNTP/dUTP, MgCl2, 
RNAsin and PCR buffer. Reverse transcription (RT) and PCR amplification are per-
formed sequentially in a single tube for each specimen in parallel with appropriate 
negative and positive controls. The enzyme mix (ENZ MIX) contains Sensiscript and 
Omniscript RT enzymes and HotStarTaq polymerase.  The final validated method, 
optimized and validated in the Specialized Molecular Diagnostics Unit (SMDU) labo-
ratory, uses 2 µl of the ENZ MIX to every 13 µl of the AMP MIX and 40 cycles of the 
thermal profile recommended by the manufacturer. Following the PCR, 8 µl of the 
PCR product was loaded onto a 2% agarose gel to identify positive PCR reactions. 
Ten µl of the latter were then denatured using the denaturing solution provided in 
the Versant HCV Genotype LiPA, 2.0 kit (Siemens Medical Diagnostics, Belgium) 
and applied to the single-stranded oligonucleotide probes bound to the membrane. 
The latter include appropriate core region probes which allow for the identification of 
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 subtype 1a (band 25), subtype 1b (band 26) or genotype 1 (presence of both bands 
25 and 26). 
Primers Sequences Position Tm (0C) 
Sense27 (-319 to –298) 5’-TCCACCATGAATCACTCCC-3’ 26-44 54.1 
Antisense KY81 (-191 to –
173) 
5’-CGGAACCGGTGAGTACACC-3’ 169-151 58.4 
Probes Genotyping 1/2/4/5 
    
Sensor 13 (-242 to –224) 5’-GTGTCGTGCAGCCTCCAGG-3’ 100-118 62.4 
Sensor 4 (-241 to –224) 5’-TGTTGTACAGCCTCCAGG-3’ 101-118 52.8 
Anchor 1(-223 to –200) 640-CCCCCCTCCCGGGAGAGCC 120-139 72.7 
Probes Genotyping 1/3 
    
Sensor 3a (-297 to –261) 5’-CACGCGGAAAGCGCCTA-3’ 65-81 60.2 
Anchor 3 (-259 to –238) 705-CCATGGCGTTAGTACGAGTGTC 83-104 58.2 
 
4.3. RESULTS 
4.3.1.  Real-time LightCycler method 
Forty-one QCMD panel specimens and 28 previously sequenced specimens were 
used for the validation and method comparison, respectively.  The viral loads of the 
specimens ranged from 600 to 1990000 IU/ml.  The results of the validation are as 
follows (Table 13):  accuracy= 55.81%, NPV= 10.52%, PPV= 100%,  sensitivity = 
53.65% and specificity = 100%. 
Table 12.  Sequence and positions of primers and probes used for the Real-Time LightCycler geno-
typing method.  Numbering at positions according to Landt et al., 2002 and in parentheses, accord-
ing to Choo et al., 1991. 
The sense and antisense primers were used in the amplification step.  The two sensor probes (sensor 13 and 4) and the an-
chor 1 probe were used in the detection of genotypes 1, 2, 4 and 5 and sensor 3a and anchor probe 3 were used to detect 
genotype 3.  
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QCMD Specimen QCMD Genotyping results LightCycler Genotyping results 
1. 3a 3 
2. 4 Not detected 
3. 1a 1 
4. 2b 2 
5. 4 Not detected 
6. 2b 2 
7. 1 Not detected 
8. 1 1 
9. 1 1 
10. 3a Not detected 
11. 1 1 
12. 1 Not detected 
13. 1 1 
14. 1 1 
15. 1 Not detected 
16. 1 Not detected 
17. 3a 3 
18. 1 Not detected 
19. 1 Not detected 
20. 1 1 
21. 2b 2 
22. 1b 1 
23. 4 4 
24. 1a 1 
25. 3a 3 
26. 4 Not detected 
27. 2b Not detected 
28. 3a Not detected 
29. 1b Not detected 
30. 5a Not detected 
31. 3a 3 
32. 5a 5 
33. 1b Not detected 
34. 3a Not detected 
35. 1b Not detected 
36. 3a Not detected 
37. 3a 3 
38. 1b 1 
39. 5a Not detected 
40. 5a 5 
41. 1b 1 
Table 13. Validation results on the Real-Time LightCycler Genotyping method as compared with 
positive QCMD results 
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1.1  Accuracy =   True positives + True negatives  
 True positives + False negatives + True negatives + False positives 
 
 = 22 + 2 
   22 + 19 + 2 + 0 
 = 55.81% 
 
1.2.  Negative Predictive Value (NPV) =  True negatives 
    True negatives + False negatives 
    = 2 
     2 + 19 
    = 10.52% 
 
1.3.  Positive Predictive Value (PPV) = True positives 
    True positives + False positives 
    = 22 
     22 + 0 
    = 100% 
 
1.4.  Sensitivity  =  True positives 
 True positives + false negatives 
 = 22 
  22+ 19 
 = 53.65% 
 
1.5.  Specificity = True negatives 
 True negatives + False positives 
 = 2 
  2 + 0 
 = 100% 
 
 
Twenty-three specimens (23/28, 82%) could be genotyped using the LightCycler 
genotyping method, but only eighteen (64%) of the results were concordant with the 
5’UTR and NS5B sequencing results (Table 14).    
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Specimen Sequencing genotyping 
results 
LightCycler genotyping results 
1. 1 1 
2. 5a  “AA” 5 
3. 4 Not detected 
4. 5  “A” 2 
5. 5  “AA” 5 
6. 5  “A” 2 
7. 5   “A” Not detected 
8. 5   “A” 1 
9. 5   “A” 5 
10. 3a 3 
11. 1a 1 
12. 5a  “AA” 1 
13. 1a 1 
14. 5a  “AA” 5 
15. 5a  “AA” 5 
16. 5a  “AA” 5 
17. 5a  “AA” 5 
18. 5a  “AA” Not detected 
19. 5a  “A” Not detected 
20. 5a  “A” Not detected 
21. 5a   “A” 2 
22. 5a  “AA” 5 
23. 5a  “AA” 5 
24. 5a  “AA” 5 
25. 5a  “AA” 5 
26. 5a  “AA” 5 
27. 5a  “AA” 5 
28. 5a  “AA” 5 
 
Genotype 5 was the predominant genotype (61%), followed by genotype 1 (22%), 
genotype 2 (13%) and genotype 3 (4%). The five specimens that did not amplify by 
the LightCycler method were from genotype 4 (N=1) and genotype 5 (N=4, 3 atypi-
cal and 1 typical; Table 14).  All three of the specimens typed as genotype 2, and 
two of the 5 typed as genotype 1 by the LightCycler method, had been found con-
clusively to cluster as genotype 5 by phylogenetic analyses in the 5’UTR and NS5B 
sequenced regions (chapter 3, Fig. 16 and 18, respectively).  Fig. 20a and table 15 
show the different melting temperatures (Tm’s) for HCV genotypes 1, 2, 3, and 5.   
Genotype 5 showed two peaks, the expected Tm (Tm of 540C and another at 600C),    
Table 14. The LightCycler Genotyping results compared to sequencing of the 5’untranslated region. 
“AA” indicates the double adenine at position 106 and 107 or “A” at position 107 only (“atypical”), re-
spectively. 
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which was responsible for the mistyping (Fig.20a).  Although, genotypes 1 and 3 
have similar Tm’s, genotype 3 can be better discriminated in the F3 channel 
(Fig.20b). The average Tm’s of the respective genotypes in channel F2 and F3 
ranged from 540C to 700C (Table 15).   
Table 15. The mean Tm’s (0C) observed for the genotypes in the study by the Real-time LightCycler 
genotyping method 
Genotype Tm0C (F2) Tm0C (F3) 
  
1 64-66   
2 62-63   
3 68-70 62-64 
5 54-57   
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4.3.2. LiPA (5’UTR) and LiPA (5’UTR plus core)  
4.3.2.1. LiPA (5’UTR) 
The validation of the LiPA (5’UTR) method against the QCMD panels (Table 16)  
were as follows: accuracy= 95%, sensitivity=  94.44%, specificity= 100%, PPV= 
100% and NPV= 66.67%.  Two genotype 1a specimens in the QCMD panel were 
subtyped by the LiPA (5’UTR) method as 1b (Table 16).  Seven of the eight mixed 
genotype infections were detected correctly by the LiPA (5’UTR) method (Table 16), 
and accuracy, sensitivity and specificity scores were greater than 94%.  
 
 
Fig.20. A representation of the Tm analyses of the LightCycler genotyping method, showing HCV 
genotypes distinguished by their different Tm’s, (a) first measured in F2 channel for LC-Red 
640emission and (b) in F3 channel to discriminate between genotypes 1 and 3. LC-Red 705 emis-
sion signals in F3 are exclusively obtained with a genotype 3 specimen as shown. 
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QCMD SPECIMENS 
QCMD expected 
results 
LiPA (5’UTR) results 
1. 1a 1b 
2. 5a 5a 
3. 3a 3a 
4. 1a + 3a 1a + 3a 
5. 
negative negative 
6. 1b 1b 
7. 5a 5a 
8. 1b + 3a 1b + 3a 
9. 5a 5a 
10. 
negative negative 
11. 1a 1a 
12. 3a + 5a 3 + 5a 
13. 3a 3 
14. 5a 5a 
15. 1b + 3a 1 + 3 
16. 3a 3  _ 
17. 5a 5a 
18. 1b + 5a 5a 
19. 1 1a 
20. 1b 1b 
21. 1b + 3a 1b + 3a 
22. 
negative negative 
23. 1 1b 
24. 3a 3a 
25. 3a 3a 
26. 1b + 3a 1b + 3a 
27. 1a 1b 
28. 5a + 3a 3a + 5a 
29. 5a Not detected 
30. 
negative negative 
31. 3a 3a 
32. 5a 5a 
 
Table 16. Validation results on the LiPA (5’UTR) method as compared with QCMD results of panels 
received in 2007 - 2010 
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Accuracy 
2.1. Accuracy =   True positives + True negatives  
 True positives + False negatives + True negatives + False positives 
 
 
=   34 + 4 
   34 + 2 + 4 + 0 
=    95% 
 
2.2.  Negative Predictive Value (NPV) =  True negatives 
    True negatives + False negatives 
    = 4 
     4 +2 
    = 66.67% 
 
2.3.  Positive Predictive Value (PPV) = True positives 
    True positives + False positives 
    = 34 
     34 + 0 
    = 100% 
 
2.4.  Sensitivity  =  True positives 
 True positives + false negatives 
 = 34 
   34 + 2 
 = 94.44% 
 
2.5.  Specificity = True negatives 
 True negatives + False positives 
  
 = 4 
   4 + 0 
 = 100% 
 
 
All specimens from the blood donor group (2006-2008), which had sufficient RNA 
(N=100), were genotyped by LiPA (5’UTR) and compared to the SBT.  Three speci-
mens typed by sequencing but not LiPA (5’UTR) had a mean viral load of 736 IU/ml 
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which was below 1000 IU/ml limit for typing by the LiPA (5’UTR) method. Table 17 
gives a breakdown of the subtypes identified by the two methods in the volunteer 
BD (2006-2008) group.  While the LiPA (5’UTR) test compared well with the SBT, at 
the genotype level, the total percentages show, there was a discrepancy at subtype 
level (Table 17).  As with the QCMD validation where LiPA (5’UTR) called 2 known-
subtype 1a specimens as subtype 1b, the test called 18 of the 20 specimens sub-
typed by the SBT as subtype 1b - 6 more than called by the SBT.   
 
The LiPA (5’UTR) method detected mixed infections (4%, Table 17) while SBT did 
not.  Specimens with mixed subtype infections, for example, specimens 9297 and 
9298 [both typed as genotype 1a/1b by LiPA (5’UTR)], grouped as outliers of the 
genotype 1 cluster (Fig.16).  Samples with mixed genotype infection, specimen 
9411 (1 + 4) and 9302 (1 + 5a) grouped within the genotype 4 and 5a clusters, re-
spectively (Fig.16).  Specimen 9411 was an outlier in the genotype 4 cluster.  
 
The LiPA (5’UTR) detected all positive specimens detected by SBT except for 3 
which were below the lower limit of viral load detection for LiPA (5’UTR).  The LiPA 
(5’UTR) showed a 100% concordance with SBT in the 5’UTR, although SBT only 
detected the major variant in the mixed genotype infections.  LiPA (5’UTR) detected 
the presence of mixed genotype infections in 4 of the 100 blood donor specimens 
(Table 17).  
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Genotyping 
(SBT)   
  
LiPA 
(5’UTR)   
  
genotypes N=103 Total (%)   N=100 Total % p-value (t-test) 
1 13 33 (32%)   9 31% 0.75 
1a 8     2     
1b 12     18     
1a/1b       2     
2 1 1 (1%) 
  
0 0% 
0.99 
3 3 21 (20%)   4 22% 0.83 
3a 18     18     
4 8 9 (9%)   1 9 (9%) 0.92 
4a 1     1     
4c/4d       1     
4h       6     
5a 39 39 (38%)   34 34% 0.71 
mixed       4 4%   
 
4.3.2.2.  LiPA (5’UTR plus core) 
Siemens recognised the inability of the LiPA (5’UTR) assay to accurately distinguish 
subtypes, particularly for genotype 1and 6.  They, therefore, introduced the LiPA 
(5’UTR plus core) assay evaluated by Verbeeck et al., 2008b. 
There was a 100% concordance between the results of the LiPA (5’UTR plus core) 
and SBT for the 31 genotype 1 specimens examined.  The subtypes of these speci-
mens were then compared using the two LiPA methods. Only 2 of the 24 genotype 
1a specimens, were correctly subtyped in the LiPA (5’UTR) assay as opposed to 
24/24 using the extended assay (LiPA 5’UTR plus core). Although all 6 of the geno-
type 1b specimens were detected by LiPA (5’UTR), a further 12 genotype 1a speci-
mens were mistyped as 1b. While LiPA (5’UTR plus core) failed to type only one 
specimen, LiPA (5’UTR) could not type 11 of the 31 specimens (Table 18). A valida-
tion of the LiPA (5’UTR plus core) against the QCMD panel showed complete  
 
 
Table 17.  Breakdown of subtypes identified by the two methods, Sequencing (SBT N=103) and LiPA 
(N=100) for the blood donor group 2006-2008 
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However, we noticed that the LIPA (5’UTR plus core) was not detecting any of the 
other mixtures. Verbeeck et al., 2008b did not validate the extended LiPA (5’UTR 
plus core) assay against mixtures.  To confirm our observation we then re-tested the 
extended assay in mixed infections (Table 19).  In 6 cases of mixed genotype 1 and 
5a infections, only genotype 5a was detected, whereas in the others, either geno-
Genotypes LiPA(5’UTR) % LiPA(5’UTR 
plus core) 
% 
1 9 29.0 1 3.2 
1a 2 6.5 24 77.4 
1b 18 58.0 6 19.4 
1a/1b 2 6.5 0 0 
Table 19.  Comparison of genotyping results in known mixed infections by LiPA (5’UTR) and LiPA 
(5’UTR plus core) 
Specimen 
number 
LiPA (5’UTR) LiPA (5’UTR 
plus core) 
Viral 
load 
(IU/ml) 
  
1. 1 + 4a 4 762000 SANBS mix 
2. 1 + 5a 5a 339000 SANBS mix 
3. 1 + 5a 1a 1130 SANBS mix 
4. 1b + 5a insufficient 437000 SANBS mix 
5. 1b + 5a 1b 14400000 Patient specimen 
6. 1b + 4 1b 1760000 Patient specimen 
7. 1b + 5a 1a 359000 Patient specimen 
8. 1 + 5a 1b 2940000 Patient specimen 
9. 1 + 5a 1b 936000 Patient specimen 
10. 1b + 5a 5a 89100 Patient specimen 
11. 1b + 5a 5a 574000 Patient specimen 
12. 1b + 5a 5a 94300 Patient specimen 
13. 1b + 5a 5a 85400 Patient specimen 
14. 1 + 5a 5a 35200 Patient specimen 
Table 18.  Subtyping of genotype 1 by LiPA (5’UTR) and LiPA (5’UTR plus core) 
agreement and the negative specimen was correctly identified (data not shown). 
Mixed infections GT0804 (1a + 3a) and GT0808 (1b+ 3a) were also correctly de-
tected by both LiPA assays. 
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4.4. DISCUSSION 
The three methods assessed in this study genotyped HCV specimens with varying 
success rates when compared to the gold standard SBT. LiPA (5’UTR plus core) 
was 100% concordant but the Real-time LightCycler method could only correctly 
type 64% of specimens.  Published real-time LightCycler studies on which the study 
method was based showed better concordance to sequencing (Schroter et al., 2002 
and Landt et al., 2002) but they either did not test genotype 5a specimens at all 
(Schroter et al., 2002) or tested only “typical” genotype 5a (Landt et al., 2002).  The 
method lacked robustness with our data set and only had an amplification efficiency 
of 82%.  Four of the 5 specimens which did not amplify were genotype 5a.  There 
may have been a loss in integrity of the RNA which resulted in poor or no amplifica-
tion.  This was also noted during the validation process, where the poor NPV and 
sensitivity values were aggravated by the high number of false negatives. 
 
All, except one of the genotype 5a sequences with the double A at positions 106 
and 107 were genotyped by the Real-time LightCycler method as they melted at an 
average Tm of 570C (Landt et al., 2002). However, the limited SNPs used by Schro-
ter et al., 2002 were insufficient for reliable genotyping of local genotype 5a which 
frequently melted at a higher temperature and could not be distinguished from geno-
types 1 and 2 (Fig.20a).   
type 1a or 1b was detected (Table 19). In mixed genotype 1and 4a infection only 
genotype 4 was detected.   As before, only the mixtures in the QCMD 2008 panel, 
consisting of genotype 3a with genotype 1a or 1b (data not shown), could be de-
tected. 
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The LiPA (5’UTR) and SBT in the 5’UTR had shown concordant results at genotype 
level.  A similar concordance was seen by Verbeeck et al., 2005 when LiPA (5’UTR) 
was compared to SBT in the NS4B region.  We have shown that the LiPA (5’UTR) is 
not only comparable to SBT, but surpasses it because it detected mixed genotype 
infections. The SBT method consistently identified only one genotype within mix-
tures.  Although LiPA (5’UTR) also uses a PCR product, both genotypes in all mixed 
infections were identified.  In a high throughput laboratory, the LiPA (5’UTR) is rec-
ommended as genotypes and to a limited extent , subtype 1, can be determined. 
 
The LiPA (5’UTR plus core) correctly discriminated genotype 1 into subtypes 1a and 
1b.  The clinical relevance of subtyping genotype 1 has not been fully ascertained. 
However, if requested, then the LiPA (5’UTR plus core) test can be used as it is a 
validated and optimized for subtyping genotype 1.  However, the cost per specimen, 
for subtyping using the core amplification assay, does increase (Table 11) and se-
quencing might be a cheaper option.  While, subtyping was better with the LiPA 
(5’UTR plus core) test, our findings have shown that mixed genotype infections, par-
ticularly of genotypes 1+4 and genotypes 1+5, cannot be detected by this test.  LiPA 
strips must be interpreted with caution to avoid mis-calling of ghost bands (Table 
11).  Also, it has been reported that point mutations caused by PCR amplification in 
the 5’UTR can alter test results (Li et al., 2008).  
 
In an attempt to explain the inability of the LiPA (5’UTR plus core) to distinguish 
some mixtures, the known 5’UTR sequences which are used as probes to distin-
guish types and subtypes of HCV were aligned and compared to core sequences. 
Sequence similarities between these regions of the 5’UTR and core (Table 20 num-
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bering according to Choo et al., 1991), suggest possible cross reactivity between 
core amplicons and/or the 5’UTR probe sequences.  Although, the manufacturer 
has recently noted that the assay is not optimised to identify mixed infection, we de-
scribe for the first time, the missing of specific mixed infections by the assay and 
suggest possible reasons for the masking of probes in the LiPA (5’UTR plus core) 
assay.   
 
Even though reports seem to indicate that mixed genotype infections were rare 
(Viazov et al., 2000,  Li et al., 2008), recent data indicate that the diagnosis of mixed 
genotypes has been increasing (Alavian et al., 2009, 4%; 1 and 3, 3 and 4 and Oh 
et al., 2008, 4.4%, genotype 1b and 2a/c).   Whether this is a result of the evolution 
of more sensitive HCV genotyping assays or an over interpretation of bands on 
LiPA strips, this needs to be ascertained by more specific approaches, like cloning 
the minor variant populations, specific PCR/sequencing primer sets for different 
genotypes (more costly) or the use of random hexamer or degenerate primers. 
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        probe 1                     
5'utr 1b       G T G T T G T G C A   
5a       - - - - C - A A - -   
4a       - - - - - - - A - -   
3a       - - - - C - - - - -   
    78-86                         
core 1b   C G - - - G - C A         
1a   T - - C - G - C A         
3a   T - - C - G A C A         
4a   T - - - - G C C A         
5a   - - - - - G - C A         
    probe 2                         
5'utr 1b   T G C C A G G A C G A C   
5a   - - - - G - - - T - - -   
4a   C - - - G - - - T - - -   
3a   C - - T G - - G T - - -   
                            
  
    49-57                         
core 1b   C - - - G C C C A         
1a   C - T - G C C C A         
3a   C - T - G C C C A         
4a   C - - - G C C C A         
5a   C - - - G C C C A         
    probe 5                       
5'utr 1b   A A T G C C T G G A G   
5a   - - - - - - C - - - -   
4a   - - - - - - C - - - -   
3a   - - - A - - C A - - A   
  09-21bp                         
core 1b G - - -   - - - A A - C   
1a - - - -   - - - A A - C   
3a A C T -   - - - A A - C   
4a - - - -   - - - A A - C   
5a - - - -   - - - A A - C   
    probe 6                       
5'utr 1b   C G A G A C T G C       
5a   - - - - - - - - -       
4a   - A - - - - - - -       
3a   - A - - - T C A -       
                            
    08-16bp                       
core 1b   - - - A T - C T A       
1a   - - - A T - C T A       
3a   - A C T T - C T A       
4a   - - - A T - C T A       
5a   - - - A T - C T A       
Table 20.  A summary of the possible overlap of amplified core sequences with the probes 1-6 used 
in the LiPA 2.0 assay.  The dash (-) indicates similarity for the nucleotide. 
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 4.5. CONCLUSION 
This comparative study has determined that the LiPA (5’UTR plus core) assay pro-
vided the best results for genotyping HCV and subtyping of genotype 1.  However, 
not all mixtures (specifically mixtures of genotype 1 together with either genotype 5 
or 4) were detected by this assay.  We have identified “masking” effects which may 
explain the ambiguity of the band patterns in this assay.  
 
The clinical usefulness of knowing the subtype of genotype 1 specimens prior to 
therapy is still uncertain, whereas the presence of genotype 1, even as a mixture, 
does affect time required for effective therapy (described further in chapter 8). Thus, 
in light of the poor performance of the LiPA (5’UTR plus core) assay with mixtures of 
genotype 1 together with genotypes 4 or 5, the extended assay may not be recom-
mended for diagnostic purposes.  However, it will be feasible to use the assay if 
subtyping of genotype 1 is specifically requested by the clinician and/or subtyping is 
required for a funded research purpose. Real time PCR for genotyping HCV is not 
universally reliable at present.  Other regions of the highly mutable HCV genome 
are being studied for use in a real-time PCR method for genotyping (Ciotti et al., 
2010). 
Of the methods examined in this chapter, the LiPA (5’UTR) assay has proven to be 
adequate for determining genotypes as required presently in our diagnostic setting.  
In surveillance – funded projects, this method is beneficial as the amplicon from the 
qualitative PCR is used for the LiPA(5’UTR) assay. Our annual validation processes 
continually assess the efficiency of this method and the LiPA (5’UTR plus core).  
With the less labour-intensive process, easy usage and quicker turn-around times 
(TAT’s), the LiPA (5’UTR) can be recommended for high throughput laboratories. 
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CHAPTER FIVE 
Palindromic-nucleotide Substitutions (PNS) Patterns within the major 
genotypes found in SA  
 
5.1.  INTRODUCTION 
Palindromic-like nucleotide substitution (PNS) patterns have been found in the stem
-loop structures of pestiviruses (Harasawa and Giangaspero, 1998) and HCV 
(Giangaspero et al., 2008) and are the result of viral evolution over time.  The con-
served palindromic substitutions stabilize the stem regions and maintain the basic 
structure (Harasawa and Giangaspero, 1998).  The stem-loop structures of domains 
IIIa, b and c (Piron et al., 2005, Fig.21a), reflect the characteristics of the HCV iso-
late, by genus, genotype and subtype (Giangaspero et al., 2008). The PNS patterns 
provide information on the base-pair signatures to which the primary sequence con-
forms to in the stem-loop.  Other than genotyping, this structural information at the 
5’UTR can be used to design targets for siRNA therapies (Prabhu et al., 2006) and 
reverse genetics (Friebe and Bartenschlager, 2009). 
   
The aim of this study was to investigate these genotype specific palindromic substi-
tutions within the 5’UTR of the HCV genotypes most prevalent in South Africa, 1 
and 5a. 
 
5.1.1. Objective:  
To investigate the genotype specific palindromic-like nucleotide substitutions (PNS) 
within the 5’UTR of genotypes, 1 and 5a, and discuss with reference to SBT and 
their usefulness as a diagnostic technique. 
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5.2.  METHODS 
Sixty-one sequences from previously genotyped specimens (genotype 1, N=26; 
genotype 5, N=35; chapter 3) were formatted and aligned using ClustalW in BioEdit, 
version 7.0 (Hall, 1997) over the informative regions (179 nucleotides) of the 5’UTR 
as described by Giangaspero et al., 2008. For genotype 1 analyses, reference 
strains, M62321 (1a), D50480 (1b), D14853 (1c) were used.  For genotype 5a 
analyses,  Y13184 (5a), AF064490 (5a), U33430 (5a), AM502711 (5a), AM502710 
(5a), DQ164748- DQ164751 (5a), AY033769 (5a) and L28057 (5a).  Sequences 
were then analysed for PNS patterns as described previously (Giangaspero et al., 
2008).  
 
5.3.  RESULTS 
Of the 26 genotype 1 specimens analysed, 20 are shown in Table 21a and of the 35 
genotype 5a specimens analysed, 16 are shown in Table 21b.  The PNS method 
scored a 100% concordance with SBT, and a 100% for NPV, PPV, sensitivity and 
specificity at the genotype level.   However, like SBT using the 5’UTR region, the 
PNS method does not discriminate subtypes well.  The characteristic genotype PNS 
patterns identified by Giangaspero et al., 2008 for genotype 1 and genotype 5a 
were observed in our study.  In the primary nucleotide alignments (Table 21a) of 
genotype 1 (141-252 or -201 to –89, according to Choo et al., 1991) and 5a se-
quences (Table 21b, 102-227 or -240 to –114, according to Choo et al., 1991), the 
shaded regions highlight important base pair signatures in the stem-loop se-
quences. Row 1 of the tables refers to the PNS pattern number (see also Figure 21, 
specifically, Fig. 21b) while row 2 gives the actual nucleotide number in the primary 
sequence data. The RNA folding is a result of base-pairing of upstream nucleotides 
128 
with complementary nucleotides further downstream. For example, PNS pattern 28 
pairs nucleotides 179 and 220 (Table 21a). 
  
The highlighted region on Fig.21a shows the PNS in the stem-loop sequences over 
the 141-252 nucleotide base pairs (Fig. 21b). The numbering of the nucleotides and 
variable structural regions is according to Giangaspero et al., 2008. The arrows in 
the tables indicate variations among genotypes observed in this study. Position 204 
(Table 21a) has a nucleotide base change from cytosine (C) to adenine (A) 
(specimens 420/LD1, 1958/H, 1956/H, 1108/H, 1485/H and 2763/H) or thymidine 
(T) (genotype 1c reference sequence (D14853), 6641/H). Position 243, identified as 
a PNS characteristic (position 10) for subtyping genotype 1 into 1a and 1b 
(Giangaspero et al., 2008), corroborates the subtype change from adenine (A) 
(genotype 1a) to guanosine (G) (genotype 1b). This 1a/1b clustering is identical to 
that seen in the phylogenetic analysis (in chapter 3, Fig.16, page 95) where speci-
mens with guanosine (G) at 243 clustered with the reference 1b strain, D50480.  
  
 
 
 
 
 
 
 
 
 
129 
 
47                        UU                                             UU 
46                      C    G                                         C    G 
45                      U    G                                         U    G 
44                      U    A                                         U    A 
43                      U    U                                         U    U 
42                      C    H                                         C    A 
41                      C    A                                         C    A(A) 
40                       U-A                                            U-A 
39                       G-C                                            G-C 
38                       G-C                                            G-C 
37                       G-C                                            G-C 
36                       C-G                                            C-G 
35                      C    C                                         C    C 
34                       A-U                                            A-U 
33                       G-CA                                         G-C 
32                       B     A                                         Y:AA 
31                       A     Y                                         A    U 
30                       G-CG                                          G-CG 
29                       G-C                                             G-C 
28                       A-U                                             G-C 
27                       C-G                                             C-G 
26                       C-G                                             C-G 
25                      G    A                                         G     A 
24                       U*G                                            U*G 
23                       U-A                                             U-A 
22                       A-U                                             A-U  
21                       A-U                                             A-U 
        A          20 G*U /19   C                 A             G*U       C 
    W     CACCG     GGG   G           U     CACCG     GGG   G 
    G     GUGGC     CCC   Y            G     GUGGC     CCC   U 
        A         17 C     . \18 G                  A             C     .       G 
16                      A     .                                           A     . 
15                      W     .                                          A     . 
14                      G-C                                            G-C 
13                       G-C                                            G-C 
12                       C-G                                            C-G 
11                       G-C                                             G-C 
10                      .     R                                           .     G 
9                         U-A                                            U-A 
8                         C-G                                            C-G 
7                        U-A                                            U-A 
6                         G-C                                            G-C 
5                         G:Y                                            G*U 
4                         U*G                                           U*G 
3                        G-C                                           G-C 
2                         A-U                                            A-U 
1                     5'-U-A-3'                                   5'-U-A-3' 
                   (HCV-1)                             (HCV-5) 
Fig.21. (a) Secondary structure of the 5’UTR of the HCV genome (Fraser and Doudna, 2007), with 
the IIIa-c region highlighted as the regions sequenced in the study.  (b) Variable locus in the secon-
dary structure of the 5’-UTR of the genotypes 1 and 5 of hepatitis C virus species, genus He-
pacivirus.  Base pairings characteristic to the genus (PNS genus specific) are shown in bold. The 
characteristic base pairings of the HCV genotypes (PNS genotype specific) are represented in bold 
and underlined. Base pairings characteristic to subtype-specific PNS are shown in bold and italic. 
Watson–Crick base pairings are indicated by a dash (–); tolerated pairings in secondary structure are 
indicated by an asterisk (*); interchangeable base pairings are indicated by a colon (:).  
R =A or G; W=A or U; Y = C or U; B= C or G or U; H=A or C or U. 
a 
b 
130 
 
Ta
bl
e
 
21
a
.
 
N
u
cl
e
o
tid
e
 
a
lig
n
m
e
n
t 
(nu
cl
e
o
tid
e
s 
14
1-
25
2) 
o
f 
ge
n
o
ty
pe
 
1 
se
qu
e
n
ce
s 
to
 
re
fe
re
n
ce
 
se
qu
e
n
ce
s 
fo
r 
PN
S 
a
n
a
lys
e
s.
 
 
 
G
e
n
Ba
n
k 
se
qu
e
n
ce
s:
 
,
 
 
M
62
32
1 
(1a
), 
D
50
48
0 
(1b
) a
n
d 
D
14
85
3 
(1c
). 
 
 
 
Th
e
 
sh
a
de
d 
re
gi
o
n
s 
(nu
cl
e
o
tid
e
s 
17
9 
pl
u
s 
22
0 
a
n
d 
24
3) 
hi
gh
lig
ht
 
st
ru
ct
u
ra
l i
n
fo
rm
a
tio
n
 
a
t b
a
se
-
pa
ir 
28
 
a
n
d 
10
,
 
re
sp
e
ct
iv
e
ly,
 
w
hi
ch
 
a
re
 
sp
e
ci
fic
 
PN
S 
si
gn
a
tu
re
s 
fo
r 
ge
n
o
ty
pe
 
1.
 
 
Th
e
 
a
rr
o
w
 
m
a
rk
s 
th
e
 
pr
e
vi
o
u
sl
y 
u
n
re
po
rte
d 
va
ria
tio
n
 
a
t n
u
cl
e
o
tid
e
 
20
4 
w
hi
ch
 
w
a
s 
o
b-
se
rv
e
d 
in
 
th
is
 
st
u
dy
.
 
Th
e
 
PN
S 
re
su
lts
 
a
re
 
co
m
pa
re
d 
to
 
se
qu
e
n
ci
n
g 
in
 
th
e
 
5’
UT
R
 
a
n
d 
N
S5
B 
re
gi
o
n
s.
 
 
1
2
3
25
26
27
28
29
30
31
39
40
41
42
 
41
40
39
38
37
28
27
26
25
24
23
22
21
13
12
11
10
9
8
7
6
5
4
3
2
1
14
1
 
14
2
14
3
17
6
17
7
17
8
17
9
 
18
0
18
1
18
2
20
1
20
2
20
3
20
4
 
20
5
20
6
20
7
20
8
20
9
22
0
 
22
1
22
2
22
3
22
4
22
5
22
6
22
7
22
8
22
9
24
2
24
3
24
4
24
5
24
6
24
7
24
8
24
9
25
0
25
1
25
2
5'
UT
R
N
S5
B
 
P
N
S
M
62
32
1(1
a
)
1a
T
A
G
G
C
C
A
G
G
A
G
A
T
C
A
A
C
C
C
T
G
G
A
G
A
T
T
C
G
C
A
A
G
A
C
T
G
C
T
A
42
0/
LD
1
1a
-
-
-
-
-
-
-
-
-
-
-
-
-
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1a
 
o
r 
1c
1a
1a
 
o
r 
1c
19
58
/H
1a
-
-
-
-
-
-
-
-
-
-
-
-
-
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1a
 
o
r 
1c
1a
1a
 
o
r 
1c
19
56
/H
1a
-
-
-
-
-
-
-
-
-
-
-
-
-
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1a
 
o
r 
1c
1a
1a
 
o
r 
1c
30
7/
H
1a
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1a
 
o
r 
1c
1a
1a
 
o
r 
1c
90
49
/L
D
1
1a
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1a
 
o
r 
1c
1a
1a
 
o
r 
1c
D
50
48
0(
1b
)
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
11
08
/H
?1
b
-
-
-
-
-
-
-
-
-
-
-
-
-
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
o
u
tli
e
r 
1a
 
o
r 
1c
N
D
1b
14
85
/H
?1
a
-
-
-
-
-
-
-
-
-
-
-
-
-
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
1a
1b
27
63
/H
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
N
D
1b
44
34
/L
D
2
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
N
D
1b
96
7/
LD
2
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
N
D
1b
27
71
/L
D
2
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
N
D
1b
25
85
/L
D
2
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
N
D
1b
53
07
/L
D
2
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
N
D
1b
38
94
/H
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
N
D
1b
63
73
/H
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
N
D
1b
12
29
/L
D
1
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
1b
1b
22
05
/L
D
1
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
1b
1b
35
6/
LD
1
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
1b
1b
11
09
/H
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
1b
1b
66
41
/H
1b
-
-
-
-
-
-
-
-
-
-
-
-
-
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
-
-
-
-
-
-
-
-
-
1b
N
D
1b
D
14
85
3(
1c
)
1c
-
-
-
-
-
-
-
-
-
-
-
-
-
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
G
e
n
o
ty
pe
P
N
S 
v
s
 
s
e
qu
e
n
c
in
g
re
fe
re
n
c
e
 
1a
re
fe
re
n
c
e
 
1c
re
fe
re
n
c
e
 
1b
St
em
 
lo
o
p 
do
m
ai
n
s 
III
 
a,
 
b,
 
c 
131 
 
Ta
bl
e
 
21
b.
 
N
u
cl
e
o
tid
e
 
a
lig
n
m
e
n
t (
n
u
cl
e
o
tid
e
s 
10
2-
11
0,
 
17
3-
18
3,
 
20
1-
20
9,
 
21
4-
21
6 
a
n
d 
22
1-
22
7) 
o
f g
e
n
o
ty
pe
 
5a
 
 
se
qu
e
n
ce
s 
to
 
re
fe
re
n
ce
 
se
qu
e
n
ce
s 
fo
r 
PN
S 
a
n
a
lys
e
s.
 
 
Th
e
 
sh
a
de
d 
re
gi
o
n
s 
(nu
cl
e
o
tid
e
s 
17
5,
 
22
5 
a
n
d 
17
9,
 
22
1 
hi
gh
lig
ht
 
st
ru
ct
u
ra
l i
n
fo
rm
a
tio
n
,
 
a
t b
a
se
pa
ir 
24
 
a
n
d 
28
,
 
re
sp
e
ct
ive
ly)
 
in
di
ca
te
 
PN
S 
si
gn
a
tu
re
s 
fo
r 
ge
n
o
ty
pe
 
5a
.
 
 
Th
e
 
co
lu
m
n
s 
w
ith
 
a
rr
o
w
s 
10
6,
 
18
3 
a
n
d 
20
7 
re
ve
a
l n
u
cl
e
o
tid
e
 
ba
se
 
su
bs
tit
u
tio
n
s 
o
bs
e
rv
e
d 
in
 
o
u
r 
st
u
dy
.
 
St
em
 
lo
o
p 
do
m
ai
n
s 
III
 
a,
 
b,
 
c 
D
o
m
ai
n
 
 
II 
 
22
 
23
24
 
25
 
26
 
27
28
 
29
30
 
31
32
 
45
 
44
 
43
 
42
 
41
 
41
40
 
39
39
 
32
 
32
 
29
28
 
27
 
26
 
25
24
 
23
 
22
10
2
 
10
3
10
4
10
5
10
6
10
7
10
8
10
9
11
0
17
3
17
4
17
5
17
6
17
7
17
8
17
9
18
0
18
1
18
2
18
3
20
1
20
2
20
3
20
4
20
5
20
6
20
7
20
8
20
9
21
6
21
5
 
21
4
22
1
22
2
22
3
22
4
22
5
22
6
22
7
Y
13
18
4
SA
G
T
C
G
A
A
C
A
G
A
T
T
G
C
C
G
G
G
A
T
G
A
T
A
A
A
-
C
C
A
A
C
C
G
G
A
G
A
T
5a
A
F0
64
49
0
SA
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
A
M
50
27
11
Fr
a
n
c
e
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
C
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
A
M
50
27
10
Fr
a
n
c
e
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
C
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
D
Q1
64
75
0
B
e
lg
iu
m
N
N
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
C
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
25
77
/L
D
1
SA
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
C
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
D
Q1
64
75
1
B
e
lg
iu
m
N
N
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
D
Q1
64
74
9
B
e
lg
iu
m
N
N
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
T
-
-
-
-
-
T
-
-
-
-
-
-
-
-
-
5a
D
Q1
64
74
8
B
e
lg
iu
m
N
N
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
U
33
43
0
C
a
n
a
da
-
-
-
-
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
34
94
/L
D
1
SA
-
-
-
-
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
-
-
-
-
-
-
-
-
-
-
-
-
a
ty
pi
c
a
l 5
a
11
16
/L
D
1
SA
-
-
-
-
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
a
ty
pi
c
a
l 5
a
37
88
/L
D
1
SA
-
-
-
-
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
a
ty
pi
c
a
l 5
a
24
73
/L
D
1
SA
-
-
-
-
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
a
ty
pi
c
a
l 5
a
10
44
/L
D
1
SA
-
-
-
-
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
a
ty
pi
c
a
l 5
a
L2
80
57
A
u
s
tr
a
lia
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5
A
Y
03
37
69
B
ra
z
il
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
-
-
-
-
-
-
-
-
-
-
-
-
5a
30
65
/L
D
1
SA
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
-
-
-
-
-
-
-
-
-
-
-
-
5a
20
14
/L
D
1
SA
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
-
-
-
-
-
-
-
-
-
-
-
-
5a
91
8/
LD
1
SA
-
-
T
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A
-
-
-
-
-
-
-
-
-
-
-
-
5a
20
31
/L
D
1
SA
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
T
-
-
-
-
-
-
-
-
-
-
-
5a
15
1/
LD
1
SA
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
39
75
/L
D
1
SA
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
51
/L
D
1
SA
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
36
3/
LD
1
SA
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
66
/L
D
1
SA
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
11
9/
LD
1
SA
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5a
G
e
n
o
ty
pe
C
o
u
n
tr
y 
o
f o
rig
in
132 
The specific combination of two base-pairings for genotype 5a were seen: a U*G at 
position 24 (also shared with genotype 1 and 6) but differs for genotype 2 (UC 
bulge) and genotypes 3 and 4 (CA bulge); and a G-C base pair at position 28 (seen 
also with genotypes, 2, 3, and 4) but differs among the genotype 1 (A-U, Gian-
gaspero et al., 2008). We also found a thymidine (T) change to cytosine (C) at posi-
tion 183 for one of our isolates, 2577/LD1, as well as two French (AM502710, 
AM502711) and one Belgium isolate (DQ164750, Table 21b). In eight of our speci-
mens and the Brazilian isolate (AY033769), there was an adenine (A) insertion at 
position 207 (only 4 of the 8 sequences are shown in Table 21b), similar to that 
seen in genotype 6a and 6b. The genotype 5a specimen sequences with these 
changes did not cluster significantly differently by phylogeny (in chapter 3, Fig.16, 
page 95). However, 2577/LD1did present with a distinct branch length.  
 
 5.4.  DISCUSSION 
 
Compared to the LiPA (5’UTR plus core), the PNS method is time-consuming. It not 
only requires sequencing, but also complex analyses of the sequence data.   Our 
results were concordant with the sequencing results and the specific patterns identi-
fied by Giangaspero et al., 2008.  We found three more variations among our geno-
type 5a sequences as indicated at positions 107, 183 and 207. Whereas the nucleo-
tide change at position 107 lies outside the stem-loop, the change at position 183 
lies in the stem region between IIIa and IIIb. The C change at position 183 has no 
effect on its complementary nucleotides AA at position 215 and 216, respectively. 
However, we indicate that the stable U-AA bond will change to a Y: AA bulge in po-
sition 32 (Fig. 21b). The insertion at position 207, seen in some of the genotype 5a 
sequences, is part of the IIIb loop.  This change is not evident in other genotypes 
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studied previously. The insertions of A at position 207 and CA at position 197 (41 
and 47 in the structural alignment respectively) were described as a unique PNS 
characteristic to two of the genotype 6 subtypes, 6a and b providing a higher secon-
dary loop structure (Giangaspero et al., 2008). These insertions were not seen for 
subtypes, 6d, g, h and k.  This insertion did not elongate the loop, but an added A at 
position 41 for the genotype 5a sequences in this study is noted. Functionally, since 
this occurs in the loop structure, little or no effect on viral viability and replication is 
expected (Wang et al., 2005) but specific changes should be taken into account for 
primer design.  
  
The PNS method differentiated subtypes 1a and 1b by the base pair change at nu-
cleotide position 243, observed in PNS position 10. However, A is also present for 
subtype 1c. Sequence information of nucleotides 1 to 80 would have cleared this 
ambiguity as the PNS characteristic for genotype 1c (GG bulge at position 7) is 
identified in the stem-loop I structure (Giangaspero et al., 2008).  
 
However our phylogenetic analyses in the 5’UTR and NS5B region (Prabdial-Sing et 
al., 2008; chapter 3, Fig. 16 and 18, respectively, page 95, 97) has shown no evi-
dence of any specimen grouping with the genotype 1c reference sequence, 
D14853. The nucleotide change seen among our genotype 1 at position 204 was 
recognised by Giangaspero et al., 2008 and seemingly had no structural change in 
the IIIb loop. 
  
5.5.  CONCLUSION 
The PNS method had successfully genotyped 1 and 5a specimens and it is now 
possible to visualise primary sequence data of the UTR as a stem-loop structure. At 
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present PNS analysis is labour intensive, but the method would have potential were 
computer programmes are easily accessible and available to fully automate the 3D 
analysis. PNS would then provide a rapid, reliable alternative to phylogenetic analy-
sis which is also capable of differentiating genotypes within the conserved 5’UTR 
region.  
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CHAPTER SIX   
Molecular characterization of genotype 5a by partial sequence analysis 
of clinical specimens 
 
6.1.   INTRODUCTION 
The HCV genome is a paradox as it has highly conserved and variable regions.  
The genome of HCV has highly variable (E1-E2), semi conserved (core, NS5B) and 
highly conserved (5’ and 3’ UTR, Fig.2) regions.  It displays both “Darwinian” and 
“neutral” evolutionary traits (Simmonds, 2004) which allow, on the one hand, viral 
fitness and immune escape and on the other hand, the “neutral drift” whereby 
changes to the nucleotide sequence has no or little effect on viral phenotype and 
accounts for the HCV genotype diversity, which is geographically distributed 
(Simmonds, 2004).  This dual nature of HCV evolution may account for the high 
turnover of closely related sequences (quasispecies) and survival in the host 
(Sarrazin and Zeuzem, 2010). 
    
This quasispecies nature, common in RNA viruses, is maintained by immunological 
pressure in vivo (Yao et al., 2005) and accounts for disease chronicity (Farci et al., 
2000) and the varied outcome of interferon-based therapy (Martell et al., 1992).  The 
viral RNA-dependent RNA-polymerase (RdRp) protein encoded by the NS5B region 
(Fig.2) lacks proof-reading and repair mechanisms and contributes to the high fre-
quency of mutations (Steinhauer et al., 1992).   
 
With the heterogeneity of the HCV sequence, it is difficult to successfully amplify full
-length HCV genomes.  It has been estimated that 12 sets of primers will be neces-
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sary for every 4 amplicons with at least a further 9 permutations per amplicon (Yao 
et al., 2005).  This process of amplification is expensive and labour-intensive.  Fur-
thermore the low titre of virus in clinical samples (<107 IU/ml, Table 1) and the lack 
of an efficient cell culture system to amplify all types of HCV makes the generation 
of long template amplicons of HCV difficult and problematic.  Relevant properties of 
HCV are summarized below (Fan et al., 2006): 
(a)  The virus is very labile and sensitive to poor handling, incorrect storage tem-
peratures and freeze/thaw cycles. 
(b) HCV folds to form secondary structures along its genome (Tuplin et al., 2004) 
severely complicating full-length cDNA synthesis. 
(c) Although HCV in vitro studies have been promising, the success is limited to 
only a few genotypes.  Concentration of virus in clinical samples is relatively 
low compared to other viruses (Fan et al., 2006). 
 
Because of these difficulties, many epidemiological surveys use small fragments for 
phylogenetic studies. Shorter sequences are quicker to generate and more reliable 
(Sheehy et al., 2005).  Care must be taken when using sub-genomic regions as not 
all regions are phylogenetically informative for all subtypes (Simmonds et al., 1993b; 
Verbeeck et al., 2006), as is the case for highly conserved regions such as the 
5’UTR (Chapter 3).  Concatenation of several sub-genomic regions is an attractive 
compromise. Verbeeck et al., 2006 found that there was more phylogenetic signal 
from the concatenated E1/NS4B region, compared to the individual E1 or NS4B, re-
spectively.  Concatenation of similarly conserved or less conserved regions may not 
skew overall results but may provide for better bootstrap values of a monophyletic 
clade (Verbeeck et al., 2006).   However, often the same sequence data is not avail-
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able for all specimens studied or reference sequences may not be available for 
comparison (Pybus et al., 2009).   
 
Currently, the International Nucleotide Sequence Database Collection (INSDC, pre-
viously known as DDBJ, EMBL, GenBank) has 44000 HCV reference sequences 
(Shin et al., 2008).  Few full genomes of the lesser known genotypes (particularly 
genotype 4 and 5) appear in the international database.  Less than 1% of these are 
genotype 5a.  Genotype 5a is not a predominant subtype in western countries and 
very few molecular studies have been performed to sequence and characterize it.  
Hence, variations of genotypes 5a are not well documented.  Pang et al., 2009 de-
termined the evolutionary branching order of genotypes in correlation to their re-
spective responses to therapy.   They looked at 348 full genome sequences from 
the European HCV database (Combet et al., 2007), of which only 2 are genotype 
5a.  Due to this poor representation, there was uncertainty with regard to the geno-
type 5a branching order and response to therapy.   
 
The aim of this part of the study was the molecular characterization of genotype 5a 
isolated from South African patients, performed by partial sequencing of sub-
genomic regions.  Different phylogenetic programs were used to best explain clus-
tering in the semi-conserved core and NS4B regions and less conserved E1 region.  
The divergence of genotype 5a from other types and subtypes in the human popula-
tion was calculated by using various phylogenetic inference packages. 
 
5.1.1. Objectives: 
(a) Sequence analyses of the core, envelope (E1) and non-structural 4B (NS4B) 
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regions of genotype 5a. 
(b) Phylogenetic relatedness of these partial sequence data with genotype 5a 
from other parts of the world. 
(c) To establish by phylogenetic evolutionary analyses, the most recent common 
ancestor (MRCA) of genotype 5a and thereby its probable divergence time as 
a discrete type in the human population. 
 
6.2. METHODS 
6.2.1. Study participants  
Partial sequencing of 25 genotype 5a, 1 genotype 1a (427), 1 genotype 1b (9400) 
and 1 genotype 4 (9411) previously genotyped specimens (chapter 3) was per-
formed. Specimen choice was dependent on the volume and condition of the stored 
retrospective serum/plasma specimens.  These were all once-off collections, so se-
rial analysis of samples was not possible.   Sampling dates were also not available 
for these specimens. Specimens sequenced were extracted from 13 anonymous 
volunteer blood donors, (acquired from SANBS), 13 patients with known liver dis-
ease and 2 HCV infected haemophiliacs.  Specimens with viral load of >105 IU/ml 
(Cobas Amplicor Monitor, Roche Diagnostics, Germany) were used.   
 
6.2.2. RNA extraction and primer design 
RNA extraction from stored sera was performed by using the QIAamp Mini RNA ex-
traction kit (Qiagen, Germany) as it was found to be more sensitive than the Mag-
naPure method.  Viral RNA was extracted from 280 µl of serum or plasma, accord-
ing to the manufacturer’s protocol and eluted in 50 µl double-distilled water.  The 
concentration of the extracted RNA was measured on the Nanodrop (Thermo-
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Scientific, USA).  Full-length genome sequencing was attempted by long template 
PCR and “sequence walking”. For long template PCR (>3000bp) the following prim-
ers were used: random hexamer primers, poly adenine/uracil primers (Transcriptor 
First Strand cDNA Synthesis, Roche Diagnostics, Germany)  and primers specific to 
genotype 5a (adapted from Fan et al., 2006, Table 22).  For “sequence walking”, 
primers for amplification of shorter fragments were designed for genotype 5a.    A 
list of the primers used for RT, PCR and sequencing of the core, E1 and NS4B re-
gions is provided in Table 22.  Primer sequences are numbered according to Choo 
et al., 1991 (Fig.2) and primer sequences of the antisense 8907, core and the NS4B 
inner antisense 4963 have been changed to suit genotype 5a sequences (Table 22). 
 
6.2.3. cDNA synthesis 
Both the reverse-transcription and PCR reactions were optimized using a variety of 
enzymes.  A comparison of the length of amplicon generated and the start-up con-
centration required for an efficient amplification is listed in Table 23, which can be 
used as a reference guide for other students.  The superscript RT III enzyme 
(Invitrogen, USA) performed best over all sub-genomic regions, could amplify low 
concentrations of material and was ideal for the clinical specimens (Table 23).  Ten 
µl of extracted RNA was added to 2 µl (1 µM) antisense primer 8907 (Table 22) and 
1.5 µl (1.3mM) dNTP mix (10 mM each dATP, dGTP, dCTP and dTTP at neutral 
pH).  The mix was heated at 650C for 5 minutes and then cooled on ice. Four µl of 
5X First Strand buffer was added to the mix, with 1 µl (5mM) DTT, 0.5 µl (20U) 
RNAse inhibitor (Protector RNAse inhibitor, Roche Diagnostics, Germany) and 1 µl 
(200U Superscript RT III enzyme).  The final volume of 20 µl was incubated at 500C 
for 75 minutes, followed by heat inactivation at 700C for 15 minutes as per 
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Table 22.  List of primers , primer details and combinations and amplicon sizes for method used (for 
the core, E1 and NS4B regions (numbering according to Choo et al., 1991)  
Enzyme (RT) Manufacturer Amplicon length Concentration re-
quired 
iScript cDNA BioRad <1kB 100fg-1µg/µl 
Superscript III Invitrogen <12kB 10pg-5µg/µl 
Transcriptor First 
strand cDNA 
Roche Diagnostics <14kB 10ng-5µg/µl 
Transcriptor Hi-
Fidelity 
Roche Diagnostics <14kB 1ng-4µg/µl 
Transcriptor Reverse 
transcriptase 
Roche Diagnostics     
RT- One Tube TITAN Roche Diagnostics <6kB 1pg-1µg/µl 
Enzyme (nest PCR)       
FastStart Taq Roche Diagnostics <3kB 10pg-100ng/µl 
Expand Long Tem-
plate 
Roche Diagnostics <22kB <500ng 
iProof Hi-Fidelity BioRad <7.5kB 1pg-10ng/µl 
Long PCR Enzyme   <21kB 2.5ng/µl 
rTth DNA poly-
merase, XL (requires 
inhibitor Trnc-21) 
Applied Biosystems 5kB-40kB 104 – 107IU/ml 
1µg 
1Chan et al., 1992; 2 Okamoto et al., 1990; 3 Bukh et al., 1994; 4Chamberlain et al., 1997; 5Legrand-Abravanel et al., 2007; 
6Verbeeck et al., 2006; 7Yao et al., 2005; sense, Sn and anti-sense, Asn, RT, reverse transcriptase; nest, nested PCR and 
seq, sequencing PCR  
Table 23.  A list of enzymes were used for reverse-transcription (RT) and first and nested PCR for 
sequencing of HCV 
Region Primer Sequence Tm 
(0C) 
G:C Amplicon size 
(bp) 
method 
GENOME Asn 8907-8924 5’- GCGCCAACGGTRAACCAG - 3’ 61 61 cDNA RT 
CORE Outer Sn 1 
(-297 -277) 
5’-CTGTGAGGAACTACTGTCTT-3’ 55 
  
45 
269 1
st
 PCR 
  
  Outer Asn2 
(508-529) 
5’-GATAGAGAAAGAGCAACCGGG-3’ 53 61 
  Inner Sn 1 
(-278-258) 
5’-TTCACGCAGAAAGCGTCTAG-3’ 55 50 
238 Nest/Seq 
    Inner Asn 3 
(458-482) 
5’-GTTGCATAGTTTATCCCGTCTTCAAGAACC-3’ 55 50 
CORE/E1 Outer Sn4 
(8-28) 
5’-CGAATCCTAAACCTCAAAG-3’ 
  
47 42 
971 1
st
 PCR 
  
  Outer Asn5 
(957-979) 
5’-ACCATTTCATCATCATGTCCCA-3’ 
  
51 41 
  Inner Sn4 
(19-48) 
5’-CCTCAAAGAAAAACCAAAAGAAACAAC – 3’ 
  
54 33 
960 Nest/Seq 
  
  Inner Asn5 
(951-979) 
5’-ACCATTTCATCATCATGTCCCATGCCAT-3’ 
  
58 43 
NS4B Outer Sn6 
(4696-4717) 
5'-ATCAACATCGACGCYCACATG - 3' 
  
57 52 
617 
1st PCR/
seq 
  
  Outer Asn6 
(5293-5313) 
5'-CCCACTGACAAAGTTCCACAT-3' 59 48 
  Or 
Inner Asn7 
(4963-4982) 
  
5'-CCCACGTGCTGGTAATGAC-3' 
  
60 
  
58 268 
  
Nest/Seq 
  
manufacturer’s protocol. 
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6.2.4. PCR and sequencing 
Five µl of cDNA was added to the first round of PCR mix of 5 µl (10X) PCR buffer 
with 2 mM MgCl2, 10 µl (5X) GC rich solution (additive for difficult templates), 2.5 µl 
(0.5uM) of each primer for the respective regions (Table 22), 1 µl (0.2 mM) of the 
dNTP mix and 0.5 µl (2.5 U) of the FastStart Taq polymerase (Roche Diagnostics, 
Germany) and a final volume of 50 µl was amplified.  The thermocycler parameters 
were programmed as 980C for 2 minutes, followed by 35-45 cycles of 980C for 1 
minute, 550C for 1 minute and 720C for 1 minute and a final extension at 720C for 5-
7 minutes.  Five µl of the first round PCR product was added to the nested amplifi-
cation mix with primers (Table 22).  The specimens that were amplified in the NS5B 
region were subjected to this protocol using the primers mentioned in chapter 3 and 
Table 8.  The PCR additives for the nested mix and the cycle parameters were the 
same as the first round.  The first round and nested PCR products were analysed on 
a 1-2% agarose gel.  PCR products were purified by the MSB Spin PCRapace clean
-up (Invitek, Germany).  Direct sequencing on both forward and reverse strands 
were performed on the purified DNA fragments using the ABI Prism BigDye Termi-
nator Cycle Sequencing reaction kit, version 3.1 (Applied Biosystems, USA).  The 
primers that were used for the nested PCR protocol (Table 22) were used for the 
sequencing reactions and the reaction mix was prepared as recommended by the 
manufacturer.  Chromatogram analyses were performed by the Sequencher, ver-
sion 4.1.4. Software. 
 
6.2.5.  Phylogenetic analyses 
A flow-chart to describe the analyses is presented in Fig.22.  Multiple sequence 
alignments were generated by the ClustalW (Higgins, 1994) program in MEGA 4.0 
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(Tamura et al., 2007) for the core, E1, NS4B, NS5B and concatenated core/NS5B 
and E1/NS4B regions.  The Kimura-2 parameter (Kimura, 1980) was chosen for the 
phylogenetic analyses for the core, NS4B and NS5B.   The number of nucleotide 
substitutions/site between the different sequences (d) was calculated to be between 
0.05 and 0.3 and Kumar et al., 2008 substantiate that if 0.05<d<0.3, then the Kimura
-2 parameter can be used, particularly if the transition/transversion rate (R) >5.  Al-
though, d was lower at 0.03 for the core region, R was >5 and the Kimura-2 pa-
rameter was used.  The higher diversity of 0.371 for the E1 region prevented pair-
wise calculations using the Kimura-2 parameter and the Jukes-Cantor (JC, Jukes 
and Cantor, 1969) parameter was chosen for this region. 
Fig.22. An explanatory flow-chart to indicate the methods used for the phylogenetic and evolutionary 
analyses conducted for the different sub-genomic regions.  
 
NJ, neighbour-joining; Kim-2, Kimura-2 parameter; MCL, Maximum composite Likelihood; ML, Maximum likelihood; UPGMA, 
Unweighted pair group method with arithmetic mean 
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Phylogenetic analyses for the concatenated regions were performed with the Maxi-
mum Composite Likelihood (MCL) parameter in MEGA 4.0 in order to compare phy-
logenies and branching order of these regions with each individual region, respec-
tively (Fig.22).  The maximum likelihood (ML) model (Phyml v.2.4.4, Guindon and 
Gascuel, 2003) provided as an online service (www.hcv.lanl.gov) was used for 
analyses on the core, E1, NS4B and NS5B regions.  For the ML analyses, fasta-
formatted sequences were submitted online and the FindModel function (a web 
function of the ModelTest script) was chosen.  For the General Time Reversible 
(GTR, Tavare, 1986) model, the discrete gamma model with the gamma shape pa-
rameter of 2 was chosen and tree topology was optimised by the online software.  
Although, the Transversion model was best suited for the core region, this model is 
not available on MEGA 4.0 or online and the Kimura-two model was used for the 
core data.  Bootstrapping for both the neighbour-joining methods, Kimura-two and 
Maximum Composite Likelihood (MCL), and the ML parameters were tested at a 
1000 replicates and consensus trees were viewed by using MEGA 4.0 and Tree-
View, respectively.  Bootstrap values of >70% were displayed on phylogenetic trees.  
The mean overall nucleotide differences were calculated per region (MEGA 4.0) 
across all genotypes and for genotype 5a only, respectively.  The concatenated re-
gions were subjected to MCL analyses only.  
 
Reference strains used in the study were attained from GenBank (accession num-
ber):  for the core region; D16789-D16795 (5a clones, Ohno et al., 1994), Z29470-
Z29474 (5a, Belgium, van Doorn et al., 1995); E1, FN553052-FN553065, 
FN552976, FN552983, FN552995 (5a, France, Henquell et al., 2004), L39281, 
L39295 (5a, Belgium, van Doorn et al., 1995); NS4B, EF026073, AM408911 (2/5a 
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recombinant, Legrand-Abravanel et al., 2007), DQ164642-DQ164747 (5a, Belgium, 
Verbeeck et al., 2006), FN553233-FN553282 (5a, France, Henquell et al., 2004); 
NS5B, AJ291281 (5a, France, Morice et al., 2001), FN553360 (5a, France, Hen-
quell et al., 2004), L29584 (5a, Belgium, Stuyver et al., 1994), AJ608776 (5a, Hen-
quell et al., 2004), FN553377 (5a, France, Henquell et al., 2004), L29602 (4, Bel-
gium, Stuyver et al., 1994), L36437 (4, Central African Republic, Henquell et al., 
2004), L29590 (4, Belgium, Stuyver et al., 1994), D86543 (4, Japan, Tokita et 
al.,1998), L78841 (4, Belgium, Stuyver et al., 1994), D86534 (4, Japan, Tokita et 
al.,1998), L36438 (4, Central African Republic, Henquell et al., 2004), L29593 (4, 
Belgium, Stuyver et al., 1994), AY685052 (4, Cameroon, Njouom et al., 2005), 
AY685012 (4, Cameroon, Njouom et al., 2005), L29618 (4, Belgium, Stuyver et al., 
1994), L29611 (4, Belgium, Stuyver et al., 1994), D86537 (4, Japan, Tokita et 
al.,1998), AY265451 (2, Cameroon, Njouom et al., 2005), AY265420 (2, Cameroon, 
Njouom et al., 2005); concatenated regions, D17763 (3a), D49374 (3b), D50480 
(1b), M62321 (1a), D14853 (1c), Y12083 (6a), D50409 (2c), D10988 (2b), D00944 
(2a). 
 
6.2.6. Evolutionary history of genotype 5a 
For this part of the analyses, we only inferred a divergence time for the genotype 5a 
cluster that consisted of our own sequences and those from the global database 
(mostly Belgium and France).  From our analyses and published articles, it has been 
inferred that genotype 2 is the oldest genotype and we hence rooted the genotype 
5a evolutionary trees to genotype 2.  The MCL method using the Unweighted Pair 
Group Method with Arithmetic mean (UPGMA, Sneath and Sokal, 1973) parameter 
(MEGA 4.0) was used for the molecular evolutionary inference for the core, E1, 
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NS4B and NS5B regions.  Bootstrap analysis was performed using 1000 replicates.  
The evolutionary rates were estimated from published records and the time line for  
each region was calculated at a 100 year interval. 
 
 6.3. RESULTS 
6.3.1. Demographics 
The sera/plasma of specimens from 25 subjects previously typed as genotype 5a in 
the 5’UTR (discussed in chapter 3) was further characterized by subgenomic se-
quencing. There were 2 specimens that genotyped as 1 and one specimen that was 
a genotype 4 in the core and E1 regions.   There were an equal number of males 
and females with a mean age of 42 years (Table 24).  The ethnicity of this group 
was mostly Blacks (54%), Whites (14%), Asian (4%) and data unknown (28%).  Al-
most half of the samples were from patients diagnosed with liver disease (LD, 46%) 
at the Charlotte Maxeke (previously known as Johannesburg Hospital) Liver Dis-
ease Clinic and the same number from the anonymous volunteer blood donors 
(46%).  There were 2(8%) haemophiliacs (Table 24).  PCR was most efficient with 
21/28 (75%) amplifiable in the core region.  This was followed by the E1 (68%) re-
gion while PCR in both the NS4B (29%) and NS5B (29%) performed sub-optimally.    
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Table 24.  A summary of the demographic and clinical data of the 28 specimens used for partial se-
quencing and analyses 
                            REGION AMPLIFIED 
Patient AGE GENDER ETHNIC CLINICAL C E1 NS4B NS5B 
1 59 M U BB POS POS NA NA 
2 U M B LD POS POS NA POS 
3 40 M B LD POS POS NA POS 
4 58 F B LD POS POS NA NA 
5 51 F B LD POS POS NA PS 
6 39 M W H POS POS NA PS 
7 36 F W LD POS POS NA POS 
8 67 M B LD POS POS NA POS 
9 42 M U H POS POS POS POS 
10 U U U LD POS POS POS POS 
11 61 U B LD POS POS NA POS 
12 51 F B LD POS POS NA PS 
13 55 F B BB POS POS NA POS 
14 U U U BB POS POS NA NA 
15 57 F B BB POS POS NA NA 
16 56 M B BB POS POS POS POS 
17 43 M B BB POS POS NA POS 
18 48 M B BB POS POS NA POS 
19 51 F B BB POS POS NA NA 
20 U M W BB POS IS IS NA 
21 50 M U BB POS IS IS NA 
22 57 F B BB IS IS POS NA 
23 63 F U BB PS IS IS NA 
24 32 M W BB PS IS IS NA 
25 64 F U LD IS IS POS POS 
26 45 F A LD IS IS POS NA 
27 48 F B LD IS IS POS POS 
28 U U U LD IS IS POS NA 
U, unknown; M, male; F, female; B, Black; W, White; A, Asian; BB, blood bank; LD, liver disease; H, haemophiliac; POS, posi-
tive; IS, insufficient specimen; NA, not amplifiable; PS, partially sequenced. 
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6.3.2. Phylogenetic analyses 
Figure 23 shows the phylogenetic clustering for each of the regions; (a) core, (b) E1, 
(c) NS4B, (d) NS5B and concatenated regions (e) core/NS5B and (f) E1/NS4B.  All 
trees were rooted to the GBV-B virus.  The monophyletic clustering of genotype 5a 
sequences were indicated by all regions sequenced and clustering occurred with 
significant genotype 5a branch bootstrap values for the NS5B region (Fig.23d) and 
concatenated regions, core/NS5B (Fig.23e) and E1/NS4B (Fig.23f). The E1 and the 
NS4B region (Fig.23b, c) showed bootstrap values >70% for some of the interior 
nodes within genotype 5a.  However, this was not evident for the core (Fig.23a) and 
the NS5B (Fig.23d) sequences. Higher bootstrap scores were also noticed for the 
concatenated region E1/NS4B (Fig.23f) compared to the core/NS5B region (Fig. 
23e).   
 
Geographical clustering of the Belgian and SA strains was not evident in the core 
(Fig.23a) and NS5B regions (chapter 3 and Fig.23d).   However, for the E1 region, 
some of our sequences did segregate with the French isolates (Fig.23b).  The NS4B 
analyses also showed clustering of our sequences (for eg. 3158, 3673, 1997) with 
RSA isolates from Verbeeck’s study (2006) and with the Belgium strains (Fig. 23c).  
For the NS4B region,  one SA specimen 3898, clustered with the BE strains 
(Fig.23c) and for the E1 region, 2 blood bank specimens, SANBS 13 and 21 and a 
SA patient specimen 3975, clustered with the FR strains (Fig.23b).  However, 3898 
did not amplify in the E1 region and 3975, SANBS 13 and 21 did not amplify in the  
NS4B region so their phylogenies in these two regions could not be compared fully.  
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The concatenated analysis of the E1/NS4B region with the MCL parameter showed 
two significantly clustered genotype 5a groups, the first included the BE and some 
RSA isolates (Verbeeck et al., 2006) and the second, sequences from this study to-
gether with the reference sequences, AF064490 (isolate SA13, inoculated in chim-
panzee, Bukh et al., 1998) and Y13184 (SA patient isolate EUH1480, Chamberlain 
et al., 1997; Fig.23f).   
 
When the two NJ methods using the Kimura-2 and MCL parameters were com-
pared, there were no significant differences in the clustering and bootstrap values of 
the respective trees.  The sum of branch lengths between the two trees was also 
very similar, indicative that the pairwise calculations of genetic distance were similar 
for the two methods. 
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Fig.23.  Neighbour-joining, rooted trees, using the Kimura-2 parameter for the South African sam-
ples.  (a) Phylogeny of a 259bp fragment in the core region.  The reference genotype 5a strains are 
denoted as follows: #SA13 isolate (Bukh et al., 1998);  ‡ SA EUH1480 isolate (Chamberlain et al., 
1997); +Belgium isolates (van Doorn et al.,1995); *5a clones (Ohno et al., 1994).  The scale bar 
represents 0.1 substitutions/nucleotide site. 
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(Fig.23b) Phylogeny of a 237bp fragment in the E1 region. The reference genotype 5a strains are 
denoted as follows: #SA13 isolate (Bukh et al., 1998);  ‡ SA EUH1480 isolate (Chamberlain et al., 
1997); +Belgium isolates (van Doorn et al., 1995); French isolates (Henquell et al., 2004).  The scale 
bar represents 0.1 substitutions/nucleotide site. 
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(Fig.23c)  Phylogeny of a 584bp fragment in the NS4B region.  The reference genotype 5a strains 
are denoted as follows: #SA13 isolate (Bukh et al., 1998);  ‡ SA EUH1480 isolate (Chamberlain et 
al., 1997); +Belgium isolates and RSA isolates (Verbeeck et al., 2006); French isolates (Henquell 
et al., 2004); recombinant 2/5 (Legrand-Abravanel et al., 2007) .  The scale bar represents 0.1 sub-
stitutions/nucleotide site. 
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(Fig.23d) Phylogeny of a 208bp fragment in the NS5B region. The reference genotype 5a strains are 
denoted as follows: #SA13 isolate (Bukh et al., 1998);  ‡ SA EUH1480 isolate (Chamberlain et al., 
1997); +Belgium isolates (Stuyver et al., 1994); French isolates (Henquell et al., 2004).  The scale 
bar represents 0.1 substitutions/nucleotide site. 
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(Fig.23e) Phylogeny of the concatenated gene fragment core/NS5B (465bp). The reference genotype 5a strains are denoted 
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(Fig.23f) Phylogeny of the concatenated gene fragment E1/NS4B (855bp). The reference genotype 5a strains are denoted as 
follows: #SA13 isolate (Bukh et al., 1998); ‡ SA EUH1480 isolate (Chamberlain et al., 1997);+Belgium isolates and RSA 
isolates (Verbeeck et al., 2006).  The scale bar represents 0.1 substitutions/nucleotide site. 
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6.3.3.  Branching order and ML phylogenies 
Output from FindModel is shown in Table 25 (the lower the log likelihood score, the 
better the model for use in ML phylogenetic analyses).  The log likelihood (LnL) and 
the Akaike Information Criterion (AIC, Akaike, 1974) values are inversely related to 
each other. The Findmodel function indicated that the GTR model was the best 
model to apply to the dataset of the E1, NS4B and NS5B and the Transversion 
model for the core region (Table 25). 
 
Table 25.  A summary of the FindModel results as obtained from a web adaptation of the Modeltest 
script to find the best phylogenetic model for data in the core, E1, NS4B and NS5B regions 
MODEL CORE   E1   NS4B   NS5B   
  AIC LnL AIC LnL AIC LnL AIC LnL 
Jukes-Cantor (JC) 4108 -2054 13191 -6595 102999 -51499 31021 -15510 
Felsenstein 1981 (F81) 2604 -1299 8242 -4118 24090 -12042 9946 -4970 
Kimura-2 (K80) 2539 -1268 7982 -3990 22722 -11360 9589 -4793 
Transversion (TM) 2507 -1246 7964 -3975 22684 -11333 9575 -4780 
Hasegawa-Kishino-Yano 
(HKY) 2540 -1266 7967 -3979 22716 -11354 9599 -4795 
Tamura-Nei (TrN) 2541 -1265 7965 -3977 22717 -11353 9559 -4774 
General Time Reversible 
(GTR) 2509 -1246 7483 -3732 22683 -11333 9535 -4759 
AIC, Akaike Information Criterion (AIC = -2(In (likelihood)) + 2 K), where likelihood is the probability of the dataset given a 
model, K is the number of free parameters in the model, LnL, log likelihood score 
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The ML phylogenies were used to look at the order of branching of genotypes by 
means of rooted, slanted cladograms.  Our results corroborate those of Pang et al., 
2009 who showed that genotype 2 branches out first and genotypes 1 and 4 last.  
Genotype 5 has an intermediate position, after genotype 2 but before genotype 4 
and 1 (Figs.24a-d).  The NS5B region was analysed by both the NJ (MCL) and the 
ML methods with identical results.  Genotype 2 branched first, followed by genotype 
6, genotype 5, genotype 3 and then genotypes 1 and 4 (Fig.24a, b).  The ML clado-
gram for the NS4B region showed that genotype 5 branched before genotype 6 and 
after genotype 2 (Fig.24c).  The amino acid ML branching of Pang’s study is similar 
to both our NS4B and E1 branching, with genotype 5 branching after genotype 2 
(Fig.24c, d).  The highly conserved core region showed a different branching pat-
tern.  Genotype 2 was still the first to branch out followed by genotype 4, 5, 6, 3 and 
1 (data not shown).  
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Fig.24. Representative branching orders on slanted cladograms, rooted to GBV for (a) NS5B (MCL), 
(b) NS5B (ML) and ML cladograms for (c) NS4B and (d) E1 
 
6.3.4. Evolutionary distance of genotype 5a 
The average evolutionary divergence per site between sequences from the different 
genotypes in the core, E1, NS4B and NS5B regions were 0.231, 0.392, 0.174 and 
0.357, respectively.  The rate of heterogeneity of the core and NS5B regions are 
comparable with rates reported by Pybus et al., 2009 (0.22 and 0.32, respectively).  
Table 26 summarises the mean evolutionary divergence per site of genotype 5a 
over the regions sequenced in this study.  The heterogeneity of sequences in the 
core and NS5B regions (0.037 and 0.079, respectively) was less than that found in 
the E1 and NS4B (0.124 and 0.1 regions, respectively).  Genotype 5a sequences in 
this study have a lower divergence in the E1 region than that reported for SA geno-
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type 5a by Verbeeck et al., 2006 (0.16)  However, the divergence rates for the 
NS4B region was similar in both studies (0.1 versus 0.12).  The rate of heterogene-
ity for genotype 5a sequences in the NS5B region was found to be 0.079, higher 
than indicated by Ribeiro et al., 2009 (0.058, Table 26). 
Table 26.  Number of base substitutions/site calculated as an average over all sequences of geno-
type 5a for the sub-genomic regions sequenced and compared to published calculations. 
Nucleotide diversity 
  
Divergence (years) 
Core 0.037 
  
152 
  
E1 0.124 0.16a 100 123a 
NS4B 0.1 0.12 a 153 143a 
NS5B 0.079 0.058b 156 
  
a
 Verbeeck et al., 2006; b Ribeiro et al., 2009 
 
6.3.5. Molecular Evolutionary Analyses 
We used the readily available UPGMA parameter in the MCL model (MEGA 4.0) to 
estimate the divergence times of genotype 5a in the population from the most com-
mon recent ancestor (MCRA).  When we rooted the genotype 5a sequences to the 
oldest genotype (genotype 2) as evident from the above section on branching order 
and used published evolutionary rates (Table 1), we had calculations of divergence 
ranging from 100-156 years (Fig.25a-d).  The estimated time of the genotype 5a di-
vergence as analysed per region sequenced were 152 years (core, Fig.25a), 100 
years (E1, Fig.25b), 153 years (NS4B, Fig.25c) and 156 years (NS5B, Fig.25d).    
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Fig.25a.  Estimated divergence time as calculated by the calibrated molecular analyses, NJ, MCL, 
UPGMA parameter for the core region.  The tree is rooted to genotype 2 reference sequences, 
D00944 and D10988.  The scale bar represents 0.02 substitutions/nucleotide site/year. 
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Fig.25b. Estimated divergence time as calculated by the calibrated molecular analyses, NJ, MCL, 
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Fig.25c. Estimated divergence time as calculated by the calibrated molecular analyses, NJ, MCL, 
UPGMA parameter for the NS4B region. The tree is rooted to genotype 2 reference sequences, 
D00944 and D10988.  The scale bar represents 0.1 substitutions/nucleotide site/year. 
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6.4. DISCUSSION 
This study looked at the molecular characterization of HCV genotype 5a across four 
regions of the genome in specimens from patients with clinical disease or volunteer 
blood donors from SA.  Although amplification of the core and E1 regions were suc-
cessful, the NS4B and NS5B were poorly resolved by PCR and sequencing.  As ex-
plained previously in chapter 3, one of the reasons is the poor specimen integrity 
and RNA degradation during transport and storage.  The published primers used in 
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the amplification of the NS4B and NS5B regions may have been suboptimal as 
primer bias has been shown to amplify only a proportion of target sequences (Yao 
et al., 2005).  The use of many combinations of genotype 5a-specific primers and/or 
degenerate primers may address this problem in future. 
 
We performed phylogenetic analyses for all regions sequenced using the NJ dis-
tance method, with Kimura-2, MCL and UPGMA parameters.  The MCL algorithm is 
a relatively new feature of the MEGA 4.0 program that uses the sum of log likelihood 
to produce distances of two neighbouring sequences simultaneously.  It is incorpo-
rated in the software to provide better clustering and higher bootstrap scores for in-
terior nodes of monophyletic clades (Tamura et al., 2007).  It implements the Ta-
mura-Nei substitution model, whereby substitution rates are considered different per 
site and nucleotide frequencies assumed unequal (Tamura and Nei, 1993).   All the 
phylogenetic trees were rooted to the outgroup, GBV-B virus and bootstrap scores 
and clustering between different NJ methods were compared.   
 
From our data, across the respective regions sequenced, we have found that there 
were no differences between the different trees using the Kimura-2 and MCL algo-
rithms.    All our tree analyses showed that genotype 5a sequences branched sepa-
rately from the rest.  The sequences within the genotype 5a clade were very closely 
related to each other, as indicated by the short branch lengths.  Significant bootstrap 
scores (>70%) were only evident for the E1 and NS4B regions.  This is to be ex-
pected since these two regions have a higher diversity or phylogenetic signal than 
that found in the core and NS5B (Table 26, 0.124 and 0.1 vs. 0.037 and 0.079 re-
spectively).  Also to be expected, these two regions did not show any geographical 
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clustering within the genotype 5a clade as was seen for the E1 and NS4B regions.  
This was exacerbated by the small sample numbers for the concatenated analyses 
and the lack of reference sequence data especially in the core/NS5B region. 
 
The genetic distances among the Belgium, French and SA isolates for the E1 and 
NS4B regions ranged from 0.157 to 0.170 and 0.1 to 0.12, respectively, according to 
Verbeeck et al., 2006.  The results of this study concur in the NS4B region (0.1) but 
divergence was lower (0.124) than reported in the E1 region.  The NS5B region was 
more diverse (0.079) than Belgium and French isolates (0.058-0.061, Ribeiro et al., 
2009).   
 
The ML and NJ rooted phylogenies were compared and found to have identical tree 
topologies for all regions sequenced.  Since the sub-genomic regions of HCV ana-
lysed are reliably grouped by the simpler and quick distance method, we conclude 
that our sequences are sufficiently conserved and do not require ML methods.  
Kumar et al., 2008 recommend ML for greater accuracy when dealing with distantly 
related sequences.   
 
The branching orders of the six genotypes were taken from the cladograms of the 
ML phylogenies.  Pang et al., 2009 showed evolutionary age (synonymous to the 
order of branching in an evolutionary tree) of genotypes corresponded to that of vi-
rological response to therapy.  Although, they do point out that full genome data is 
required, the NS5B region concurred with that of the ML full genome nucleotide tree 
of Pang et al., 2009. Genotype 2 branched first followed by genotype 6.  However, 
genotype 5 branches before genotype 3 suggesting that it is older.  NS4B analysis 
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indicates that genotype 5 is even older than genotype 6 as it branches after geno-
type 2 but before genotype 6. This was also evident in the ML (amino acid, aa) tree 
of Pang et al., 2009.  Genotypes 2 and 3 respond better to PEG-IFN and ribavirin 
therapy than genotypes 1 and 4 (Nguyen and Keeffe, 2005).  Pang’s study showed 
older genotypes respond better to therapy.  The evolution of HCV is thought to be a 
result of several factors, including host immune selective pressure and the intrinsic 
ability of the virus to resist IFN action.  The phylogeography of HCV genotypes and 
the spread between host populations with inherent immune differences could drive 
viral evolution (Pang et al., 2009).  In a small prospective study on the responses to 
therapy of different genotypes in South African patients, we have shown that pa-
tients infected with genotype 5a did respond as well to therapy as those with geno-
type 3 (see Chapter 8).   However, not many prospective studies on the responses 
to therapy for genotypes 5 and 6 have been conducted, but it is thought that these 
genotypes might respond between the two extremes (Antaki et al., 2008) and the 
branching of these genotypes, as shown by this study and Pang et al., 2009, has 
indicated this. 
 
It has been estimated that genotype 2 was introduced in Guinea-Bissau, West Af-
rica, in 1470 (~540 years ago, Markov et al., 2009), compared to the introduction of 
the younger genotype 1 which was introduced to the US, in the early 1940’s 
(Tanaka et al., 2006) and to Japan, in the 1880’s (Tanaka et al., 2002).  Some stud-
ies estimate that HCV may have emerged thousands of years ago (Pybus et al., 
2009) and not just hundreds (Markov et al., 2009).  However, based on Pang’s 
analyses, genotype 2 was used to root the UPGMA trees to access divergence 
times for genotype 5a.  The inferred times of divergence of the two sequences of 
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genotype 2 used to root the tree ranged from 238 (E1) to 498 (core) years.   
Although genotype 5a is predominantly found in SA, it is unlikely that genotype 5a 
subsequently spread from SA to Belgium by trade/travel routes. Verbeeck’s coales-
cent approach indicated that genotype 5a was introduced into Belgium and SA at 
approximately the same time (137-143 years, Verbeeck et al., 2006).  This co-
introduction may have involved a re-introduction in to regional pockets of Africa. It is 
thought that the slave trade in the early 1800’s, which transported slaves from west 
to other parts of Africa may have played a role in the dissemination of HCV (Markov 
et al., 2009; Verbeeck et al., 2006).   
 
Estimated divergence times of genotype 5a date its MRCA approximately 150 
years, earlier than that estimated by Verbeeck et al., 2006.  However, estimates 
were based on the assumption that all specimens analysed were infected at the 
same time and the MCL approach assumes that evolutionary rates among the sites 
are equal.  Sample numbers for each of the HCV regions were also very small and 
the molecular clock analysis relied on estimated evolutionary rates.  However, diver-
gence times were similar for the core, NS4B and NS5B regions while the E1 region 
estimate a MRCA 100 years later.  Verbeeck’s study, also predicted a more recent 
divergence (123 years) using the E1 region as compared to the NS4B region (143 
years).   
 
6.5. CONCLUSION 
Genotype 5a is the most conserved genotype as it has only one subtype.  From the 
sequencing of the subgenomic regions, we were able to determine the rate of het-
erogeneity among the genotype 5a sequences, with E1 being the most variable as 
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expected, then the NS4B and NS5B.  The weakness in the study is the poor amplifi-
cation in the NS4B and NS5B (also shown in chapter 3).  Optimization of the RNA 
extraction and genotype 5a-specific primers needs to be implemented, so as to try 
many permutations to obtain better PCR and sequencing results. The possibility of a 
vast number of 5a quasispecies within a single individual may also hamper amplifi-
cation with gene-specific primers.  Cloning of variants and/or next-generation se-
quencing will be investigated in future studies.   
 
This study has made it possible to compare phylogenies of our local 5a isolates to 
that of other countries where genotype 5a has been reported, in particular, Belgium 
and France.  Evolutionary age of genotype 5a was inferred by the branching order 
of genotype 5a relative to other genotypes and divergence times of 100-150 years 
were estimated.  This is the first time genotype 5a has been characterized in this 
country. 
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CHAPTER SEVEN 
 
Epitope analysis on Hepatitis C Virus (HCV) genotypes, particularly 
genotype 5a, against South African Human Leukocyte Antigen (HLA) 
backgrounds 
 
7.1. INTRODUCTION 
 
As HCV is a relatively “new” virus, only identified in 1989 (Choo et al., 1989) and 
first cultured successfully in 2005 (Wakita et al., 2005), there is much that is un-
known about HCV which has hindered the development of an effective vaccine. The 
challenges to a vaccine design against HCV include:  
(a) The high mutability of the virus which varies within and between genotypes. 
Genotypes also partition geographically, and exist as quasispecies within the 
host. 
(b) Host cell responses to infection are poorly defined and, in addition, inconsis-
tent between infected individuals.  CD4+ and CD8+ T-cell responses are also 
not cross-protective to heterologous genotypes (Schulze zur Wiesch et al., 
2007) and, to date, there is no immunodominant epitope that is consistently 
found in all HCV-positive individuals (Klade et al., 2009). 
(c) Humans are the only natural host of HCV, and suitable laboratory models 
have only been developed recently. The chimpanzee has been infected in the 
laboratory (Bukh, 2004), but studies on this model are expensive and limited 
by this and constraints of availability. More practical and plausible is the cur-
rent development of a mouse model for viral pathogenesis studies (Ploss and 
Rice, 2009).    
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Epitope-based vaccines activate an immune response by presenting immunogenic 
peptides (viral genotype-specific) bound to major histocompatibility (MHC) mole-
cules (host specific) to the T cell receptor. Class II proteins are presented to T 
helper cells by antigen presenting cells (APCs) with the aid of the CD4 co-receptor 
whereas Class I proteins are presented by infected target cell to cytotoxic T cells 
with the aid of the CD8 co-receptor.  The T helper response is important in directing 
and activating the immune response, including the effectiveness of CD8+ T cells 
(Grakoui et al., 2003).  A good vaccine must be capable of inducing and maintaining 
powerful CD4 and CD8 T-cell immunity in the greatest proportion of its target popu-
lation.  
 
Both HCV genotype and HLA allele frequency are distributed geographically. South 
Africa has a diverse and unique cultural heritage. Statistics South Africa’s website 
(http://www.statssa.gov.za, 2010-12-08) estimates that of the mid-year population 
(N = 49. 99 million) the predominant ethnicities in the South African population are: 
African (79.4%, including Zulus), White (9.2%), Mixed race (8.8%) and Indian/
Asians (2.6%).  Ethnicity (Wang et al., 2009) and HLA class I (Neumann-Haefelin et 
al., 2008) and class II alleles (Sarobe et al., 2006), appear to be associated with ei-
ther HCV disease progression or sustained response to therapy (Satapathy et al., 
2010, Tables 3,4). Most putative peptide-based vaccines and diagnostics are cho-
sen based on the sequence of HCV genotype 1 epitopes and restriction by common 
Caucasian HLA alleles, and HLA-A*2 in particular (New allele Frequency Database, 
2003, http://www.allefrequencies.net 2010-11-10).  We have seen in chapter 3 that 
genotype 5a is predominant in patients with liver disease in SA.  
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The aim of the study was to describe the heterogeneity of HCV epitope sequences, 
together with local HLA-types and how this can affect vaccine efficacy in the ethni-
cally diverse SA population. 
 
7.1.1.   Objectives:  
(a) To examine the variation in selected published immunogenic epitopes within 
target antigens 
(b) To predict their immunogenicity in the context of prevalent alleles in the South 
African target population  
 
7.2.  METHODS 
7.2.1. Epitope Sequences 
The literature was searched for known published Class I- and II-restricted immuno-
genic regions from the core to the NS5B which ranged in length from 9 bp (Wei et 
al. 2008) to 683 bp (Lang et. al, 2008). Seven class I- and six class II- epitopes were 
chosen for the analyses (Table 27) using the following criteria:  
 Extensively studied immunogenic epitopes 
 Published in the peer reviewed literature 
 Known HLA restriction and  
 Recommended for putative vaccines. 
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Alignments of representative reference sequences were obtained over these immu-
nogenic regions using sequence data from each of the genotypes with the aid of pre
-aligned and updated amino acid sequence data from the International Nucleotide 
Sequence Database Collaboration (INSDC; Shin et al. 2008). The percentage of the 
total number of sequences available per epitope region varies greatly by genotype, 
ranging from 4-24% (genotypes 4 and 5) to 54-82% for genotype 1 (subtypes 1a 
and 1b).  
 
Because there were, comparatively, few sequences of genotype 5a on the interna-
tional databases, we included our own sequence data, in the alignments of the core, 
Table 27.  Seven HCV Immunodominant  HLA Class 1- and six HLA  class II- restricted epitopes 
were chosen for the analysis in this study 
CLASS I 
EPITOPES 
SEQUENCE RESTRIC-
TION 
REFERENCE 
NS3 1073-
1081 
CINGVCWTV A02 Wertheimer et al., 2003; Wedemeyer et al., 2009 
NS3 1406-
1415 
KLVALGINAV A02 Wei et al., 2008; Memarnejadian et al., 2009 
NS3/NS4 
1628-1637 
GAVQNEITL (?) Frelin et al., 2003;  Lang et al., 2008 
NS4 1807-
1816 
LLFNILGGWV A02 Cerny et al., 1995;  Martin et al., 2008 
NS4 1851-
1859 
ILAGYGAGV A02 Wei et al., 2008 
NS5B 2422-
2433 
MSYSWTGALVTP B15 Wei et al., 2008 
NS5B 2727-
2735 
GLQDCTMLV A02 Wei et al., 2008 
CLASS II       
Core 17-35 RRPQDVKFPGGGQIVGGVY* 
  
Lamonaca et al., 1999 
Core 21-40 DVKFPGGGQIVGGVYLLPRR 
  
Lamonaca et al., 1999; Day et al., 2002; Wedemeyer et 
al., 2009 
NS3 1248-
1261 
GYKVRVLNPSVAAT 
  
Diepolder et al., 1997; Martin et al., 2008; Wedemeyer 
et al., 2009 
NS4A 1781-
1800 
LPGNPAIASLMAFTASITSP 
  
Martin et al., 2008 
NS4A 1801-
1820 
LTTQNTLLFNILGGWVAAQL 
  
Martin et al., 2008 
NS5 2571-
2590 
KGGRKPARLIVFPDLGVRVC 
  
Day et al., 2002; Schulze zur Weisch et al, 2005; Mar-
tin et al., 2008; Klade et al., 2009 
NS5 2661-
2680 
QCCDLDPQARVAIKSLTERL 
  
Day et al., 2002; Schulze zur Weisch, 2005 
* indicates promiscuous epitopes that would bind to more than one DR-allele 
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NS4 and NS5B regions of genotype 5a wherever possible.  Care was taken to en-
sure that all our own data, as well as data used from public databases, corre-
sponded to one sequence per subject.   
 
BioEdit, version 7.0 software (Hall, 1997), was used to align all the amino acid se-
quences.   The consensus sequence of immunogenic regions, for each of the geno-
types, was obtained using the Web based software, WebLogo, version 2.8.2 (http://
weblogo.berkeley.edu/logo.cg; 2008-09-08). Numbering was according to Choo et 
al., 1991.   The WebLogo program produces a consensus of input sequences con-
sisting of stacks of letters, each representing a column in the sequence alignment.  
The height of each letter within the stack is proportional to the relative frequency of 
the representative amino acid at that position in the sequence (Crooks et al., 2004).  
The Weblogo software incorporates a “small sample number” correction, to correct 
for potential bias.   
 
The conservation of epitopes was calculated as the percentage of polymorphic sites 
over the epitope length when compared to the HCV consensus sequence. The latter 
was determined by taking the most common amino acid from each site of the re-
spective genotype consensus sequences in the 7 weblogos (genotypes 1a, 1b, 2, 3, 
4, 5 and 6). A minimal class I-restricted epitope length of 9 nucleotides was used for 
all class I-restricted epitopes.  Class II- restricted epitopes are longer with overlap-
ping regions, thus, the number of amino acids varied per sequence. The statistical 
analysis was performed using the analysis of variance (ANOVA) tests of signifi-
cance in the Statistica software, version 9.1.   
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7.2.2.  South African MHC probabilities 
The most common HLA alleles in the SA population were determined in order for 
the binding predictions to have relevance to the local population.  HLA information 
regarding the different SA ethnic groups is not readily available in the literature, and 
this data will serve as a useful resource for future studies.  Relevant studies (Table 
28) were identified by searching the literature using PubMed, (http://
www.ncbi.nlm.nih.gov/sites/entrez; 2009-11-18) and this information was supple-
mented from relevant ethnic allele frequencies stored in the MHC database accessi-
ble from the New allele Frequency Database, http://www.allelefrequencies.net (2010
-11-30). 
The most common allele frequencies were tabulated for each of the major ethnic 
groups in South Africa (MS Excel).  Information was gathered for the following Class 
I alleles:  HLA-A, -B and Class II HLA-DR alleles. Ethnic groups examined included 
Blacks (B), Caucasians (Ca), Coloureds (CC) and Indians (I).  
Table 28.  A summary of South African studies collated for the HLA/ epitope analysis 
studies HLA Ethnic groupsa 
Study popu-
lation size Reference 
1 A, B, Cw B 295 Kiepiela et al., 2004 
2 A, B, Cw, DR B 2366 Cassim et al., 1994 
3 A 
  
B 
  
Cw 
  
DRB1 
  
B 
Ca 
B 
Ca 
B 
Ca 
B 
Ca 
198 
100 
195 
98 
183 
99 
194 
95 
 Paximadis M., unpublished 
  
  
  
  
  
  
  
  
  
  
  
  
  
4 A, B, C 
  
  
DRB1 
  
  
B 
CC 
Ca 
B 
CC 
Ca 
1027 
3716 
1059 
322 
549 
365 
 Du Toit et al., 1988 
  
  
  
  
  
  
  
  
  
5 DRB1 CC 624 Klemp et al., 1988 
6 DRB B 117 Lombard et al., 2006 
7 A, B, Cw I 51 Hammond and Moshal., 1980 
8 A, B, Cw B 756 Hammond et al., 1980 
9 A, B B 41 Coetzee, 2006 
10 A, B B 100 Middleton et al., 2000 
11 DRB B 138 Rudwaleit et al., 1995 
12 A, B, Cw B, CC, Ca, I 13 Venter et al., 2003 
13 A, DRB B 448 Alkharsah et al., 2007 
aB, Black; CC, Coloured; Ca, Caucasian; I, Indian 
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7.2.3 Immunogenicities 
It was evident from a previous study that there is a good correlation between immu-
nogenicity and MHC class I binding affinity (Sette et al., 1994).  Therefore we used 
two well-documented programs to determine binding predictions for the published 
Class I and II epitopes in the context of SA host alleles. Only HLA alleles with high 
frequencies were tabulated with scores. 
 
7.2.3.1. Immune Epitope database project (IEDB) 
The IEDB web based resources, version 2.0 (http://tools.immuneepitope.org/main/
jsp/menu.jsp; 2009-09-09), is a manually curated database of experimentally char-
acterized immune epitopes. The “Peptide Binding to MHC Class I molecules” re-
source takes submitted proteins and splits them into all possible peptides and then 
determines their binding to each of the MHC alleles selected according to the artifi-
cial neural network (ANN) algorithm (Nielsen et al., 2003), our chosen prediction 
method. This method accounts for the position of the amino acid and the probability 
of adjacent amino acids competing for a space in the MHC pocket (Nielsen et al., 
2003).  Predicted binding efficiencies (in units of IC50 nM) were calculated for each 
of the possible HLA-class I epitopes. IC50 values <50 nM are considered high affin-
ity, <500 nM intermediate affinity and <5000 nM low affinity (http://
tools.immuneepitope.org/main/jsp/menu.jsp). MHC alleles prevalent in one or other 
of the SA population groups were of interest for the purposes of this study.  Other 
matrix-based methods, like ProPred 1 (http://www.imtech.res.in/raghava/propredI/
index.html, 2010-11-30) and SYFPEITHI (Rammensee et al., 1999) were used to 
compare binding efficiencies.  However, for brevity, only scores for IEDB are shown. 
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7.2.3.2.  ProPred MHC Class II binding prediction Server 
Propred II (http://www.imtech.res.in/raghava/propred/index.html, 2010-10-20, Singh 
and Raghava, 2001) was used to predict binding of HLA-class II epitopes. This tool 
uses a linear prediction model based on values stored in allele specific coefficient 
tables, or quantitative matrices, generated according to the properties and position 
of the different amino acids in the epitope. The program is useful in locating promis-
cuous, versus allele specific, binding regions in a query peptide sequence.  A strin-
gency threshold between 1-10% can be chosen to facilitate high (no false positives) 
or low (no false negatives) stringency cut-off values and a value of 10% was used in 
all cases.  Note that interpretation of the scoring is quite different to that of the IEDB 
program as a high percentage score is indicative of good binding between the rele-
vant peptide and the specific HLA class I or II allele. The score is a percentage of 
the highest score possible by any peptide to bind with the given allele. The score is, 
therefore, a reflection of the binding characteristics of the query allele. There is no 
clear cut off as with IEDB ANN scoring, and actual percentages cannot necessarily 
be compared. For this reason the highest stringency was used to reduce to a mini-
mum the false positives making all binding significant.  
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7.3. RESULTS 
 
7.3.1 Degree of epitope conservation 
 
The Weblogo consensus alignment for each genotype was generated for each of 
the chosen published class I (7 epitopes) and class II (6 epitopes) regions.  From 
the alignments, the consensus and percentage conservation of each epitope within 
each genotype was calculated (Table 29). The variation between the epitopes for 
each genotype was not statistically significant, however,  the  class I epitopes 
NS4B1807-1816,  NS5B2422-2433 and five of  the six class II epitopes (all except NS5B2661
-2680) had the highest average conservation (>80%; Table 29).   Published class II-
restricted epitopes were in general better conserved than the class I epitopes and 
well conserved across genotypes, as well as within genotypes.   
 
Genotype 1 is the most conserved genotype even though more sequences were ex-
amined.  Genotype 4 shows a high conservation but had the smallest sample num-
ber of sequences so this may not be a true reflection. Genotype 6 shows the most 
variability which is a reflection of the fact that this genotype has the most number of 
subtypes (22), 6a-6v (Noppornpanth et al., 2008). Notably two of the class I epi-
topes, NS31628-1637 (44%) and NS5B2727-2735 (33%) are very poorly conserved in 
genotype 6. 
 
7.3.2 .  South African HLA population group characteristics 
 
Figures 26 a, b, c show the major HLA frequencies for the South African population 
groups.  
The most common HLA-A alleles in the South African Black population were in de-
scending order: A30 (24.36%), A68 (17.33%), A02 (14,70%), A29 (12.74%), A23 
(12.20%), A31 (12.00%) and A03 (9.76%, Fig.26a). 
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  A01 A02 A03 A11 A23 A24 A26 A29 A30 A31 A32 A33 A34 A68 
B 
4.4
8 14.7 9.76 1 12.2 2.2 2.33 12.7 24.4 12 1.3 4.3 6.1 17.3 
CC 8.5 17 7.7 6.5 5.9 9.9 4.5 4.4 9.6 1.1 3.7 3.3 2.6 NA 
C 
17.
1 26.5 13.5 5.95 1.8 8.3 2.1 5.05 3.3 1.85 3.35 1.25 NA 2.5 
I 17 17 5 18 NA 16 2 1 1 7 1 7 NA 8 
Mean in the popu-
lation 11.8 18.8 8.99 7.86 6.63 9.1 2.73 5.8 9.57 5.49 2.34 3.96 4.35 9.28 
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Fig.26a.  Collated data of HLA-A studies in South Africa indicating the frequency of common alleles 
in the main 4 ethnic groups in the country (B, Black; CC, Coloured; C, Caucasian; I, Indian) 
  B07 B08 B13 B14 B15 B18 B27 B35 B42 B44 B45 B51 B52 B53 B57 B58 
B 9.6 11.1 4.03 5.02 19.3 4.22 0.2 3.33 20.5 11 9.5 NA NA 3.7 7 23 
CC 10.7 4.8 2 3.4 NA 5 2.3 5.8 3.1 8.8 2.7 2.4 2 1.3 4.3 8.6 
C 15.3 13 1 2.5 11 5.1 4.5 7.5 NA 12 NA 4.6 1 NA 4 2 
I 4 7 6 NA 13 3 1 9 NA 1 NA 9 8 NA 10 2 
Mean in 
the popu-
lation 9.9 8.99 3.26 3.64 14.4 4.33 2 6.41 11.8 8.2 6.1 5.33 3.67 2.5 6.33 8.9 
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Fig.26b. Collated data of HLA-B studies in South Africa indicating the frequency of common alleles in 
the main 4 ethnic groups in the country(B, Black; CC, Coloured; C, Caucasian; I, Indian) 
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 B58 (23%), B42 (21%) and B15 (19.3%) have the highest frequency in the Black 
population. B07 (9.6%), B08 (11.1%),  B44 (11%) and B45 (9.5) have intermediate 
frequencies (Fig.26b).  
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Fig.26c.  Collated data of HLA-Class II studies in South Africa indicating the frequency of common 
alleles in the main 3 ethnic groups in the country (B, Black; CC, Coloured; C, Caucasian) 
 
DRB1*03:01 (22.54%), DRB1*11:01 (20.75%), and DRB1*13:01 (18.04%) are the 
predominant Class II epitopes in the Black population (Fig. 26c).   
 
7.3.3. Epitope Binding Prediction 
The predicted binding values of epitope variants of HCV subtype 1a, 1b and geno-
type 5a to as many of our local HLA class I and II alleles were generated (Table 30 
and 31) and used in population coverage estimations.   
  
DRB
1* *01:01 *03:01 *04:01 *07:01 *08:01 *09:01 *10:01 *11:01 *12:01 *13:01 *13:02 *13:03 *14:01 *15:01 
B   6.5 22.5 5.79 7.85 5.6 1.63 1.95 20.8 2.23 18 4.35 1.8 1.3 10 
C   7.4 12.2 11.2 9.5 3.2 2.1 0.8 5.8 1 6.3 3.7 1.6 2.6 11.2 
CC   8.35 15 16.1 19.2 3.8 1.36 1.12 NA NA NA NA NA NA NA 
mean in the 
population 7.42 16.6 11 12.2 4.2 1.7 1.29 13.3 1.61 12.2 4.03 1.7 1.95 10.6 
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7.3.3.1. Class I alleles 
The HLA Class I epitopes NS31073-1081,  NS31406-1415 , NS4B1807-1816, NS4B1851-1859and
  
NS5B2727-2735 have all been reported to be HLA-A2 restricted (Table 27).  Predicted 
binding scores of all Class I epitopes and their variants with the relevant HLA-A and 
–B alleles are shown in Table 30.  
 
HLA-A and –B Class 1 restricted binding 
Binding predictions were performed for all the major HLA alleles in the SA popula-
tion.  The alleles were grouped according to supertypes (Sidney et al., 2008).  Posi-
tive binding scores were, for the most part, in agreement for the same given allele 
between the IEDB and Propred I software. The notable exception is the allele HLA-
B*27:05 which the more reliable IEDB ANN predicts will not bind to any epitope 
used in this study (Table 30).    
 
Four of the five published HLA-A2 restricted epitopes bound to the A*02 allele over 
all variants despite the fact that only genotype 1a and/or 1b sequences were used in 
the original experiments.  As most of the epitopes are A*02-restricted, we have seen 
good binding affinities for alleles A*02:01 and A*68:02 (both of the supertype A02) 
to NS31073-1081 and NS4B1851-1859 in particular (Table 30).  Binding scores for relevant 
alleles from supertype A03 showed very low binding for the most part and only 
scores for A*68:01 are shown.  The peptide, NS4B1807-1816, had predicted binding 
scores >500 IC50nM for all except the genotype 3a sequence in the context of HLA-
A*23:01 (Table 30) and scores of <1000 IC50nM for the alleles B*57:01 and B*58:01 
(supertype B58).    
 
The published B*15-restricted NS5B2422-2433 epitope is the only epitope to have 
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shown high affinity across supertypes.  This epitope bound strongly <200 IC50nM to 
B*15:03 (B27 supertype), to B*58:01 (B58 supertype), to B*35:01 (B07 supertype) 
as well as A*68:02 (Table 30). 
  
Class I  cross reactivity 
There was a limited amount of cross reactivity with the rest of the HLA-A alleles. 
While the A*02:01 allele was predicted to bind with one of the NS31406-1415 genotype 
1a variants (KLVALGINA and the genotype 1b epitope (KLSGLGLNA), it did not 
cross-react with the genotype 5a variants.  
 
Allele A*30:01, which falls into supertype 24, showed high affinity to the genotypes 4 
and 5 variants of NS5B2727-2735 but only intermediate to poor binding to the genotype 
1 equivalents. The broad A24 allele cross- reacted with the genotype 5a A*02-
restricted variant CINGVMWTL of NS31073-1081, NS31628-1637 and the HLA-B restricted 
Class I epitopes NS5B2422-2433 when ProPred 1 was used.   
 
Binding was consistent across the supertype when affinity was good, for example, 
CINGVCWTV and variants of NS31073-1081 to supertype A02.  However, many of the 
epitopes in this study were intermediate to poor binders and did not bind all alleles 
in a supertype (Table 30).  
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7.3.3.2. Class II alleles 
The longer Class II epitopes were placed into the ProPred II program which found 
overlapping regions within the epitope. The output list contained possible peptides, 
all nine amino acids long. From these we tabulated all possible binders, together 
with their percentage of binding when compared with the log value of the best possi-
ble peptide for each allele (Table 31). For example, CORE17-40 returned two se-
quences VYLLPRRGP and VGGVYLLPR which scored similarly for alleles HLA-
DRB1*03:01 and HLA-DRB1*15:01 (Table 31), but the former peptide, 
VYLLPRRGP, had a much higher binding score (48%) than its flanking sequence 
VGGVYLLPR (10%) in the context of DRB1*13:01. No predicted class II epitopes 
were found in the first 14 amino acids of CORE17-40. Although CORE17-40 was the 
second most conserved epitope (Table 29), it was not predicted to bind with HLA-
DRB1*01:01, HLA-DRB1*01:02 or HLA-DRB1*04:01 and only VGGVYLLPR was 
predicted to bind with HLA-DRB1*07:01 (9%, Table 31). 
 
The most consistent class II binder was also the best conserved epitope, NS31248-
1261(Table 29), specifically the region 1252-1260 LVLNPSVAA, which bound all 
eight of the alleles tested. The least promiscuous allele was HLA-DRB1*04:01 which 
only bound the NS31248-1261 peptides. The most promiscuous allele of those tested 
was HLA-DRB1*15:01 as a positive binding score was predicted with all but five of 
the 18 peptides output by the program (Table 31).  
 
The highest binding score (60%) was obtained from NS5B2571-2590 for allele HLA-
DRB1*15:01. This particular sequence is conserved for genotypes 3 and 5.   
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 7.4.  DISCUSSION 
In this study we looked at the heterogeneity of epitopes proposed for HCV vaccines 
across the six genotypes and the binding efficacy of these epitopes and their vari-
ants to common HLA alleles in the SA population. There are many epitopes that 
could have been included in this chapter but those that are discussed here have 
been considered as epitopes in multi-epitopic (Wei et al., 2008), therapeutic 
(Wedemeyer et al., 2009), minigene (Martin et al., 2008) and DNA polytope 
(Memarnejadian et al., 2009) vaccines.  All these vaccine studies have focused on 
genotype 1a and 1b strains and the A*02-restricted epitopes.  Although genotypes 
1, 3 and 4 have been found in the SA population, genotype 5a is predominant 
(Prabdial-Sing et al., 2008). Genotype 2 is rare and, to date, genotype 6 has not 
been identified in SA.  Hence, the present study was focused on genotype 5a se-
quences. We included all of our available sequence data, sequences from Verbeeck 
et al., 2006 (Belgium and South Africa), and Henquell et al., 2004 (France) in our 
alignments, in order to improve the representation of genotype 5a.  Class I and II 
epitope sequences of genotype 5a were found to be relatively conserved compared 
to other genotypes.  There were some epitope regions that were highly conserved, 
for eg. the NS31628-1637 and NS41807-1816 and others like the NS5B2661-2680 which were 
highly variable.   
 
The divergent mutational potential of the genotypes reported by Rauch et al., 2009 
is also evident in the alignments and conservation table generated for this study.  
The consensus within known epitopes represents sites best adapted to T cell re-
sponses acting on these sites across the host population, however, polymorphic 
sites frequently have different consensus amino acids between the genotypes.  This 
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was clearly illustrated in the Class I epitope binding table as there were many varia-
tions of the same epitope seen.   In light of this data, we suggest that epitope-based 
vaccines would need to contain a mixture of epitopes from all of the genotypes and 
their coverage potential checked against local HLA allele frequencies. Because of 
this variation, representative epitopes from all genotypes would need to be included 
in the vaccine and their population coverage assessed.  A new web server, Opti-
Tope (Toussaint and Kohlbacher 2009), recently became available which uses the 
same 4 steps as used in this study to suggest candidate epitope sequences for use 
in epitope vaccines. However, rather than assessing a given epitope-based vaccine 
as we have done, the output is a set of optimal epitopes. When we placed a set of 
10 optimal epitopes, generated from a sample alignment of predominantly HCV 
genotype 1 sequences, into the IEDB epitope analysis program, coverage of only 
44% was found in the Zulu population.  This indicates that there is a 44% chance for 
a person from this target population to carry one of the alleles covered in the analy-
sis, and hence respond to the vaccine.  This questions the efficacy of a vaccine, 
based firstly on genotypes not seen in the majority of our patients and secondly, 
poor T-cell responses due to inadequate binding of epitope to HLA allele.  Interest-
ingly, the coverage of a putative vaccine containing 29 epitopes adapted for geno-
types from the 13 chosen in this study only increased the coverage in the Zulu 
population to 51%.  This re-iterates the fact that the optimum epitope set will only be 
as good as the data placed into the program.  Alignments of genotypes prevalent in 
the country and detailed, accurate population allele frequencies should produce re-
sults of epitopes better matched to the target population.   
 
This study used well-characterized and published epitopes, some of which are al
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ready in use.   NS31073-1081 , NS4B1801-1820 and NS5B2571-2590 are contained in IC41, 
an add-on to standard drug therapy (Wedemeyer et al., 2009).  Although some of 
the epitopes in this study are well conserved among genotypes 4 and 5, their bind-
ing scores to relevant HLA alleles in SA were poor.  There is a lack of cross-
reactivity between genotypes, and this may explain the lack of cross-protection high-
lighted in earlier studies (Farci et al. 1992, Accapezzato et al. 2002, Rauch et al. 
2009).  Manipulating epitopes chosen for another population can never produce a 
multi-epitopic therapeutic vaccine for the SA population infected with genotype 5a. 
However, based on binding affinities predicted for epitopes expected in the local 
population and prevalent HLA alleles used in this study, the following class I-
restricted epitopes, NS4B1807-1816 (LLFNILGGWV; Cerny et al., 1995, Wei et al., 
2008, Martin et al., 2008), NS5B2422-2433 (MSYSWTGAL; Wei et al., 2008), NS5B2727-
2735
 (KLRDCTLLV; of the published epitope sequence GLQDCTMLV; Wei et al., 
2008) and class II-restricted epitopes NS31252-1260 (LVLNPSVAA; Day et al., 2002) 
and NS4B1809-1817(overlapping peptide to class I-restricted 1807, FNILGGWVA; Mar-
tin et al., 2008) are best suited for a local vaccine. 
 
From the many putative epitopes which can be discovered by computational predic-
tion methods, the most conserved among strains which also show good binding af-
finities to many HLA alleles (promiscuous) are the best candidates for in vitro and/or 
in vivo testing.  It is known that of the peptides predicted in silico, only one or two 
may actually bind to a particular MHC (Donnes et al., 2002) and it remains essential 
to test predicted peptides so as to ascertain that the needed T-cell response is elic-
ited.   
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7.5.  CONCLUSION 
It is becoming imperative to know how host genetic differences can influence dis-
ease, preventative (vaccine) and treatment outcomes.  Genome-wide association 
studies have revealed the host’s ability to defend itself from disease for example,  
SNPs on IL-28 (Ge et al., 2009, Tanaka et al., 2009) and 6 HLA alleles have shown 
significant association for HCV absence (B*57:01, B*57:03) or viraemia 
(DRB1*01:01, DQB1*03:01, Cw*01:02 and DRB1*03:01) (Kuniholm et al., 2010). 
 
Here, we have considered HLA heterogeneity in South African ethnic groups, as 
well as viral variability of well published epitopes, in the light of less-studied geno-
types 4 and 5.  As indicated earlier in chapter 1 (1.6.2), the main caveat to vaccine 
development for HCV lies in these two variable factors.  We have seen that even 
with the most published A*02- restricted epitope candidate, NS31073-1081, there were 
many changes seen across HCV genotypes. This poor and semi-conserved nature 
of Class I epitopes may be the first challenge towards generating a good CTL re-
sponse.   
 
The targets for most of the multi-epitopic studies are the A*02 allele. As expected, 
the best prediction binding scores were seen to this allele for the A2-restricted epi-
topes NS31073-1081, NS31406-1415 , NS4B1851-1859 and NS5B2727-2735.  Poor binding affini-
ties of these epitopes to the common SA alleles were observed in this study.  De-
spite the homogeneity of genotype 1 and genotype 5 over the epitopes proposed in 
vaccine studies, host differences will make the vaccine less effective in the South 
African setting.  Of the 13 published and well-characterized epitopes selected for 
our analysis, we have found that 3 class I- and 2 class II-restricted epitopes would 
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be beneficial in a multi-topic therapeutic vaccine for genotype 5a infection for our 
population. While in vivo and in vitro studies are needed to confirm immunogenic 
epitopes, data mining studies provide a sound basis which take into account local 
HCV variation and host allele frequency on which to design the most suitable HCV 
vaccine for local populations.  Whether it will be feasible for a personalized HCV 
vaccine at individual and population level still needs to be established. 
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CHAPTER EIGHT 
 HCV genotypes and response to therapy in a South African study group 
 
8.1.  INTRODUCTION 
The overall goal of anti-HCV therapy in acute and chronic infection is to eradicate 
the virus from the body, that is, treat to cure. This may not always be possible as 
alluded to in the previous chapter, as viral (genotype, load and mutations, Yen et al., 
2008) and host factors (ethnicity, race, HLA, IL28B gene polymorphisms, Ge et al., 
2009; Tanaka et al., 2009) are associated with response to therapy (reviewed in 
Rodriguez-Torres, 2010). The recommended treatment is combination therapy with 
pegylated-interferon (PEG-IFN) alfa-2a and ribavirin (Manns et al., 2001). PEG-IFN 
is a molecule engineered to mimic IFN which the body produces in response to in-
fection as part of the innate defence system.  Attaching a polyethylene glycol (PEG) 
moiety to IFN to produce PEG-IFN extends the half-life of IFN (Thomas and Foster, 
2007).  Ribavirin is a nucleoside analogue and is thought to support a type 1 cyto-
kine-mediated response (Graci and Cameron, 2006) against the virus in the host.  
Together with PEG-IFN, viral RNA metabolism and thus HCV replication is inhibited 
(Coelmont et al., 2006).   
 
Both the type of response to combination therapy and the ideal duration of the treat-
ment regime vary dependent on the HCV viral genotype (Botha et al., 2005). Indi-
viduals infected with genotypes 1 and 4 respond poorly to therapy when compared 
to those infected with genotypes 2 or 3 (Nguyen and Keeffe, 2005).  Because geno-
type is a good predictor of response rate to therapy (as indicated in Chapter 1), 
genotyping has become an important tool in design of treatment regimes.  Table 32 
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summarizes the different terms used to evaluate the response to HCV treatment 
(WHO, 2002; Ghany et al., 2009). Corey et al., 2010 performed a meta-analysis of 
22 published studies on early HCV treatments and conclude that if HCV has not 
spontaneously cleared by week 12 post infection, then treatment should commence 
so as to ensure a good chance of clearance.  This 12-week cut-off corresponds to 
early virological response (EVR, Table 32) in treated chronic patients and is thus 
termed “acute EVR”, to indicate spontaneous clearance in acute infection by 12 
weeks.  This early treatment regime is the recommended post exposure prophylaxis 
(PEP) for HCV (National guidelines for the prevention and control of Hepatitis C vi-
rus in SA, final draft, 2010) but not commonly used as the acute phase is predomi-
nantly asymptomatic. 
 
Previously, response to therapy was measured at 12 weeks but a recent study rec-
ommends response rates as early as 4 weeks (Zeuzem et al., 2009).  For genotype 
2 and 3 infection, patients without RVR at 4 weeks can be treated for 48 weeks.  At 
12 weeks, if patients have not achieved a pEVR, then treatment may be stopped.  
Treatment may also be discontinued if the patient, although has attained pEVR but 
is HCV RNA positive at week 24.  However, if there is a >2 log reduction in viral 
load, treatment can be extended to 72 weeks (Zeuzem et al., 2009) except when 
HCV RNA is not detected at 12 weeks in which case, treatment is continued to 48 
weeks.  This guideline is currently in use in SA (Botha et al., 2010).  To date, how-
ever, global data on responses of patients infected with genotype 5a, one of the pre-
dominant genotypes found in South Africa, is limited (Antaki et al., 2009; Nieuwoudt 
et al., 2007).  
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Response Explanation 
SVR (sustained 
virological re-
sponse) 
HCV RNA negative 24 weeks after treatment ends.  HCV is not detectable in blood 
together with persistent normalization of serum ALT six months after completing 
treatment. Patients with a SVR will remain HCV RNA negative for at least 5 years 
after stopping therapy and experience a long-term biochemical and histological out-
come with a decrease in total inflammatory activity and a decrease in the reversible 
components of fibrosis.  HCV RNA may still be detectable in the liver of serum HCV 
RNA negative patients showing ongoing inflammatory change. Nevertheless, patients 
with a SVR have a highly reduced risk of disease progression. 
EVR (early vi-
rological re-
sponse) 
HCV viral load has dropped by at least 2 logs (partial EVR) or is undetectable after 
12 weeks (complete EVR) of treatment.  A patient who does not have an EVR has a 
poor prognosis of attaining SVR.  Can choose to discontinue treatment or switch to a 
lower dose maintenance therapy although maintenance therapy is contraindicated by 
recent negative results from the HALT-C (Hepatitis C anti-viral long-term treatment 
against cirrhosis) program being performed by the National Institute of Diabetes, Di-
gestive and kidney disease, NIDDK, which is part of the National Institutes of Health, 
NIH (http://digestive.niddk.nih.gov/, 2010). 
ETR (end-of-
treatment) re-
sponse 
No HCV is detected by HCV viral load assay at completion of therapy at week 24 or 
48.  Some patients with an ETR will see HCV viral load return, usually 12-24 weeks 
after treatment has stopped. End-of-treatment response is assessed by ALT and/or 
HCV RNA estimation when therapy is completed. 
Relapser Reappearance of HCV RNA after therapy is discontinued. 
Breakthrough Reappearance of HCV RNA while patient is still on therapy. 
Non-responder 
Patients who do not have an EVR or, if they complete the course of therapy, do not 
attain at least a 2 log drop in viral load or never test undetectable for HCV RNA while 
on treatment. 
Null-responder 
Patients who fail to decrease HCV RNA by at least a 2 log drop after 24 weeks of 
therapy. 
RVR (rapid vi-
rological re-
sponse) 
Response to therapy after 4 weeks is called a RVR.  If viral load is undetectable at 
that point, it is a good predictor of an SVR later.  However, RVR is not good at pre-
dicting who is unlikely to respond, so treatment should not be suspended if there is 
no RVR. 
Table 32.  Terms used to evaluate response to HCV treatment  
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The aim of this study was to describe the response rates of HCV-infected individuals 
with single or mixed genotype infections to combination therapy in SA.  
 
8.1.1. Objectives: 
(a) To describe the genotypes of patients receiving therapy. 
(b) To determine how patients infected with single or mixed genotypes, particularly 
genotype 5a, respond to therapy  
 
8.2. METHODS 
This prospective study began in 2008, and presently includes 56 patients from state 
hospitals in Durban (KZN), Johannesburg, Pretoria, Rustenburg, Garankuwa and 
Bloemfontein for which clinical and demographic information is available.  The inclu-
sion criteria for patient selection were: confirmed HCV positive by qualitative PCR 
and HCV genotype, a detectable HCV viral load, age >18 years and verbal and writ-
ten consent at point of collection (participating hospital/clinic).  Patients were ex-
cluded if: the laboratory results were inconclusive or negative, individuals did not 
meet the above inclusion criteria and if the patient had any contraindications to ther-
apy.    HIV and HBV infections were managed appropriately by the clinician respon-
sible for treating the HCV positive patient.   
 
The specimens for testing were only eligible when collected in EDTA tubes (10-20 
ml whole blood or 5 ml plasma/serum) and specimens were transported within 24-
36 hours to the laboratory on dry ice for viral load and genotyping tests.  The sam-
ples that were excluded for testing were those that were not collected in EDTA 
tubes, were insufficient in volume and HCV tests were not confirmed positive.   
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PEG-IFN (Pegasys, Roche) and ribavirin (Copegus, Roche) were administered at a 
dose of 180 µg weekly and 800 mg/day (for those under 75 kg) and 1200 mg/day 
(for those over 75 kg), respectively.  Specimens were collected before therapy and 
sent to the NICD laboratory for HCV testing.  Each specimen was assigned a unique 
laboratory identification number and a database was established with the identifica-
tion number and patient information, only traceable and maintained by the principal 
investigator.  A validated commercial line probe assay (LiPA, version 2.0, Siemens) 
was used to determine the genotype as detailed in chapter 4.  The COBAS Am-
pliprep/COBAS TaqMan HCV test (Roche Diagnostics, Germany), found to be a reli-
able and sensitive assay to predict response to therapy in HCV-infected individuals 
(Kanda et al., 2010) and has a lower limit of detection of 15 IU/ml, was used for 
quantitative viral load determination. Specimens were received at the laboratory 
from patients on therapy for 4 weeks, 12 weeks, 24 weeks and 48 weeks.  The 
study is an ongoing collaboration with Roche Pharmaceuticals and clinicians from 
the various participating hospitals.  
 
8.3.  RESULTS 
Twenty-nine patients completed therapy at 48 weeks, 1 patient is receiving ex-
tended therapy to 72 weeks and 1 patient had end-stage renal disease (ESRD) and 
was excluded from the study.  A further 20 patients are still receiving therapy, 10 of 
these are presently at weeks 2-3 while other 10 patients are at 4-6 weeks.  Five of 
the patients have defaulted on the treatment program.   
 
Table 33a gives a summary of the available demographics of the study group.  The 
mean age of the study group is 47 years, with 35/56 (62.5%) males and 21/56 
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(37.5%) females.  Of the non-responders, two were over the age of 60 and three 
were <43 years.  Thirty-eighty (67.86%) had chronic liver disease (fibrosis scores of 
F2-F4), 17/56 (30.36%) were HCV infected haemophiliacs and 1/56 (1.78%) had 
renal disease.  Fifty percent were Blacks, 14/56 (25%) were Whites and 25% were 
Indians.  The mean viral load was 5.9X105IU/ml (Table 33a).  Patients with liver dis-
ease and genotype 1b (9/17) were older (48.25 years) than those infected with 
genotype 1b (5/17) with haemophilia (27.2 years).  Patients with genotype 3a and 
liver disease (4/10) had a mean age of 42 years, similar to those with CLD infected 
with genotype 1b.   
 
Table 33b provide a summary of the genotypes identified in the study group, with a 
breakdown of the SVR and RVR responses per genotype.  Genotype 1 had the 
poorest response rate (combined SVR and RVR) of 41% and the one patient with 
the mixed infection did attain SVR.   
 
Table 33c provides the overall responses for the cohort.  The breakdown into the 
subtypes include genotypes 1(subtypes a and b), 3(subtype a), 4 (subtypes c/d, f 
and h), genotype 5 (subtype a) and one mixed infection (1b+5a) (Fig. 27).  12 pa-
tients were excluded from the response rate analysis, as 10 had just begun therapy 
(<4 weeks), 1 had ESRD and 1 patient was placed on the extended treatment re-
gime according to the study protocol (Table 33c).  Thirty-four individuals responded 
to therapy, with SVR in 24/44 (54.56%) and RVR in 10/44 (22.72%; Fig.28).  Five 
patients defaulted (non-compliant) and were withdrawn from the study (Table 33c, 
Fig. 28). SVR was not seen in 5 individuals: P2 (genotype 1b), P9 (genotype 1b), 
P12 (genotype 1b), P48 (genotype 4f) [Fig.29a] and P13 (genotype 3a, Fig.29b).  
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Patient  2 did not clear infection at 13 weeks.  P9 and P12 were viraemic at 25 
weeks and P48 did not attain RVR at week 8 (Fig. 29a).  The patient (P21) with 
mixed genotype (1b + 5a) infection cleared the virus after 32 weeks (Fig. 29a).  All 
individuals with genotype 5a, on therapy, responded well, (RVR 22% and SVR 56%; 
Fig.30).   A patient (P13) with genotype 3 did not clear infection at 28 weeks 
(Fig.29b) but all other patients with genotype 3 or genotype 5a cleared infection, 
some as early as 4 weeks. 
(a) Demographics       (b) Genotypes of the study group 
 
  N=56 
  
Age (years)a 
  
47± 13.6 
  
Mean Viral Load (IU/
ml)a 
590930 ± 4598528 
Male 35 (62.5%) 
Female 21 (37.5%) 
CLD 38 (67.86%) 
Haem 17 (30.36%) 
ESRD 1 (1.78%) 
ETHNIC:   
C 14 (25%) 
B 28 (50%) 
I 14 (25%) 
GENOTYPES 
(N=56) 
SUBTYPES SVR+RVR 
responses 
1 17 
(30.35%) 
1 (3/17) 
1a (1/17) 
1b (13/17) 
17.64% 
5.89% 
76.47% 
7/17 (41%) 
3 10 
(17.86%) 
3 (2/10) 
3a (8/10) 
20% 
80% 
7/10 (70%) 
4 10 
(17.86%) 
4 (6/10) 
4c/d (1/10) 
4f (1/10) 
4h (2/10) 
60% 
10% 
10% 
20% 
5/10 (50%) 
5 18 (32.15%) 14/18 (77%) 
Mixed 1 (1.78%) 100% 
(c) Overall responses 
a
 Mean +/- std deviation; CLD, chronic liver disease; Haem, haemophiliac; C, Caucasians; B, Blacks; I, Indians; SVR, sus-
tained virological response; RVR, rapid virological response; ESRD, end-stage renal disease 
RESPONSES ACROSS ALL PATIENTS (N=56) 
SVR 24 (42.86%) 
RVR 10 (17.86%) 
No SVR 5 (8.93%) 
<4 Weeks 10 (17.86%) 
Default (non-compliant) 5 (8.93%) 
ESRD 1 (1.78%) 
extended 1 (1.78%) 
Table 33.  HCV positive patients on combination therapy 2008-2010; (a) Demographics, (b) geno-
types of the study group and (c) overall responses to date 
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Fig.27.  A breakdown of genotypes and subtypes in patients receiving combination therapy.  The ma-
jority of patients had genotype 5a, followed by genotype 1b and one patient was co-infected with 
genotypes 1b and 5a. 
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Fig.28.  Responses of 44 patients receiving combination therapy for HCV infection across all geno-
types.  SVR was observed in 54.56% of patients and RVR in 22.72%.  Five individuals did not attain 
SVR (genotypes 1b, 4f and 3a). 
196 
0
1
2
3
4
5
6
7
8
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48
duration of therapy (weeks)
lo
g 
v
ira
l l
o
ad
P2
P8
P9
P12
P19
P21
P23
P24
P25
P27
P29
P31
P32
P38
P45
P48
P55
Fig.29a.  Responses to combination therapy in patients infected with genotype 1 or genotype 4 and 
one patient with a mixed infection (1b+5a), P21. 
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Fig.29b.  Responses to combination therapy in patients with genotype 3 or genotype 5.   
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Fig.30.  The different responses to combination therapy in patients infected with genotype 5a.  SVR 
was observed in 56% and RVR in 22% of patients infected with genotype 5a.   
 
 
 
8.4. DISCUSSION 
The current standard of care for people infected with hepatitis C in South Africa is 
combination therapy with PEG-IFN and ribavirin (Botha et al., 2010).  There were no 
prospective studies on the treatment of HCV genotype 5a in the country (Antaki et 
al., 2010), so the present study provides vital information and a well-maintained da-
tabase on patient responses to therapy, particularly, genotype 5a in the SA popula-
tion.  Data from small retrospective studies indicate an SVR for genotype 5a infec-
tions in Belgium (21 patients, 48% D’Heygere et al., 2005); Syria (26 patients, 54%, 
Antaki et al.,2008) and France (12 patients and 87 patients, 67% and 60%,, Legrand
-Abravanel et al., 2004 and Bonny et al., 2006 respectively). This is the first report 
on treatment responses in South Africa to combined therapy in single and mixed 
genotype infection which includes 5a.  This has relevance because mixed genotype 
infections are rare (chapter 4), and extended therapy durations, dependent on geno-
type, may be necessary in the case of mixed infection. Studies have reported on 
slower response rates in African Americans compared to American Caucasians 
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(Donlin et al., 2007; Yee et al., 2009) however, there were no significant differences 
among the ethnic groups in this study.   
 
Contrary to USA reports on the high prevalence of HCV and HIV co-infection (16% 
in adult clinical group; Sherman et al., 2002 and 75% in IVDUs; Strasfeld et al., 
2003), the prevalence in SA is low (1-1.9%; Lodenyo et al., 2000 and Amin et al., 
2004, respectively).  However, with the rise in the HIV epidemic in SA, one would 
expect an increase in the number of people infected with HCV and HIV as these 
RNA viruses share a common exposure route (13.4% of N=1937 patients, Parboos-
ing et al., 2008; Table 2, page 40).    One patient in our study (1/56) was HIV-
coinfected and had just started HCV treatment (< 4 weeks) with HIV therapy, opti-
mally managed by the treating clinician.  In SA, all individuals positive for hepatitis C 
should be screened for HIV and patients with a CD4 count <200 cells/µL, the HIV 
should be treated and managed first before beginning HCV therapy and patients 
with a CD4 count >200 cells/µL,  HCV infection should be treated first (Botha et al., 
2010).  PEG-IFN and ribavirin, together with HAART, was found to be effective in 
coinfected individuals (Chung et al., 2004).  Anti-HIV drugs (didanosine, stavudine 
and AZT) with ribavirin are contraindicated and should be avoided (Botha et al., 
2010).  With these and other drug interactions which lower antiretroviral drug effi-
cacy, increase toxicity and morbidity/mortality, newer anti-HIV (reviewed in Brook et 
al., 2010) and anti-HCV drugs (reviewed in Rodriguez-Torres, 2010) need to be con-
sidered in co-infected or mono-infected individuals. 
 
HCV genotypes vary in distribution with transmission routes (Zeuzem et al., 1996, 
explained in chapter 3) and age (Zeuzem et al., 1996; Idrees and Riazuddin., 2008).  
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Individuals infected with genotype 1a and 1b (transfusion-related or unknown risk) 
were reported to be comparatively older than those with genotype 3a (IVDUs) 
(Zeuzem et al., 1996; Idrees and Riazuddin, 2008). Although not statistically signifi-
cant, our study shows that patients with CLD, infected with genotypes 1b and 3a 
were older (48 and 42 years, respectively) than those with genotype 1b and haemo-
philia (27 years).  So, it appears that risk of transmission may be more related to 
genotype distribution, than age as in SA.  Diagnosis of HCV appears to be earlier in 
the haemophilia population compared to other non-haemophilia patient populations 
(chapter 3). Age and degree of cirrhosis have been shown to be independently as-
sociated with SVR (Legrand-Abravanel et al., 2009b), we have not been able to 
show that in this study as the numbers are small.  All the patients that did not re-
spond to therapy had CLD and one had an F4 score on the liver fibrosis pathology. 
 
SVR rates of 42-46% have been reported for genotype 1 (Manns et al., 2001); 55-
66% for genotype 4 (Kamal et al., 2005); 76-82% for genotypes 2 and 3 (Manns et 
al., 2001) and 48-67% for genotype 5a (Antaki et al., 2008).  The results from the 
present study show a higher response rate (calculated as SVR+RVR combined), 
77% for genotype 5a. Lower SVR+RVR combined rates were recorded, however, 
for genotype 1 (41%), genotype 3 (70%) and genotype 4 (50%).   We do expect our 
overall SVR rates to increase as almost 20% of patients had RVR and a RVR (viral 
load negative at 4 weeks) is considered a good predictor of SVR, particularly in 
genotype 2 and 3 infections (Tarantino and Craxi, 2009).  Genotype 5a infections 
had response rates (>70%) similar to those seen for genotypes 2 and 3 (Manns et 
al., 2001).  One patient with genotype 3a did not attain an SVR.  Genotype 3 has 
recently been associated with progressive liver fibrosis (Bochud et al., 2009) and 
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alcohol use. Overweight and iron overload (Zeuzem et al., 2009) may have also 
been factors found to be affiliated to a poor response.   Although there are other 
drug therapies offered to patients with seemingly easier-to-treat HCV infections 
(such as genotype 3), the response rates of these also vary according to genotype.  
The protease inhibitor; telaprevir (Foster, 2009) and boceprevir (Kwo et al., 2009) 
have shown good SVR for genotypes 1 and 2, but not 3 and 4 and the polymerase 
non-nucleoside inhibitors have been reported to successfully target genotype 1 
(Soriano et al., 2009).  In Legrand-Abravanel’s study 2009a, patients with subtype 
1a showed a lower response to therapy as compared to those with 1b.  We had only 
one patient with subtype 1a in our cohort and it was too early to comment as ther-
apy had just begun.  However, subtyping and responses to therapy need to be 
monitored in this and future studies, not only for genotype 1, but also genotype 3 
and 4.  If response rates are found to be associated with different subtypes, then 
clinicians need to be informed so as to request for subtype diagnostic tests (chapter 
4). 
 
Most people with a sustained virological response (SVR, Table 32) remain virus-
free, however, a recent study indicates the sustained presence of low levels of virus 
in blood/tissue (Corey et al., 2010).  These levels may be too low to have a signifi-
cant effect on the liver (Corey et al., 2010).  Long-term follow-up studies are needed 
to ascertain whether a resurgence or re-activation of the virus is possible in these 
individuals. 
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8.5. CONCLUSION 
This is the first prospective surveillance study on responses to HCV therapy in SA. 
Though the study numbers are small, the treatment response for genotype 5a is 
higher in this study compared to previous global studies.  Response rates for geno-
type 5a were found to be comparable to results for genotypes 2 and 3 in developed 
countries. Longer duration of therapy (32 weeks) was necessary for SVR in the pa-
tient co-infected with genotypes 1b+5a in this study.  This is an important observa-
tion which needs to be considered in patients infected with a mixture of poor and 
good responder subtypes. Present results predict an intermediate treatment re-
sponse time will be feasible for patients with genotype 5a.  Further prospects on this 
study would be to screen for SNPs in the IL28B gene in patients receiving therapy to 
predict responses and identify whether mutations in the NS5A-ISDR correlate with 
SVR in genotype 1b infections. 
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CHAPTER NINE 
 
FINAL DISCUSSION AND FUTURE DIRECTION 
 
As HCV is a relatively “new” virus, there is much more to learn about the virus and 
its interaction with the human host.  In SA, knowledge about HCV is still in its in-
fancy and more needs to be done to create awareness and educate the public.  This 
is the first extensive molecular study on the hepatitis C virus in this country and it 
has provided added insight regarding circulating genotypes, host immuno-genetics 
and patients responses to combination therapy.   
 
The study determined the number of PCR positives in HCV-seropositive hospital-
based study groups.  Twenty-one % of the seropositive specimens were found to be 
RNA negative, indicating that seroprevalence data must be looked at with caution.  
A positive HCV PCR result is necessary to confirm active infection.   The availability 
of an accredited and validated PCR test at the NICD laboratory allows for quick and 
early diagnosis of infection.  This testing algorithm is recommended in the SA Na-
tional Guidelines for HCV prevention and treatment which will soon be available on 
the NDoH website (expected date 2012).  A National HCV surveillance database 
was established to collate all data from public health laboratories.  This comprehen-
sive database links patient demographics with HCV laboratory results.  This base-
line data will be available for future molecular and epidemiological studies and treat-
ment and preventative initiatives.  A public health study is projected in the next year 
to extend this database. Amongst other things, transmission risks in SA are of inter-
est.  The national HCV surveillance system will routinely inform the NDoH of re-
ported HCV positive cases in the different sentinel groups. Of the 621 HCV PCR 
positive specimens reported to NDoH for the period 2004-2008, only <10% have 
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been treated or are currently on treatment.   We recommend that early treatment be 
provided for all HCV PCR positive patients so to prevent huge costs later with re-
gard to liver transplants and hospitalization.  
 
The repository of data made it possible to retrospectively determine genotypes in 
two hospital-based study groups and a volunteer blood donor group.  A sequencing 
based genotyping technique (SBT) was compared for two regions (5’UTR and 
NS5B) of the HCV genome.  There was a 100% concordance between the two re-
gions at genotype level.  Subtyping within genotypes was better determined using   
the NS5B region.  Subtypes of genotype 4, not previously described in this country, 
were found in our study cohorts.  Although, genotype 5a is still the predominant 
genotype in the country, we have noted an increase in frequencies of other geno-
types, like genotypes 3 and 4.   
 
The methods used to genotype HCV are summarized in Table 34 to indicate the 
most cost efficient, less time-consuming and quick method from a public health per-
spective  for diagnostics and surveillance.  Even though, SBT is a gold standard for 
genotyping HCV, it is time-consuming and labour intensive, especially in high 
throughput laboratories.  Three molecular-based tests for genotyping HCV were 
compared to the SBT method.  To date, the LiPA (5’UTR) was found to surpass the 
other genotyping tests at genotype level.  The PCR amplicon from the qualitative 
PCR test is used in the LiPA (5’UTR) assay and this has improved turn around 
times.  The validated genotyping test, LiPA (5’UTR) was used to type the SANBS 
cohort and this separate database for the volunteer blood donor group is used by 
SANBS who store HCV positive specimens.  Genotype testing has allowed the sup-
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ply of unique genotypes, such as genotype 5a and genotype 4 to the external qual-
ity assurance program, QCMD.  Although the LiPA (5’UTR plus core) was validated 
as a method for subtyping genotype 1, it was found to miss mixed genotype infec-
tions, particularly the mixtures of genotypes 1+4 and genotypes 1+5.  Sequence 
similarities between the 5’UTR and core regions used as probes in the assay were 
found.  It is speculated that these could be responsible for the loss of discernment of 
the LiPA assay when the core amplicon was added.    
 
Although the PNS method can also be used for genotyping, it was found to be la-
bour-intensive and requires computer programmes.  Subtyping of genotype 1 is also 
not possible if upstream 5’UTR sequences are not available.  However, the tech-
nique allows the visualisation of the primary sequence data of the 5’UTR as a stem-
loop structure. 
  SEQUENCING   LiPA   PNS 
5’UTR NS5B 5’UTR 5’UTR+CORE 5’UTR 
subtyping Not efficient good Not efficient good Efficient if all 
relevant re-
gions are se-
quenced 
costs high high Use dena-
tured ampli-
cons, only 
detection 
costs 
Kit-based amplifi-
cation and detec-
tion 
Requires com-
puter software 
time Time-
consuming 
Time-
consuming 
Quick and 
easy 
Added amplifica-
tion step 
Time-
consuming 
skill high high Easy to 
teach 
high Software 
knowledge re-
quired 
Lab-
intensive 
yes yes no yes yes 
Output 
TAT 
3-5 days 3-5 days 4 hours 6 hours 3-10 days (incl. 
analysis) 
Mixed 
infections 
no no yes Yes (only partly) no 
Table 34.  A summary of the five different methods used to genotype HCV in this study 
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Genotype 5a specimens were further characterized by sequencing regions, other 
than the 5’UTR. For the first time in a South African laboratory, molecular sequence 
analyses of the core, E1, NS4B and NS5B regions have been determined   Nucleo-
tide sequence data of genotype 5a in South African patients have been compared to 
that which is available on global databases and phylogenetic inferences have been 
made.  The E1 and NS4B regions showed a greater diversity than the core and 
NS5B regions.  Geographical clustering of the SA isolates was more evident in the 
E1 and NS4B regions.  The branching order of genotype 5a after genotype 2 but 
before genotype 3 may suggest that genotype 5a is older than genotype 3.  If older 
genotypes respond better to treatment as has been speculated, then we can infer 
that patients with genotype 5a may respond better than those infected with geno-
type 3.  However, it is noted that although these results concur with previous stud-
ies, this study was conducted on sub-genomic regions.  Full genome amplification 
and phylogenetic analyses requires further optimization.  The divergence estimate 
of genotype 5a from the oldest genotype (genotype 2) was found to be between 152 
and 156 years for the core, NS4B and NS5B regions.  The analyses in the E1 re-
gion estimated a more recent divergence of 100 years.   
 
The nucleotide sequences generated in the core, NS4B and NS5B regions were 
translated into amino acids and these were used in epitope analyses across immu-
nodominant regions.  We found that the HCV class II-restricted epitope sequences 
were more conserved among genotypes than the class I-restricted epitope se-
quences.  Although both class I and II-restricted epitope sequences of genotype 5a 
were found to be relatively conserved compared to other genotypes, for example 
genotype 6, we have shown that the binding prediction scores to HLA-alleles found 
206 
in the SA population were poor.  This indicates that an epitope-based vaccine, tar-
geting genotype 1 and the A02 allele may be of limited benefit to individuals infected 
with other genotypes and with different HLA backgrounds. This data-mining study 
proposed a cocktail of highly conserved MHC Class-I and Class-II epitopes.  This 
took into consideration their respective binding efficiencies to common HLA alleles 
in the different ethnic groups, for a putative therapeutic vaccine, targeting our local 
population.  Although it was reported that only a few HLA alleles are significantly as-
sociated with HCV disease or clearance, it remains vital that host genetic factors of 
infected individuals be studied so as to understand their immune responses during 
the infection and whether they will respond to therapy or not.   
 
A prospective study of the responses to combination therapy of patients with liver 
disease or haemophilia, having either single or mixed genotype infection, was car-
ried out.  This study found a higher response rate to therapy in patients infected with 
genotype 5a compared to other genotype 5a response studies.  Response rates for 
genotype 5a were found to be comparable to those seen for genotypes 2 and 3. 
This study has also shown that longer duration of therapy was necessary for a pa-
tient co-infected with genotypes 1b+5a in this study.  This is an important observa-
tion which needs to be considered in patients infected with a mixture of poor and 
good responder subtypes. This has reference to the genotyping method used to de-
tect genotypes prior to therapy as many methods do not detect mixtures.  Although 
our patient numbers are small, we intend to continue this study nationally.   
 
This study has improved data collection and reporting systems, sharing of informa-
tion with clinicians and scientists locally and abroad, continuous teaching and train-
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ing of professionals and our future collaborative effort with the NDoH, is to inform 
the public about HCV, the available therapies and the risk of transmission. 
 
FUTURE WORK 
(1) Continue updating the surveillance system by adding more demographic 
data to include clinical information and possible risk of transmission as this 
is not well-defined in the general population of SA. 
(2) Continue testing of sentinel groups and include high-risk groups for acquisi-
tion of HCV, for eg., prisoners, HIV-infected individuals 
(2) From point (1), it will be possible to determine persons with multiple expo-
sures to various genotypes of HCV, for eg. the intravenous drug users 
(IVDU) and further investigate the likelihood of mixed genotype infections 
and/or recombinants. 
(3) Continue our collaboration with pharmaceutical companies so as to in-
crease the numbers of genotype 5a-infected individuals on therapy and 
monitor their response on a 24 or 48-week regime. 
(4) Identification of acute infections on serology-negative specimens in patients 
with high index of suspicion. 
(5) To conduct practical laboratory-based studies to confirm our prediction 
studies on conserved and semi-conserved epitopes. 
(6) Collaboration with HIV research teams regarding co-infection studies 
(7) HLA class I and II typing of prospective patients and of patients on therapy 
(8) Sequencing of host genes, like IL-28, to determine polymorphisms, KIR-
typing and its association with HLA-C alleles to determine the influence on 
disease and/or response to therapy in genotype1 and 5a infections. 
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